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ABSTRACT 
 
Domain Analysis for Estrogen Receptor/Sp1-mediated  
Transactivation and Detection of Estrogen Receptor/Sp1 Protein Interactions  
in Living Cells. (August 2004) 
KyoungHyun Kim, B.S., Hallym University; 
M.S., Rutgers University 
Chair of Advisory Committee: Dr. Stephen H. Safe 
 
 
Estrogen Receptor α (ERα)/Sp1 activation of GC-rich gene promoters in 
breast cancer cells is dependent, in part, on the activation function 1 (AF1) of 
ERα. This study investigates contributions of the DNA binding domain (C) and 
AF2 (DEF) regions of ERα on activation of ERα/Sp1. 17Beta-estradiol (E2) and 
the antiestrogens 4-hydroxytamoxifen and ICI 182,780 induced reporter gene 
activity in MCF-7 and MDA-MB-231 cells cotransfected with human or mouse 
ERα (hERα or MOR), but not ERβ and GC-rich constructs containing three 
tandem Sp1 binding sites (pSp13) or other E2-responsive GC-rich promoters. 
Estrogen and antiestrogen activation of hERα/Sp1 was dependent on 
overlapping and different regions of the C, D, E, and F domains of ERα. 
Antiestrogen-induced activation of hERα/Sp1 was lost using hERα mutants 
deleted in zinc finger 1 (amino acids (aa) 185-205), zinc finger 2 (aa 218-245), 
and the hinge/helix 1 (aa 265-330) domains. In contrast with antiestrogens, E2-
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dependent activation of hERα/Sp1 required the C-terminal F domain (aa 579-
595), which contains a β-strand structural motif. Moreover, in peptide 
competition experiments overexpression of NR-box peptides inhibits E2-
induced luciferase activity of pERE3, which contains three tandem repeats of 
consensus ERE sites, whereas E2-induced hERα/Sp1 action was not inhibited 
by NR-box peptide expression.  In contrast, overexpression of a C-terminal (aa 
575-595) F domain peptide specifically blocked E2-dependent activation of 
hERα/Sp1, but not on activation of pERE3, suggesting that F domain 
interactions with nuclear cofactors are specifically required for ERα/Sp1 action. 
Furthermore, direct physical interactions between hERα and Sp1 protein 
in vivo have been investigated by using Fluorescence Resonance Energy 
Transfer (FRET) microscopy and image analysis. Consistent with results from 
transient transfection assay, E2, 4OHT, and ICI enhanced hERα/Sp1 
interactions in living cells and these interactions were also confirmed by 
coimmunoprecipitation. In addition, endogenous hERα/Sp1 action was 
evaluated by using si RNA for Sp1 and a significant decrease in ligand-induced 
hERα/Sp1 action was observed after decreased Sp1 expression.  
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CHAPTER I 
 
INTRODUCTION 
 
1.1  Cancer 
1.1.1 What is cancer? 
Cancer, also called neoplasia or malignant tumor, is defined as “ a group 
of diseases characterized by uncontrolled growth and spread of abnormal cells. 
If the spread is not controlled, it can result in death” (Hahn and Weinberg, 2002). 
The word cancer is derived from the Latin for crab, because of the way it 
protrudes out from a central body like “the arms of crab”. Even though cancer is 
often regarded as a single condition, it consists of more than 100 different 
diseases depending on its tissue origin. Compared to physiology of normal cells, 
cancerous cells exhibit deregulated homeostasis, uncontrolled growth, and 
invasiveness that are caused by cellular genetic or epigenetic alterations. 
Cancer is the second leading cause of death after heart disease in the 
U.S.  About 1.3 million new cases of cancer will be diagnosed in 2003 and 
approximately 0.55 million people will die from this disease. Approximately, 1 out 
of 4 deaths are due to cancer. The 5-year relative survival rate of all cancer 
combined after first diagnosis is approximately 62%, whether in remission, under 
treatment, or disease-free (Jernal et al., 2003). 
   
1.1.2 Cancer risk factors 
This dissertation follows the style of Gene. 
 
 
 2
A single and ultimate cause of cancer has not been identified. However, it 
is certain that multiple factors including genetics, lifestyle, working environment, 
or combinations of these factors are linked to the development of cancer (Table 
1) (Peto, 2001).  
An inherited genetic alteration is one of the major risk factors for 
development of cancer. Polymorphisms in genes involved in hormone 
production or in metabolism of exo- or endogenous mutagens can also increase 
the risk of cancer. For example, the N-acetyltransferase (NAT2) slow acetylator 
phenotype, which is involved in the metabolism of certain carcinogenic aromatic 
amines, is associated with an increased risk of bladder cancer (Hein, 2002; 
Cartwright et al., 1982). Mutations in proto-oncogenes or tumor suppressor 
genes also confer increased cancer risk. A single base mutation of the APC 
gene (I1307K) among Ashkenazi Jews almost doubles the risk of colon cancer 
(Woodage et al., 1998). 
Although there has been a marked reduction in cigarette smoking, it is 
estimated that at least one third of all cancers are related to smoking.  Lung 
cancer incidence increases dramatically among heavy smokers especially those 
people who begin smoking at an early age (Doll, 1978). Smoking also elevates 
the risk of other cancers including pancreas, bladder, kidney, larynx, and 
esophagus (Doll and Peto, 1981). Recent reports indicated that cigarette 
smoking also increases the incidence of tumors in the stomach, liver, and cervix 
(Doll, 1996; Liu et al., 1998).   
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Diet has recently received considerable attention as an important lifestyle 
factor that influences development of cancer since many dietary nutrients 
contain pro-, anti-carcinogens, or both. It has been suggested that about one 
third of all cancers may be related to dietary factors and some of these can be 
avoided by dietary changes (Josefson, 2001). 
 
Table 1 
Risk factors for cancer (Peto, 2001) 
Internal Factors External Factors 
Gene-Polymorphisms 
Gene-Mutations  
Hormones 
immune states 
Aging 
Diet and exercise (lifestyle) 
Tobacco 
Chemicals  
Occupational or environmental 
conditions 
Radiation 
Infectious organisms  
(Virus, bacteria, etc) 
 
A variety of bioactive compounds in the diet influence either genetic or 
epigenetic changes, and metabolism relevant to the initiation and progression of 
cancer (Hong and Sporn, 1997). Vitamin D, calcium, folate, the isoflavone, 
genistein are currently being evaluated as chemopreventive agents that inhibit 
carcinogenesis at various stages (Kelloff et al., 2000).  
Infectious pathogens such as bacteria, viruses, or parasites can also 
cause cancer by diverse mechanisms of actions. A chronic bacterial infection, 
helicobacter pylori, causes gastric ulcers, which leads to development of 
stomach cancer (Miehlke et al., 1997). Many types of human papilloma viruses 
are detectable in all cervical cancers (Walboomers et al., 1999). The relationship 
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between liver cancer and hepatitis-B virus infections has been established and 
its synergistic interaction of this virus with smoking has been reported (Liu et al., 
1998). 
Asbestos exposure can result in a high incidence of lung cancer and 
asbestos is the leading cause of occupational- and environmental- related 
cancer deaths. Its carcinogenic properties are related to asbestos fibers, which 
cause asbestosis and mesothelioma (Wikeley, 1992) 
1.1.3 Basic characteristic of cancer 
Since the National Cancer Act of 1971, signed by President Nixon, 
remarkable progress has been made in our understanding of the cellular, 
biochemical, and genetic changes that occur during cancer development. The 
current paradigm is that cancer development is a multistep process reflecting the 
progressive acquisition of mutations in growth enhancing genes (oncogenes) 
and recessive mutations in growth inhibitory genes (tumor suppressor genes) 
(Land et al., 1983 and Marshall, 1991). Transformation of primary rodent cells 
into tumorigenic cells only occurs by coexpression of two different oncogenes 
(Hahn and Weinberg, 2002).  The tumorigenic conversion of human epithelial 
cells has been observed only when multiple oncogenes like SV-40 Large T 
antigen, H-ras, and telomerase are ectopically expressed together.  
Furthermore, various transgenic animal models of tumorigenesis support a 
multistep carcinogenesis model with many rate-limiting steps (Bergers et al., 
1998).  
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Carcinogenesis has three basic steps of initiation, promotion, and 
progression. The initiation stage of cancer development is associated with 
Irreversible DNA damage in normal cells by chemicals, radiation, or viruses and 
this is coupled with inappropriate DNA repair, leading to formation of neoplastic 
cells.  
 
ig. 1. Multistep carcinogenesis (Klaunig et al., 2000).  
 
Secondly, the perturbation of growth regulatory circuits in the damaged 
cells are enhanced, resulting in increased cell proliferation and transformation, 
leading to a premalignant lesion through the process of a clonal expansion. 
Tumors in the final stage of progression exhibit karyotypic instability; 
chromosome changes including insertions, deletions, breaks, and a metastatic 
capacity, result in the invasion of invading neighboring tissues (Fig. 1). 
Cancer cells generate their own mitogenic growth signals and become 
independent of exogenous growth factors. In contrast, normal cells do not grow 
in the absence of the exogenous mitogens. The autonomy of growth factor 
  
  F
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signaling in cancer cells is achieved by alterations of these pathways. For 
example, the epidermal growth factor receptor (EGF-R/erbB) is upregulated in 
stomach and breast cancers (Slamon, 1987) and constitutively active form of the 
Ras protein is also upregulated in some cancers, resulting in increased 
mitogenic signals without activation by upstream growth stimulatory signals 
(Medema et al., 1993).    
Cellular quiescence or differentiation in normal cells requires growth 
inhibitory signals that inhibit cell cycle progression, however, cancer cells evade 
those antiproliferative signals and grow exponentially. A pRB family of proteins 
are tumor suppressor genes and code phosphoproteins with molecular weights 
ranging from 104 kD to 115 kD. One copy of the wild-type RB gene is necessary 
for normal retinal development and loss or inactivation of both alleles at this 
locus results in retinoblastoma. Disruption of the pRB pathway renders cells to 
be insensitive to antigrowth signals (Fynan and Reiss, 1993; Kinzler and 
Vogelstein, 1996).  
Cancer cells also acquire resistance to apoptosis or programmed cell 
death. p53 protein is inactivated in more than 50% of human cancers. Thus, the 
functionally altered p53 protein that normally triggers apoptosis to eliminate 
damaged cells has been inhibited in cancer cells, which thereby evade the death 
signal (Benard et al., 2003). 
Acquisition of limitless replicative potential is essential for cancer 
development. For example, maintenance of teleomers at the ends of 
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chromosomes is observed in virtually all types of maliganant cancer cells (Shay, 
1997).  Ectopic expression of telomerase, an enzyme that adds hexanucleotide 
repeats to the ends of chromosome, resulting in the immortalization of cells with 
unlimited replicative potential (Bodnar et al., 1998).  
Rapidly growing cancer cells need oxygen and nutrients from blood to be 
more proliferative and subsequently, acquire the capacity to generate signals for 
new vessel formation or angiogenesis (Folkman, 1997).  Vascular endothelial 
growth factor (VEGF) is one of well-known angiogenic signals that cancer cells 
frequently produce. 
Approximately 90% of human cancer deaths are due to the acquisition of 
invasive and metastatic potential of primary tumor cells, which move to distant 
sites and colonize other tissues. E-cadherin expression, a homotypic cell to cell 
interacting protein that suppresses invasion and metastasis is deregulated 
observed in a majority of epithelial cancers (Christofori and Semb, 1999). Some 
of the important acquired characteristics of cancer cells during are summarized 
in Table 2. 
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Table 2 
Acquired characteristics of cancer cells (Hanahan and Weinberg, 2000) 
Acquired capability Example of mechanism 
Self-sufficiency in growth signals 
Insensitivity to anti-growth signals 
 
Evading apoptosis 
Limitless replicative potential 
Sustained angiogenesis 
Tissue invasion&metastasis 
Activated H-ras oncogene 
Loss of retinoblastoma protein growth 
suppression 
Inactivation of p53 protein function 
Activation of telomerase 
Activation of VEGF 
Inactivation of E-cadherin 
            
1.2  Breast cancer 
Breast cancer is by far the most common type of cancer and second 
leading cause of cancer deaths among women in the western world. Statistics 
indicates that one out of nine women will develop breast cancer during her 
lifetime. Breast cancer treatments that have decreased mortality from this 
disease include early detection, surgical removal combined with chemotherapy, 
hormone therapy, or radiation therapy (Hortobagyi and Buzdar, 2000). However, 
there is no effective treatment for recurrent-, endocrine-resistant, metastatic 
tumors.  
1.2.1 Parallel between mammary gland development and breast cancer 
The mammary gland is a highly unique organ in mammals responsible for 
providing nutrition to the young. Development of the mammary gland can be 
divided into 5 distinct stages from embryonic and prepubertal stage, puberty, 
pregnancy, lactation, to involution. Interestingly, the cycle of mammary gland 
development displays many characteristics associated with breast cancer. 
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Moreover, many of the vital factors required for mammary development are also 
involved in breast cancer.  
In the mouse embryo, mammary gland development begins with 
formation of ectodermal placodes running ventrally just inside the limbs. These 
placodes appear around day 10 or 11 of gestation, form an epithelial bud, and 
increase in size up to day 15. During this period, intensive cell proliferation 
occurs at the tip of the epithelial bud. This epithelial bud grows out of the 
surrounding mammary mesenchyme toward the mammary fat pad, ultimately 
forming a primary sprout that bifurcates and grows into a small duct system at 
the time of birth. In contrast, the mammary buds in male embryos undergo a 
programmed cell death; the connection between the epithelial stalk and the 
epidermis is cut off so that nipple formation does not occur. Mammary anlage 
formation is arrested in mice that lack the transcription factor LEF1, suggesting 
the involvement of the wnt signal in this development (van Genderen et al., 
1994). Mice deficient in Max1 and Max2 transcription factors exhibit a similar 
developmental arrest (Satokata et al., 2000). Tissue recombination experiments 
have demonstrated that these primary mesenchyme markers induced by the 
mammary epithelium are temporal and are downregulated at a later stage of 
development (Heuberger et al., 1982).  
Parathyroid hormone related peptide (PTHrP) is an autocrine/paracrine 
factor involved in a variety of cellular activities. It is often overexpressed in 
human tumors, can lead hypercalcemia of malignancy (HHM) and is supposed 
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to play role in tumorigenesis. PTHrP is expressed in mammary epithelium and 
its signal is received by the surrounding mesenchyme expressing its receptor. 
The disruption of PTHrP signaling in the knock out mouse model results in 
mammary gland developmental arrest before bud elongation is initiated and the 
primary mesenchyme markers are not expressed in the absence of this signal 
(Wysolmerski et al., 1998). The ectopic expression of PTHrP in the epidermis 
causes the differentiation of the adjacent dermal cells into the primary 
mesenchyme and nipple cells (Foley et al., 2001). Therefore, PTHrP has been 
recognized as the first signaling molecule to determine cell fate in the 
surrounding mesenchyme. In this early stage, the crosstalk between epithelial 
and stromal or surrounding mesenchyme is important for the mammary 
development.       
The secretion of ovarian hormones such as estrogen and progesterone 
during puberty stimulates ductal development. Large-club like structures 
composed of cuboidal epithelial cells, called terminal end buds (TEBs), develop 
at the distal end of the mammary ducts. These terminal end buds actively 
proliferate, elongate, and develop secondary and tertiary ducts until the ducts 
penetrate the entire fat pad. In the terminal end buds, there are two different cell 
types: body cells that give rise to mammary epithelial cells and cap cells that are 
precursors of myoepithelial cells. Side branching also occurs from the mature 
duct (Fig. 2). During each estrous cycle, cyclic changes in the level of estrogen 
and progesterone induce active proliferation in late proestrous, the formation of 
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small side branches in estrous phase, followed by the regression with increased 
apoptosis in diestrus. 
 
 
Fig. 2. The two distinct mechanisms of branching morphogenesis in the pubertal 
mouse mammary gland (Wiseman and Werb, 2002). 
 
The role of both estrogen and progesterone in puberty for ductal growth 
has been demonstrated by hormone ablation and reconstitution experiments 
(Imagawa et al., 2002).  Most steroid hormone action is mediated through ligand 
binding to nuclear receptors such as the estrogen receptor (ER) or progesterone 
receptor (PR). Both ER and PR are highly expressed in ovary, uterus, mammary 
and pituitary glands. There are two ER isoforms, denoted as ERα and ERβ, 
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which exhibit different tissue distribution and functionality. Differences between 
two ER will be discussed in section 1.5.  
Transplantation studies have demonstrated that ERα expression is 
required in both epithelial and stromal compartments for normal duct growth. 
High dose estrogen and progesterone treatment induces mammary duct growth 
in ERα-deficient epithelium but not in ERα-deficient stroma, suggesting a 
rudimentary role of ERα in the epithelium in mammary duct growth (Mueller et 
al., 2002).  Gene targeting approaches have characterized infertility and 
impaired mammary duct growth during puberty in female ERα-null mice. It is 
also reported that levels of prolactin inhibit mammary duct development 
(Bocchinfuso et al., 1999). 
Progesterone receptor A (PR-A) and Progesterone receptor B (PR-B) are 
transcribed from two distinct promoter start sites on the same gene and PR-A 
contains 165 additional N-terminal amino acids. Mice lacking both isoforms 
display limited ductal side branching and deregulated ovulation (Lydon et al., 
1995). By using Cre/loxP recombination strategy, mice only expressing PR-B 
form have been generated. Unlike the mice deficient both isoforms, the PR-A 
null mice develop normal ductal branching and alveolar budding, suggesting that 
PR-B not PR-A mediates the progesterone signaling in mammary gland 
development (Mulac-Jericevic et al., 2002). The epithelial glucocorticoid receptor 
(GR) is required for normal duct development but the function of the GR in 
alveolar development can be rescued by upregulation of the mineralcorticoid 
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receptor during pregnancy (Kinsley-Kallesen et al., 2002). Interestingly, 
transplantation studies have shown the direct involvement of the IGF signaling 
pathway in ductal outgrowth. IGF-R1 deficient epithelium displayed reduced cell 
proliferation in terminal end buds (Bonnette and Hadsell, 2001).  
Mammary gland development is completed only when pregnancy and 
lactation occur. During pregnancy, reproductive hormones stimulate active cell 
proliferation in ducts and alveoli, resulting in the expansion of lobular 
compartment of the gland and induction of terminal differentiation of mammary 
epithelium into lobular alveoli that secrete and produce milk. Prolactin and 
placental lactogens are the major hormones in alveolar development and in 
differentiation of secretary cells. It is therefore obvious that disruption of   
prolactin receptor (PrlR) signaling pathway inhibits alveolar development. 
Deletion of the prolactin gene resulted in reduced ductal growth in adult animal 
virgins (Horseman et al., 1997). Heterozygous mice containing only one intact 
PrlR allele fail to lactate after their first pregnancy. However, older female mice 
or mice after second pregnancy successfully lactate, indicating that continuous 
hormone stimuli will lead to fully functional mammary gland development 
(Ormandy et al., 1997).  Even though Stat5a and 5b exhibit 96% homology and 
similar biochemical features in tissue culture, Stat5a-deficient mice are 
incapable of lactation due to the failure of mammary gland differentiation during 
pregnancy whereas Stat5b-deficient mice maintain their pregnancy, deliver 
litters and lactate normally (Liu et al., 1997). Inactivation of transcription factor 
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C/EBPβ unexpectedly causes the phenotype similar to that of PrlR knock out 
mice and exhibit reduced ductal growth, abrogation of alveolar differentiation 
and high levels of PR positive cells in the mammary gland. It was suggested that 
cell-to-cell communication in paracrine manner is affected in C/EBPβ-null mice 
(Robinson et al., 1998, Seagroves et al., 1998 and 2000).  
Cyclin D1-null mice also fail to expand and differentiate alveoli during 
pregnancy (Sicinski et al., 1995;Fantl et al., 1995). Interestingly, transgenic mice 
expressing the neu and ras oncogenes develop mammary tumors within a few 
months in mice overexpressing cyclin D1 whereas tumors are not induced in the 
absence of cyclin D1 (Yu et al., 2001). In contrast, mice overexpressing c-myc 
and wnt1 develop mammary tumors independent of cyclin D1 expression, 
indicating that at least two distinct pathways leads to mammary tumor 
development. Unexpectedly, normal mammary development is restored in the 
double knockout mice carrying null mutations on both cyclin D1 and p27, a 
cyclin-dependent kinase inhibitor, whereas the impaired mammary development 
is observed in either p27- deficient or cyclinD1-deficient mice, respectively 
(Geng et al., 2001). The Id2 gene encodes a basic helix-loop-helix transcription 
factor that inhibits cell proliferation and differentiation in many developmental 
processes. Moreover, silencing of Id2 expression in mammary epithelium 
decreased proliferation and differentiation (Mori et al., 2000).  After lactation is 
terminated, there is decreased prolactin release from pituitary when the pups no 
longer suckle on the mammary gland. The secretory mammary gland epithelium 
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induces proapoptotic genes and subsequent apoptosis occurs in alveoli cells, 
leading to massive remodeling of the alveolar compartment with high tissue 
protease activity, resulting in a process called involution. In stat3-deficient 
alveolar epithelial cells, the involution is delayed at an early stage, suggesting 
that Stat3 may trigger apoptosis at this early stage (Humphreys and 
Hennighausen, 1999).  Mice lacking plasminogen, a protease that degrades 
extracellualr matrix, also display reduced apoptosis and remodeling of the 
mammary gland whereas mice deficient in TIMP3, an inhibitor of 
metalloprotease, exhibit accelerated involution (Lund et al., 2000; Fata et al., 
2001). Thus, remodeling of the mammary gland requires different proteases and 
protease inhibitors at the different stages of mammary development.     
As described above, the developing mammary gland displays many of the 
same properties associated with the stepwise development of cancer. Namely; 
invasion of the terminal end bud into stromal tissue or fat pad, much like a solid 
tumor, maintenance of epithelial cell proliferation potential throughout its lifetime, 
resistance of the lactating mammary gland to premature involution, inhibitors of 
apoptotic signals and angiogenic-dependent remodeling of the blood supply 
required for mammary gland development. It is therefore not surprising that the 
factors essential for mammary gland development are also associated with 
breast cancer development. 
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1.2.2 Classification, grade, and stage of breast cancer 
Breast cancers are histologically divided into three major categories: 
Noninvasive carcinoma (in situ carcinoma), invasive (nonfiltrating) carcinoma 
and Paget’s disease. Noninvasive carcinoma consists of two subtypes of 
intraductal carcinoma (Ductal Carcinoma In Situ: DICS) and lobular carcinoma in 
situ (LICS). DICS is defined as a malignant population of epithelial cells within 
ducts originating from the end of the terminal lobular duct, which lacks the 
capacity to invade through the basement membrane. It is frequently diagnosed 
by mammography in approximately 20-30% of all breast cancer patients. 
However, these cells are still capable of spreading out throughout the ducts to 
the entire breast. There are 4 microscopic variants of DICS: comedo, solid, 
papillary, and cribiform carcinomas. Lobular carcinoma in situ (LCIS) is confined 
to the lobules and is generally considered as a marker for a precancerous stage 
of breast cancer. The cells in the lesion are loosely cohesive and are larger than 
normal cells. 
Invasive or infiltrating carcinoma has two subtypes: invasive ductal 
carcinoma (IDC) and invasive lobular carcinoma (ILC). Invasive ductal 
carcinoma is the most common type, accounting for 65-80% of all breast 
cancers. The tumor cells invade the connective stromal tissue and display 
malignant cells lining the ducts, solid cell nests, tubules and glands. Medullary 
carcinoma is one of variants of IDC and accounts for only 1-5% of all mammary 
carcinomas. These tumors are usually 2-3 centimeters in size but can exceed 5 
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centimeters. Desmolplasia, a formation of fibrous tissue, which is commonly 
observed in many cancerous lesions, does not appear in medullary carcinoma, 
which exhibits more a soft and fleshy consistency. Colloid or mucinious 
carcinoma, other variants of IDC, tend to occur in older women and grow slowly 
in the course of cancer development. Extreme softness and appearance of pale 
gray-blue gelatin features characterize this type of tumor. Invasive lobular 
carcinoma is usually bilateral and multicentric with a distinct morphology 
probably arising from the terminal ductules of breast lobule.  
Paget’s disease is characterized by the presence of large cells with 
abundant clear or light staining cytoplasm and atypical nucleoli in the surface 
epithelium of the nipple. Skin lesions are associated with an underlying DICS, 
which are frequently fissured and ulcerated.  
All types of breast cancers are rated depending on the tumor cell growth 
rate and pattern ranging from 1 to 3. Higher ratings are given to tumors with 
more disorganized and irregular patterns of the cell growth. Breast cancers are 
also staged from 0 to IV by their size, invasiveness and   pattern of spreading. 
Stage 0 describes non-invasive breast cancer. In stage I, the tumor cells invade 
neighboring normal tissue but not lymph nodes and their size is less than two 
centimeters. Invasion of the tumor cells into the lymph nodes under the arm is 
observed in stage II tumors and the tumor size varies from two centimeters to 
five centimeters. Tumors larger than five centimeters that have spread to the 
breast skin and chest walls are classified as stage III.  The breast skin looks like 
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the peel of naval orange and is a sign of inflammatory breast cancer. Finally, 
stage IV tumors display massive invasion of the tumor cell beyond the breast, 
under the arms and into internal mammary lymph nodes.   
1.2.3 Genetic and epigenetic alterations of breast cancer 
The accumulation of molecular alterations during tumor progression 
results from interactions between genetic and environmental factors, leading to 
deregulated cell proliferation, apoptosis, and loss of genetic stability. It has been 
demonstrated that aberrant activities of genes involved in these processes also 
predispose women to breast caner. 
In hereditary breast cancer, germline mutations in BRCA1 have been 
identified and account for 15-20% women with a family history of both breast 
and ovarian cancer (Couch et al., 1997; Peto et al., 1999). BRCA1 is a 220 kD 
nuclear protein, containing a zinc-binding ring finger domain at the amino 
terminal and a conserved transcriptional coactivation domain at the carboxy 
terminal. This protein functions in DNA repair and cell cycle checkpoint control. 
Several studies have identified a new role of the ring finger domain as an 
essential structural subunit of E3 ubiquitin ligases. Moreover, BRCA1 exhibits 
ubiquitin ligase activity in vitro (Venkitaraman, 2002; Lee and Boyer, 2001). The 
BRCT domain is found predominantly in proteins involved in cell cycle 
checkpoint functions responsive to DNA damage. The C-terminal domain of 
BRCA1 is characterized by tandem a BRCT domain that has been found in a 
diverse group of proteins but has no known specific cellular function. However, 
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this BRCT domain mediates its interaction with many proteins such as RNA 
helicase A, CtIP, and histone deacetylase. Several studies indicated that BRCA1 
is involved in DNA repair and cell cycle progression. Moreover, Ataxia 
telangiectasia mutated (ATM) and check point kinase 2 (CHK2) catalyze 
phosphorylation of BRCA1 in response to DNA damage and the arrest of the cell 
cycle in G2 after DNA damage in cells lacking functional BRCA1. However, 
tissue specificity of the BRCA1 mutation and its precise roles in development of 
breast and ovarian cancer are not fully understood (Venkitaraman, 2002). 
BRCA2, a second breast caner susceptibility gene, also functions in DNA 
damage pathways. Men with germline mutations in BRCA2 have 100-fold 
increase over the normal male population in their risk for the development of 
breast cancer (Phelan et al., 1996). This mutation may be also associated with 
an increased risk for colon, prostate, and stomach cancers. Phosphatase and 
tensin homologue on chromosome 10 (PTEN), a lipid phosphatase, is germline-
mutated in Cowden syndrome and PTEN mutations are risk factors for breast 
cancer. Loss of heterozygocity at the PTEN locus occurs 30-40% of human 
breast cancers (Perren et al., 1999). p53 is a well-characterized tumor 
suppressor gene that functions as a transcription factor for regulation of cell 
cycle progression. The germline mutation of p53 cause Li-Fraumeni syndrome 
which is associated with childhood leukemias, brain tumors, breast carcinomas, 
soft tissue sarcomas, and osteosarcomas (Vogelstein, 2000). ATM is a 
serine/threonine kinase that functions as a signal transducer of DNA damage 
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responses such as DNA double strand breaks. Recent data indicate that the 
ATM missense mutation may exert a dominant negative effect on wild type ATM 
(Scott et al., 2002) and account for the occurrence of breast cancer in about 3% 
of families (Finkel, 2002). However all of these germline mutations found in 
breast cancer including BRCA1, 2, and other low penetrance variants only 
account for 5-10% of breast cancer overall and 15-20% of hereditary breast 
cancer.  
For sporadic breast cancer, Somatic mutations, amplification, deletion or 
truncation of tumor suppressor genes and proto-oncogenes have been 
identified. The epidermal growth factor (EGF) ligand/receptor family has been 
strongly implicated in breast cancer.  EGFs as potent mitogens, binds the EGF 
receptor tyrosine kinases that activate downstream target such as c-myc and 
cyclin D1 (Hynes, 2000). There are four closely related EGF receptor genes: 
EGFR/HER/erbB1, HER2/erbB2/Neu, erbB3/HER3, and erbB4/HER4. ErbB2 is 
the most frequently upregulated gene among members of ErbB family and is 
amplified or overexpressed in 15-30% of breast cancers (Slamon, 1987). 
Increased ErbB2 level may occur in an early stage of tumorigenesis and is 
detected in up to 60% of DCIS, particularly in the comedo type (Revillion et al., 
1998). HER/ErbB1 overexpression is also observed in 20-40% of breast tumors 
and is associated with poor prognosis (Toi et al., 1991). The upregulation of 
several EGF ligands such as epidermal growth factors (EGFs) or transforming 
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growth factor α (TGFα) is also observed in primary and metastatic breast 
cancers (Salomon et al., 1995).  
Insulin-like growth factor-II (IGFII) is highly expressed in the stromal 
compartment of breast tumors and is also correlated with poor prognosis. 
Among breast cancer patients, elevated serum IGF-1 levels was associated with 
increasing risks of developing breast cancer. IRS-1, a downstream signaling 
molecule in the IGF pathway and the main docking protein for binding and 
activation of insulin-stimulated PI 3-kinase, is correlated with ER status, and 
associated with poor prognosis in breast cancers (Zhang and Yee, 2000). Wnts 
are a family of secreted signaling proteins that exert critical roles in 
development. Overexpression of specific subset of these proteins such as Wnt2, 
Wnt4, and Wnt5A has been identified in some breast cancers. In the Wnt 
pathway, β catenin act as a downstream signaling mediator for regulating cyclin 
D expression and overexpression of β catenin in some type of breast cancer has 
been observed (Lin et al., 2000).  
c-Src is an intracellular non-receptor tyrosine kinase that acts as proto-
oncogene by augmenting signals from extracellular growth factors and by 
morphogenetic remodeling of cells to promote tumorigenesis. Overexpression of 
c-Src is observed in up to 70% of breast cancer specimens and overexpression 
of both c-Src and HER1 has also been identified in a subset of breast cancers 
(Biscardi et al., 2000). In approximately 20% of mammary carcinomas, cyclin D1 
is amplified and especially overexpressed in 50% of primary ductal carcinomas. 
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Interestingly, cyclin D1-deficient mice develop normal mammary glands, which 
fail to proliferate in pregnancy, indicating the unique role of cyclin D1 in 
mammary development (Sutherland and Musgrove, 2002). Recent data show 
that truncation of CHK2, a serine/threonine kinase and a downstreram mediator 
of ATM, is 4-5 times more frequently observed in individuals with breast cancer. 
This kinase–inactive variant is considered as one of the low penetrance breast 
cancer susceptibility genes (Meijers-Heijboer et al., 2002). Compared to normal 
breast epithelium, chemokine receptors CCR7 and CXCR4 are significantly 
upregulated in primary breast cancers.  
Chemokines are small-secreted proteins that bind G-protein coupled cell 
surface receptors to direct the migration and invasion of specific tumor sets to 
their preferred metastatic sites (Muller et al., 2001). E-cadherin is a large 
glycoprotein that is involved in cell-to-cell and cell to extracellular matrix 
adhesion. Up to 85% of lobular breast cancers do not express any E-cadherin 
due to LOH at 16q22.1, suggesting that E-cadherin functions as a tumor 
suppressor gene to repress  breast cancer invasion (Berx and Van Roy, 2001).   
1.2.4 Estrogen and breast cancer treatment 
Estrogens are ovarian steroid hormones required for establishment and 
maintenance of the female reproductive tract. They also play important roles in 
development of the male reproductive tract, in bone formation, lipid metabolism 
and maintenance of the cardiovascular and nervous systems (McDonnell et al., 
2001; Nilsson et al., 2001). Because of their homeostatic functions, estrogens 
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have been widely used for treatment of menopausal symptoms such as hot 
flash, urogenital atrophy, and osteoporosis. These benefits of hormone 
replacement therapy (HRT) for treatment of symptoms in postmenopausal 
women have been documented (Ettinger, 1998). However, it has been 
repeatedly shown that prolonged exposure to cycling estrogen levels contribute 
to the development of breast cancer. Over 100 years ago, it was first reported 
that the removal of endogenous estrogen via oophorectomy resulted in 
remission of breast cancer, suggesting a role for estrogens in breast cancer 
development (Leake, 1996).      
Indeed, clinical and experimental data also indicate that breast cancer is 
dependent upon estrogen exposure (Clemons and Goss, 2001). Late 
menopause and early age at menache are associated with an increased risk for 
developing breast cancer (Trichopoulos et al., 1972; Kampert et at al., 1988) 
The use of estrogen and oral contraception increase the risk of breast cancer 
(Ursin et al., 1998). In postmenopausal women, a major source of estrogen is 
adipose tissue in which androgenic precursors can be converted to estrogen by 
the enzyme aromatase. Not surprisingly, obese postmenopausal women with 
obesity have increased estrogen levels and are more likely to develop breast 
cancer (Cauley et al., 1999; Maehle and Tretli, 1996) Therefore, those factors 
that increase estrogen exposure such as early menarche, late menopause, and 
nulliparity are associated with an increased risk  
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4-hydoroxytamoxifen Estradiol-17β 
Raloxifene  ICI 182, 780 
Fig. 3. Chemical structures of estrogen and antiestrogens. 
 
of developing breast cancer. In addition, a number of studies report that long-
term administration of estrogen also can increase the risk for breast, ovarian,  
and endometrial cancers (Persson, 2000) whereas decreased estrogen 
exposure is regarded as protective. Early ovarian failure substantially decreases 
the incidence of breast cancer. However, this is accompanied by unfavorable 
long-term problems such as osteoporosis (Pike at al., 1983). Similarly, a longer 
lactation time and moderate exercise that could decrease the total number of 
ovulatory cycles can be protective (Bernstein et al 1994; Yuan et al 1988). The 
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role of estrogen exposure in development of breast cancer has restricted the 
pharmacological use of estrogens and this has been replaced by selective 
estrogen receptor modulators (SERMs) which exhibits tissue-specific ER 
agonistic and antagonistic activity: SERMs that exhibit ER antagonistic activity in 
the mammary gland are extensively used for treatment of breast cancer (Fig. 3).                   
Tamoxifen is a SERM that was originally developed as an oral contraceptive, but 
animal studies indicated that this compound was a potential antiestrogen 
(Harper and Walpole, 1967). Tamoxifen is beneficial for treatment of both pre- 
and postmenopausal women with ER-positive breast tumors. The optimal 
treatment period of 5 years reduces the risk of death by 28% and the incidence 
of contralateral breast cancer is decreased by 47% (Anonymous, 1998). For 
treatment of metastatic breast cancer, tamoxifen causes regression in 
approximately 30% of these cancers. More recent data shows that application of 
tamoxifen after surgery for primary breast cancer decreases micrometastasis, 
undetectable secondary tumors and ultimate causes of the cancer deaths 
among these patients (Osborne, 1998). Tamoxifen is now the first-line endocrine 
agent for treatment of breast cancer in pre-and post-menopausal women 
(Jordan, 2000). However, mixed ER agonistic and antagonistic activities of 
tamoxifen have been observed in animal studies. For example, tamoxifen 
maintains bone density in post-menopausal women and lowers the circulating 
cholesterol levels, but also increases the risk of endometrial and uterine cancer 
(Neven et al., 1997; Fisher et al., 1998; Fornander et al., 1993). Some ER-
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dependent growths of breast tumors are probably related to tamoxifen 
resistance (Plotkin et al., 1978). To avoid adverse of effects of tamoxifen, 
improved SERMs such as raloxifene or ICI 182,780 (Faslodex) have been 
developed and these drugs have minimal effects on endometrial cancer. 
Raloxifene is a benzothiophene derivative that also exerts mixed ER agonist and 
antagonist activities. It was initially developed to prevent fractures in 
osteoporetic women (Delmas et al., 1997). The More trial of raloxifene was 
started in 1994 to evaluate its effects as another potential SERM. There was a 
76% decrease in the incidence of breast cancer for women on raloxifene; 
significant decreases in the incidence of osteoporosis and serum cholesterol 
levels were observed (Cummings et al., 1999; Ettinger et al., 1999). However, 
unlike tamoxifen, an increased risk of heart disease was observed whereas 
endometrial cancer incidence was not increased after clinical studies (Barrett-
Connor et al, 2002; Goldstein et al., 2000). These studies clearly indicated 
tissue-specific estrogenic or antiestrogenic effects of raloxifene that differed from 
those of tamoxifen.  
Development of improved SERMs with minimal ER agonism for treatment 
of breast cancer risks or thromboembolism would improve clinical efficacy. ICI 
182,780 is a pure antiestrogen that does not exhibit partial ER agonist activities 
and these antiestrogenic activities are advantageous for treatment of estrogen-
dependent disease. ICI 182,780 has an ER binding affinity approximately 100 
times greater than that of tamoxifen and exerts no agonistic activity on estrogen-
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responsive tissues such as the uterus (Wakeling and Bowler, 1992; Parisot et 
al., 1995). In nude-mice xenograft studies, ICI 182,780 treatment suppressed 
the growth of established tumors for almost twice as long as tamoxifen treatment 
(Plotkin et al., 1978). Uterine stimulatory effects were not detected in animals 
treated with ICI 182,780 (Dukes et al., 1992). In a proportion of patients with 
metastatic tumors that relapsed from tamoxifen resistance, ICI182,780 still 
exerted inhibitory activities as an ER antagonist (Hu et al., 1993). Phase III 
studies of ICI 182, 780 are now underway to further examine its efficacy in 
comparison with other SERMs (Howell et al., 1996).  
1.3  Transcription 
1.3.1 Overview 
Appropriate expression of genes in eukaryotes is required for the 
development, growth, and survival of the whole organism. Expression of genes 
encoding protein is regulated in a highly orchestrated and elaborate fashion to 
guarantee the expression of specific subsets of genes in a temporally and 
spatially appropriate manner. Genetic imprinting, cell growth and death signals, 
environmental stimulus, and tissue-specific restriction are critical factors that 
control gene expression in eukaryotes. These precisely controlled patterns of 
gene expression ultimately contribute to the overall function of the organism.  
Although regulation of gene expression takes place at multiple levels from 
transcription, mRNA processing, translation to post-translational modifications, a 
major regulatory step for gene expression is transcription that is defined as “the 
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copying of any DNA strand nucleotide by nucleotide following the base-pairing 
rules by an RNA polymerase to produce a complementary RNA copy in 
eukaryotes in the nucleus” (Orphanides and Reinberg, 2002). RNA production in 
eukaryotes is regulated by three different types of RNA polymerases; RNA 
polymerase I transcribes ribosomal RNA (rRNA), RNA polymerase III transfer 
RNA (tRNA) and other small RNAs, and RNA polymerase II nuclear strucutural 
genes encoding mRNA for protein synthesis. The following sections will focus on 
RNA polymerase II-mediated transcriptional process for mRNA production in 
detail.  
1.3.2 Chromatin structure and gene expression in eukaryotic transcription 
In eukaryotic cells, genetic information is stored as the sequence of 
deoxyribonucleic acid (DNA) that is highly organized and densely packed in a 
structure known as chromatin. It is estimated that the human genome contains 
30,000-75,000 genes that encode functional gene products including proteins, 
rRNAs, and tRNAs, and this represents only 5% of the entire genome. The 
remaining 95% consists of non-coding intron sequences and other repetitive 
DNA sequences (Venter et al., 2001). Genes are distributed among 3.2 billion 
base pairs of DNA that are tightly compacted into a high ordered chromatin 
structure via association with histones and other non-histone proteins, finally 
packaged into 23 pairs of chromosomes. Approximately, 146 base pair of DNA 
are wrapped slightly less than two turns around an octameric protein core, 
consisting of two copies of each histone including H2A, H2B, H3, and H4, which 
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result in “bead-on-a-string appearance”. The “bead” is nucleosome of around 
10nM diameter and the “string” is connecting DNA. Nucleosomes are further 
coiled into 30nm fibers of solenoids that contain six nucleosomes per turn. A fifth 
histone, H1, is associated with each nucleosome on the inside of the solenoid 
structure. Finally, these chromatin fibers are packaged into chromosomes (Fig. 
4).  
Nucleosome 
core particle 30 nm FiberChromosome 
Free DNALooped domains Nucleosome
    (10 nm) 
Fig. 4. Chromatin structure (Johnstone, 2002 )  
 
However, not all the chromatin is the same and chromatin structure 
depends on its state of packaging. In terms of DNA accessibility, there are two 
major types of chromatins: heterochromatin and euchromatin. The portion of 
genome that remains condensed during the transition from metaphase to 
interphase is initially described as heterochomatin (Henikoff, 2000). The 
richness in repetitive sequences, low gene density, and regularly spaced 
nucleosomes suggest that heterochromatin may function as a gene-silencing 
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module. In contrast, euchromatin displays irregularity in nucleosomal arrays with 
a punctuated pattern of nucleosome-free hypersensitive sites associated with 
the active transcribed region for gene expression. Packaging in a 
heterochromatic form typically silences genes normally active in a euchromatin 
region and this effect is known as a position effect varigation (PEV). This reflects 
heterochromatic assembly of previous euchromatic regions at the boundary 
between euchromatin and heterochromatin in a stochastic mechanism (Grewal 
and Elgin, 2002). In reality, there are a number of intermediate states of 
chromatin from constitutively silenced state of X chromosome inactivation to fully 
active states that regulate gene expression. In fact, this highly ordered hierarchy 
of chromatin structure in eukaryotes creates barriers for gene transcription at 
various levels. Most importantly, transcription requires the alteration of DNA 
packaging and the enhancement of DNA accessibility at the transcriptional 
initiation step.  
The fundamental units required for gene regulation consist of three types 
of specific DNA sequences that determine levels of expression under specific 
physiological conditions. Firstly, the coding sequences that contain the 
information that encodes a functional gene product such as protein, rRNA, or 
tRNA. Secondly, the core promoter sequences that recognize RNA polymerase 
and include TATA box (TATA) and Initiator (Inr) sequences usually located on 5’ 
upstream of the coding sequence. Thirdly, regulatory sequences can negatively 
or positively affect gene transcription. Operator or repressor sequences act as 
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negative control elements to inhibit unnecessary transcription. In contrast, 
enhancer sequences that are recognized by activators stimulate the transcription 
from the promoter either proximally or distally from the initiation start site (Struhl, 
1999).  
The complexities of gene regulation in eukaryotes arise from the fact that 
eukaryotic DNA is packaged into chromatin templates. In prokaryotes, RNA 
polymerase can access to the DNA template without any inherent restriction and 
initiate transcription both in vivo and in vitro without any specific activator 
protein. In contrast, even a strong core promoter sequence can be inactive in 
eukaryotes, depending on chromatin structure (Fig. 5).  The ground state for 
transcriptional activation is inherently restrictive and chromatin acts as a general 
inhibitor of protein access to DNA (Workman and Kingston, 1998). Therefore, 
eukaryotic genes essentially require activator proteins that enhance transcription 
by interaction with enhancer sequences located at proximal or distal sites on the 
gene promoter. There are primarily two ways in which activators could enhance 
gene transcription in eukaryotes. Firstly, activators bound to the enhancer 
sequence increase gene transcription either through enhancing direct 
association with the basic transcriptional machinery and secondly, through 
increasing the recruitment of the transcriptional machinery to the promoter by 
altering chromatin structure (Ptashne and Gann, 1997).  
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ENH TATA 
Fig. 5. Transcriptional states in prokaryotes and eukaryotes (modified from 
Struhl, 1999). 
 
1.3.3 General transcription factors (GTFs) in basal transcription 
The essential components of the eukaryotic transcription apparatus are 
General Transcription Factors (GTFs) and the Core Promoter. GTFs are 
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required for accurate initiation by RNA polymerase II in vitro and the core 
promoter is minimal DNA sequence for initiation of transcription by RNA 
polymerase II in a reconstituted cell-free system. RNA polymerase II is a 
multienzyme complex, consisting of 12 evolutionary conserved subunits, which 
catalyze the synthesis of mRNA from the DNA template (Roeder, 1991 and 
1996). However, along with the RNA polymerase II, accurate and efficient 
transcription even from the strong core promoter requires other essential 
auxiliary factors, termed as “basal” or “general transcription factors”. There are 
six evolutionary well-conserved and -characterized general transcription factors 
that include TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH (Table 3) (Roeder, 
1996). It has been demonstrated that the purified factors along with the core 
promoters can assemble into a transcriptional preinitiation complex (PIC) with 
the following sequential order: TFIID, TFIIB, RNA polymeraseII-TFIIH complex, 
TFIIE, and then TFIIH (Weil et al., 1979; Orphanides et al., 1996). TFIID is a 
multisubunit protein that consists of TBP (TATA-box binding protein) and 13 TBP 
associated factors (TAFs). The TFIID complex containing TATA-binding protein 
(TBP) and at least 12 other TBP-associated factors initially recognize and bind 
to the TATA box. TFIIA, composing of 3 smaller subunits, then binds the TFIID 
complex and stabilizes the complex. TFIIB immediately forms a TFIID-A-B 
complex that recruits the RNA polymerase II and TFIIF. Finally, TFIIE and TFIIH 
are added to the complex, which constitutes PIC that is now ready for DNA 
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melting and gene transcription (Roeder, 1996; Albright and Tjian 2000; Reinberg 
et al., 1998). 
 
Table 3 
General transcription factors associated with RNA pol II in human cells (Roeder, 
1996) 
Factor Number of 
subunits 
Mw.(kD) Function 
TFIID-TBP 
TFIID-TAFs 
 
TFIIA 
 
TFIIB 
TFIIF 
 
TFIIE 
 
 
TFIIH 
1 
12 
 
3 
 
1 
2 
 
2 
 
 
9 
38 
15-250 
 
12,19,35 
 
35 
30,74 
 
34,57 
 
 
89,80,62,52, 
44,34,32,38, 
40 
Recognize promoter; Recruit TFIIB 
Assist transcription activation; 
Assist promoter recognition 
Stablize TFIID and promoter 
binding 
Recruit RNA Pol II and TFIIF 
Assist RNA Pol II to reach 
promoter 
Recruit TFIIH;Modulate TFIIH 
helicase, ATPase and kinase 
activities 
Promoter melting using helicase 
activity, DNA repair 
                              
1.3.4 Core promoter motifs in basal transcription 
Typically, the core promoter contains the transcriptional initiation site and 
extends either upstream or downstream for additional –35 nucleotides (nt). 
There are several cis-acting DNA elements that are commonly found in core 
promoters such as TATA box, intiator (Inr), TFIIB recognition element (BRE), 
and down stream core promoter element (DPE) (Fig. 6). These motifs recognize 
different general transcription factors and exert specific functions in PIC 
formation.   The TATA box was the first eukaryotic core promoter motif identified 
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and this motif is typically located about 25-30nt upstream of the transcription 
start site (Breathnach and Chambon 1981). Although the consensus sequence 
for the TATA box is TATAAA, a wide range of sequences still can function as a 
TATA box (Singer et al. 1990). The predominant TATA-box binding protein is 
TBP. 
 
 
Fig. 6. Core promoter elements. Each of these elements is found in only a 
subset of core promoters. Any specific core promoter may contain some, all, or 
none of these motifs. The BRE is an upstream extension of a subset of TATA 
boxes. The DPE requires an Inr, and is located precisely at +28 to +32 relative 
to the A+1 nucleotide in the Inr. The DPE consensus was determined 
withDrosophila transcription factors and core promoters. The Inr consensus 
sequence is shown for both Drosophila (Dm) and humans (Hs)                                                      
(Butler and Kadonaga, 2002). 
   
It is, however, important to consider that there are TBP-related factors, 
termed TRFs, with different biochemical properties (Berk, 2000). For an 
example, TRF2, a TBP-related factor that does not bind to the TATA box, is 
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required for expression of a specific set of genes (Maldonado 1999; Moore et al., 
1999).   
The Initiator (Inr) motif is located at the transcription start site of many 
eukaryotic promoters and is found in both TATA-containing and TATA-less core 
promoters (Corden et al., 1980; Smale et al., 1998). TAFII150 and TAFII250, key 
subunits of TFIID, interact with the Inr in a sequence-specific manner (Verrijzer 
et al., 1995; Kaufmann et al., 1998). It also has been observed that purified RNA 
pol II can also bind to the Inr and mediates transcription in the absence of TAFs, 
suggesting that TFIID and RNA pol II may interact with the Inr in different steps 
of the transcriptional process (Carcamo et al., 1991; Weis and Reinberg, 1997). 
Interactions between the Inr and sequence specific-DNA binding factors such as 
TFII-I and YY1 indicate that there is communication between specific promoter–
binding factors and the general transcriptional machinery (Roy et al., 1997; 
Grueneberg et al., 1997).  
DPE, a down stream core promoter binding site for TFIID but not for TBP, 
is frequently found in TATA-less promoters. TAFII60 and TAFII40 interact with 
the DPE to stimulate DPE-dependent but TATA-less transcription and repress 
TATA-dependent but DPE-less transcription by recruiting the inhibitory NC2/Dr1-
Drap protein complex (Willy et al., 2000). Transcriptional activation in DPE-
dependent promoters vs transcriptional repression in TATA-dependent promoter 
illustrates fundamental mechanistic differences in transcription by assembling 
promoter specific protein complexes. 
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BRE is a TFIIB recognition motif located immediately upstream from 
some TATA box binding sites. This motif is frequently a GC-rich sequence in 
eukaryotes (Lagrange et al., 1998). Furthermore, X-ray crystallography has 
demonstrated the formation of a TFIIB-TBP-DNA complex and confirms the 
interactions of these protein-DNA complexes (Tsai and Sigler, 2000). 
Since methylation of cytosine at the 5-position and subsequent 
deamination of the 5-methylcytosine will generate a TpG dinucleotide, which 
does not undergo DNA repair, the CG dinucleotide is underrepresented in 
vertebrate genomes. However, relatively GC-rich and mostly unmethylated 
stretches of DNA, termed CpG islands, are frequently found upstream from the 
transcription initiation sites of many genes that are transcribed at low rate and 
encode enzymes for intermediary metabolism. CpG islands range in size from 
0.5 to 2 kbp and may contain multiple weak promoters that are distributed over a 
region of 100 nt. Typically, CpG islands lacks TATA or DPE core promoter 
elements but contains multiple GC box motifs that are bound by Sp1 and other 
Sp family of transcription factors. Sp1 not only contributes to the maintenance of 
the hypomethylated state of CpG islands but also plays role in mediating 
transcription initiation in concert with general transcription factors (Brandeis et 
al., 1994; Macleod et al., 1994). It has been observed that the Sp1 binding sites 
in conjunction with an Inr motif can activate transcription in the absence of TATA 
box (Smale and Baltimore, 1989; Emami et al., 1995).  
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As described above, there are different combinations of the core promoter 
elements such as DPE-less but TATA- and Inr-dependent, TATA-less but CpG 
islands-and Inr-depedent, or Inr-less but BRE-TATA dependent. These exhibit 
another level of transcriptional regulation depending on the combination of each 
individual motif on the core promoter. 
1.3.5 Transcription factors and mediator complexes in eukaryotic transcription 
1.3.5.1 Transcription factors 
In addition to GTFs required for basal transcription in reconstituted cell-
free in vitro systems, there are many inducible or sequence-specific transcription 
factors that bind to motifs in gene promoters to either enhance or inhibit gene 
transcription (Morimoto, 1992). These transcription factors (TFs) typically contain 
two functional domains; a sequence-specific DNA binding domain and a 
transactivation domain that mediates downstream events. Eukaryotic 
transcription factors are often classified by in their respective DNA binding 
domains (Harrison, 1991; Mitchell and Tjian, 1989). Typically, α helices in the 
DNA binding domain of transcription factors are oriented to make contacts with 
the major groove of DNA through hydrogen bonding and Van der Waals 
interactions. In some cases, the interactions of atoms between the sugar-
phosphate backbone and in the DNA minor groove also contribute to the 
protein/DNA binding. DNA binding motifs in the TFs generally contain consensus 
amino acid sequences that characterize the type of transcription factors. Some 
examples of transcription factors classified by their conserved structural motifs 
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are homeobox, zinc-finger, winged helix or forkhead, leucine zipper, and helix- 
loop-helix families of proteins (Pabo and Saucer, 1992).  
How does transcription factor binding to enhancer elements activate gene 
transcription from motifs that are distal (up to several kbs) from the 
transcriptional initiation site? What are the biochemical mechanisms of these 
activation processes? Briefly, there are two popular models for these processes. 
One is a “looping” model that involves tethering of the enhancer and promoter 
elements, by an interval of freely mobile DNA that enhances the probability of 
their interaction and results in increased gene transcription (Rippe et al., 1995; 
Ptashne and Gann, 1997). However, as the distance between two elements is 
lengthened, the “looping “structure becomes unstable and formation of large 
loops is less likely. The other model is a “scanning or tracking” mechanism in 
which enhancer binding protein complexes move along the DNA until they 
encounter their cognate promoters (Plon and Wang, 1986).  
However, this model also does not explain how enhancers on one 
chromosome activate transcription from an alleic promoter on another 
chromosome such as a transvection event in bacteria or how an enhancer 
activates transcription from a tail hairpin structure, protruding from a double 
stranded circular DNA, results in blocking the scanning process.  
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Fig. 7. A facilitated tracking model for enhancer function. (Blackwood and 
Kadonaga, 1998). 
 
Recent models of a ”facilitated tracking” mechanism has shown the 
consistency with the broad range of phenomena associated with enhancer 
functions including long distance, orientation–independent transactivation, and 
transvection (Blackwood and Kadonaga, 1998). In this model, enhancer-bound 
protein complexes track along the chromatin until they encounter the cognate 
promoter while a stable small loop structure is maintained (Fig. 7).  
In conjunction with these models, transactivation domains of transcription 
factors exert a variety of biochemical functions in concert with their sequence-
specific DNA binding domains. These domains facilitate recruitment of chromatin 
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remodeling complexes and the covalent modification of chromatin structure. 
Enhancement of direct interaction between GTFs and their cognate promoter 
and the relocalization of the promoter region to active nucleolus region (Milot et 
al., 1996; Csink and Henikoff, 1996), and changes in the topological structure of 
DNA is also mediated, in part, by transactivation domains (Freeman and Garrad, 
1992). These functions of transcription factors will be discussed in following 
sections in conjunction with other protein complexes.           
1.3.5.2 Mediator complex 
A minimal set of GTFs and purified RNA pol II is sufficient for accurate 
initiation of transcription in vitro. However, highly orchestrated transcriptional 
activation in response to sequence-specific transcriptional activators does not 
occur in these in vitro assays. This deficiency between GTFs and the 
transcriptional activators led to the discovery of various sets of mediator 
complexes (Hampsey and Reinberg, 1999). For example, the yeast mediator 
comprises at least 20 subunits including Srb and med proteins and this purified 
mediator complex binds to the Carboxy Terminal Domain (CTD) of pol II (Myers 
and Kornberg, 2000). In humans, several mediator complexes homologous to 
the yeast mediator complex have been independently identified (Rachez and 
Freedman, 2001). The subunit composition of these complexes ranges from 7 to 
at least 18 polypeptides and contains both conserved and unique components 
with no homology to the yeast mediator subunits. Unlike RNA pol II, GTFs, or 
ATP-dependent chromatin remodeling complexes, mediator itself is unable to 
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bind DNA but physically interacts with RNA pol II without being a component of 
RNA pol II. 
Mediator also activates basal transcription and regulates TFIIH CTD 
kinase activity (Parvin and Young, 1998). The largest subunit of RNA pol II is a 
CTD that contains heptapeptide repeats phosphorylated by various CTD 
kinases. This phophorylation plays a critical role in transcriptional initiation and 
coordination of mRNA processing (Proudfoot et al., 2002). It has been 
suggested that mediator complexes are present in the nucleus free from both 
RNA pol II machinery and transcriptional activators. Through their ability to 
interact with the RNA pol II and activators, they serve as interfaces that interact 
with other coregulator proteins to modulate gene expression either positively or 
negatively, depending on subunit composition. For example, CDK8/cyclinC 
complex can phosphorylate the cyclin H subunit of TFIIH at two serine residues, 
thereby repressing both TFIIH activity and transcription. NAT mediator complex 
devoid of CDK8 (by immunodepletion) confers coactivation in vitro, but addition 
of CDK8 to this complex leads to repression. Thus, CDK8/cyclinC may act as a 
repressor module within the mediator complex (Akoulitchev et al., 2000). In 
addition, identification of the distinctive yeast Paf1 complex that transmits 
regulatory information from protein kinase C signaling to RNA pol II suggests 
that other unidentified signaling-or gene-specific mediator complexes may exist 
(Chang et al., 1999b). In summary, mediator is a modular complex that functions 
as a bridging factor between gene–specific regulatory proteins and GTFs. 
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However, the exact mechanism of mediator action is not yet fully understood 
and is currently being investigated in several laboratories.  
1.3.6 Chromatin remodeling complexes in eukaryotic transcription 
Before transcription is initiated, the chromatin structure of DNA/protein 
complexes is altered to facilitate access of transcription factors and RNA 
polymerase. This requires melting and reformation of the DNA duplex. Several 
distinct multiprotein complexes that catalyze remodeling have been identified. 
ATP-dependent remodeling complexes can change the position of the 
nucleosome, thereby exposing or occluding the specific transcription factor 
binding sites and RNA polymerase. Other complexes modify the nucleosome 
covalently either by adding or removing various chemical moieties. The N-
termini of histone are extensively modified by acetylation, phosphorylation, 
methylation, and ubiquitination and this can impact chromatin structure.   
1.3.6.1 ATP-dependent remodeling complexes 
ATP-dependent remodeling complexes increase the accessibility of 
nucleosomal DNA by using ATP hydrolysis. There are three different classes of 
these complexes based on the identity of ATPase domain and the variable but 
distinct subdomains (SWI2/SNF2 family, ISWI family, and Mi-2 Family). The 
central core ATPase can alter chromatin structure in the absence of other 
remaining factors in the complex, However, the addition of other factors in the 
core ATPase complexes exhibits different biochemical activities in vivo (Kingston 
and Narlikor, 1999; Wang and Zhang, 2001). For an example, a Drosophila 
 
 
 44
ISWI-based complex cannot remodel nucleosomes lacking histone N-terminal 
tails whereas the human and yeast SWI/SNF complex can remodel these 
nucleosomes (Langst and Becker, 2001). The N-termini of histone 4 is critical for 
stimulation of ATPase activity of the ISWI complex but not the SWI/SNF 
complex, indicating differences in the substrate requirement by these two distinct 
remodeling complexes (Clapier et al., 2001). Both Mi-2 and ISWI complex can 
change the translational position of a nucleosome. Interestingly, the ISWI 
complex moves the nucleosomal histone octamer toward the end of a 248 base 
pair DNA fragment whereas the Mi-2 complex moves the nucleosome to the 
central position. Unlike ISWI, the Mi-2 complex can remodel a nucleosome in 
which the N-terminal tails of the histone H4, H3, and H2A have been deleted 
(Brehm et al., 2000). In a DNA extrusion assay that measures the capacity of the 
remodeling complexes to form a cruciform DNA from inverted repeats of DNA, 
the SWI/SNF complex can form a cruciform DNA from both naked DNA and 
chromatin templates. In contrast, this was not observed for the ISWI and Mi-2 
complexes (Langst and Becker, 2001). This biochemical characterization of the 
ATP-dependent remodeling complexes provides evidence for mechanistic and 
functional differences between ISWI, SWI/SNF, and Mi-2 complexes. 
Mechanistically, how does the exposure of a nucleosomal DNA occur? 
There are two models for the mechanism of ATP-dependent nucleosome 
remodeling. A classical “sliding” model explains that sliding of the DNA with 
respect to the nucleosome in the same direction can change the translational 
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position of the nucleosome on DNA (Fig. 8A). This leads to the exposure of the 
DNA that previously interacts with the histone octamer. It has been reported that 
all three families of ATP-dependent remodeling complexes can reposition the 
nucleosome on DNA. In nucleosomal arrays, certain restriction enzyme sites are 
blocked by SWI/SNF action, implicating that previously accessible DNA sites 
has been repositioned (Schnitzler et al., 2001). 
 
 
 
Fig. 8. Two models for the mechanism of ATP-dependent nucleosome 
remodeling. Sliding model (A) vs conformational change model (B) (Narlikar et 
al., 2002)  
 
In addition, ISWI action can create regularly spaced nucleosomes from a 
randomly distributed nucleosomal array (Langst and Becker, 2001). However, 
this sliding mechanism cannot explain increased DNA accessibility in tightly 
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spaced nucleosomes since sliding will not increase the amount of exposed DNA 
but simply changes the location of the exposed DNA. Another unresolved 
problem arises from the fact that any transient changes of twist or writhe of linker 
DNA by repositioning the nucleosome will be transient. However, the stable 
topological changes introduced by SWI/SNF action can be stable and this does 
not fit the sliding model (Guyon et al., 2001).  
Therefore, another explanation may be that the remodeling complex can 
induce conformational changes of nucleosomes to expose the nucleosomal DNA 
on the surface of the histone octamer (Fig. 8B) (Lorch et al., 1999; Studitsky et 
al., 1994). The SWI/SNF complex can increase DNase and restriction enzyme 
sensitivity on DNA sites of a mononucleosome lacking the flanking DNA space 
in which the histone octamer can slide (Kingstone and Narlikar, 1999). The site-
specific crosslinking of the DNA to the histone octamer that prevents sliding of 
the DNA cannot hinder the remodeling of chromatin by SWI/SNF (Lee et al., 
1999).   
All of the data for ISWI-based complexes is consistent with the sliding 
model. Gradual movement of the histones along the DNA is characteristic of 
canonical nucleosomes in nucleosomal sliding, assembly, and spacing assays. 
ISWI-based complexes exhibit lower activity on mononucleosomes that does not 
contain any flanking DNA, which support the evidence of translational 
repositioning of histone octamers as expected for the silding model (Hamiche et 
al., 1999). In contrast, SWI/SNF action is more compatible with the idea that 
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conformational change of the histone octamer can expose nucleosomal DNA. 
Although the results from the SWI/SNF-and ISWI-based complex assays have 
suggested two different mechanisms of action, the molecular actions of ATP-
dependent remodeling complexes have not been completely delineated. 
1.3.6.2 Covalent modifications of chromatin 
As mentioned previously, the amino termini of the core histones (H2A, H 
2B, H3 and H4) are covalently modified by various chemical moieties; 
acetylation, phosphorylation, methylation, and ubiquitination, which can alter 
chromatin structure (Table 4) (Berger, 2001). The tail domains of histones, 
protruding from the surface of chromatin polymers, are protease sensitive and 
compose 25-30% mass of the individual histone (Wolffe and Hayes, 1999; 
Kornberg and Lorch, 1999). There are two current models for the function of 
histone modifications. One is that modifications directly affect the structure of 
chromatin by influencing either histone-DNA or histone-histone contacts. 
Considering the fact that maintenance of electroststic charges is required for the 
proper folding of chromatin structure and histone acetylation that neutralizes a 
positive charge and histone phosphorylation that adds a negative charge on the 
chromatin would cause decondensation of the chromatin fibers (Annunziato and 
Hansen, 2000). This would allow increased accessibility of specific DNA-binding 
factors to the chromatin. The second hypothesis is that various combinations of 
histone modifications constitute specific patterns that can recruit unique 
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biological complexes for mediating further downstream events. This is called 
“histone code” hypothesis (Strahl and Allis, 2000).  
  
Table 4 
Histone modifications (Berger, 2001) 
Modification Histones affected Function 
Acetylation 
 
 
 
Phosphorylation 
 
 
Methylation 
 
Ubiquitination 
All four core histones 
 
 
 
H3 and H2B 
 
 
H3 (arginine) 
H3 and H4 (lysine) 
H2B and Linker H1 
Transcriptional activation and 
repression 
Recombination 
Transcriptional silencing 
Transcriptional activation  
Mitotic and Meiotic chromosome 
condensation  
Transcriptional activation  
Heterochromatic silencing 
Transcriptional activation  
 
In yeast, the proper segregation and condensation of chromosomes 
during mitosis and meiosis require histone H3 phosphoryation at serine 10, 
possibly in conjunction with phosphorylation at serine 28 (Wei et al., 1999). The 
same phosphorylation at serine 10 also results in higher enzamatic acitivity of 
Gcn5 acetyltransferase on the neighboring lysine 14 (Cheung et al., 2000).  
Bromodomains are 110 amino acid long domains that are found in many 
chromatin-associated proteins that interact specifically with acetylated lysines. 
The bromodomain of PCAF, a histone acetyltransferase, promotes interactions 
with acetylated lysine in the context of H3 and H4 tail sequences to facilitate 
histone acetylation (Dhalluin et al., 1999). In contrast, the methylated lysine 9 of 
histone H3, targeted by the methyltransferase Su(var)39, interacts with the 
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chromodomain of the heterochromatic protein HP1 (Bannister et al., 2001). 
Increasing evidence suggests that multiple histone modifications act in a 
combinatorial or sequential fashion on one or multiple histone tails, resulting in 
recruitment of protein or protein modules to specify unique downstream 
functions.    
Actively transcribed genes are strongly correlated with hyperacetylation 
state of lysines in the N-termini of the core histones whereas hypoacetylation of 
histones are associated with silenced genes, such as those located in 
heterochromatin. Not surprisingly, up to 13 of the 30-tail lysine residues are 
acetylated in a histone octamer (Roth et al., 2001). In vitro, histone acetylation 
enhances the DNA accessibility via multiple mechanisms; namely, by lowering 
the stability of histone-DNA interactions by introducing positive charges, by 
decreasing the compaction of nucleosomal arrays through disruption of 
internucleosomal interactions, and by recruiting additional transcription factors 
by forming a specific pattern of  “ histone code”. Indeed, many transcriptional 
coactivators and corepressors contain subunits that possess either histone 
acetylase or histone deacetylase activity. Representatively, CREB-binding 
protein (CBP) and a related E1A-interacting protein p300 exhibit histone 
acetylase activity whereas Sin3 and NurD repressor complexes exhibit histone 
deacetyl transferase activity (Roth et al., 2001; Ahringer, 2000). Recent 
chromatin immunoprecipitation studies (CHIP), using specific antibodies bound 
to acetylated histones, have shown that there is a strong correlation between 
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increased acetylation in the proximal promoter region of specific genes and 
increased gene expression (Kuo et al., 2000). In contrast, hypoacetylation at 
specific promoters is clearly involved in recruiting histone deacetylase complex 
to the repressed genes (Khochbin et al., 2001). These histone-modifying 
activities exhibit substrate specificity for particular histones as well as individual 
lysines within the N-termini of histones. For example, yeast Gcn5 histone 
acetylase preferably acetylates histone H4 whereas other P/CAF and hGCN5 
histone acetylase acetylate only histone 3 (Kuo et al., 1996). Steroid receptor 
coactivators-1 (SRC-1) acetylate all four core histones but ACTR appears to 
acetylate only histones 3 and 4 (Chen et al., 1997).  
Coactivator-associated arginine methyltransferase 1 (CARM1) that binds 
to the carboxyl-terminal region of p160 coactivators, enhanced transcriptional 
activation by nuclear receptors, only with coexpression of GRIP1 or SRC-1 
(Chen et al., 1999a). More recent studies have shown that arginine methylation 
in the tail of histone 3 by CARM1 functions as a molecular switch that regulates 
the decision to express either genes induced by ligand-activated nuclear 
receptors or those activated by CREB transcription factor (Xu et al., 2001; 
Nishioka and Reinberg, 2001). CARM1 not only methylates H3 but also an 
arginine residue in a domain of p300/CBP required for interaction with CREB, 
thus, inactivating the transcriptional activity of CREB. In this regard, CARM1 not 
only functions as a coactivator for nuclear receptor-mediated transcription but at 
the same time acts as a corepressor for CREB-mediated transcription. 
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Lysine 123 within the histone H2B carboxy-terminal tail is ubiquitinated by 
Rad6 ubiquitin ligase and this modification is important for mitotic and meiotic 
growth in yeast (Robzyk et al., 2000). TAFII250 in TBP-associated TFIID 
complex ubiquitinates histone H1, leading to gene activation (Pham and Sauer, 
2000). These data suggest that histone ubiquitination is involved in gene 
transcription.  
1.3.7 Communications between various complexes in transcription 
The identification of various types of functional coactivators or 
corepressor complexes including ATP-dependent remodeling complexes, 
mediator complexes, and histone acetylase/deacetylase complexes raise the 
many questions; namely, are there differences in the requirements for recruiting 
functionally distinct protein complexes to a specific gene promoter? Additionally, 
Is there any order for recruitment of different complexes temporally or spatially in 
expression of a specific gene?  
In yeast, Gcn5p histone acetylase seems to be required for the 
expression of only 5% of entire yeast genes. Mutations in subunits of SWI/SNF 
complex reveals that this complex is not only related to the expression of only 
6% of all yeast genes in genome-wide expression studies but also is required 
repression of some genes (Holstege et al., 1998; Sudarsanam et al., 2000). 
These studies suggest that a specific subset of genes requires different set of 
complexes in mediating their gene expression or repression.  
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There is evidence that ATP-dependent chromatin remodeling complexes 
and covalent modification complexes work to regulate gene expression either in 
a coordinated or sequential manner. Chromatin immunoprecipitation studies 
(CHIP) have shown that both BRG1 and p300/CBP are present on estrogen –
responsive genes at the same time after the estrogen treatment, which supports 
the idea of cooperative model (Direnzo et al., 2000; Shang et al., 2000). In 
contrast, other studies suggest that acetylation of chromatin may stabilize the 
interaction between the SWI/SNF complex with specific gene promoter regions. 
For example, the yeast Gcn5p histone acetylase acetylates the PHO5 promoter 
region, and then bromodomain of Gcn5p stabilizes binding of SWI/SNF complex 
to the newly hyperacetylated region. It has also been shown that the SWI/SNF 
complex preferentially binds to an acetylated template in vitro (Hassan et al., 
2001).  
The temporal requirement for recruitment of different complexes to the 
same promoter region is also variable. In yeast, the inducible GAL1 promoter 
only requires Gcn5p histone acetylase during interphase. However, both the 
Gcn5p and SWI/SNF complexes are required for induction of this gene in late 
mitosis, a stage when chromatin structure is more condensed (Krebs et al., 
2000).  
It is assumed that there is no single dominant factor that can lead gene 
activation/repression in eukaryotic transcription.  The combinatorial, sequential, 
and temporal requirement for specific gene expression is dependent on multiple 
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factors including DNA accessibility of the gene promoter, the context of the core 
promoter elements, the enhancer elements that recruit specific transcription 
factors, and the temporal and spatial recruitment of functionally different 
complexes. The covalent or non-covalent modification of the subunits of the 
coactivator/corepressor complexes or specific transcription factors that are 
recruited to the specific promoter site also contributes to the regulation of gene 
transcription (Freiman and Tjian, 2003). 
1.4  Nuclear receptor superfamily 
The nuclear receptor (NR) superfamily is the single largest family of 
metazoan transcription factors that plays a role in various biological and 
physiological processes including development, metabolism, and reproduction 
(Tsai and O’Malley, 1994; Aranda and Pascual, 2001). More than 50 nuclear 
receptors have been reported and ligands have been identified for at least half of 
the receptors. Evolutionary analysis subdivides these receptors into 6 subgroups 
(Laudet, 1997). Nuclear receptors are typically defined as ligand-inducible 
transcription factors that directly interact with a specific DNA element in target 
genes as monomers, homodimers, or heterodimers. In general, nuclear 
receptors consist of conserved structural modules that behave independently.   
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.  
Fig. 9. Schematic representation of nuclear receptor (Aranda and Pascual, 
2001). 
 
These domains have been named A through F and include activation 
function 1 (AF1) in the N-terminal (A/B) region, a specific DNA binding domain 
(C), a variable hinge region (D), AF2 for ligand–dependent transcriptional 
activation (E), and another variable C-terminal region that modulates AF2 
activity (F)(Fig. 9).  
  Different NR families interact with specific DNA sequences termed 
response elements (REs). The core RE sequences usually contain a single 
conserved hexanucleotide that exhibit variability in their spacing and orientation. 
These REs can be panlindromic (Pal), direct repeats (DR), inverted repeats (IR) 
or hemisites. Tandem repeated REs are called direct repeats (DRs) and these 
DRs can vary in their spacing from a one base pair insertion (DR-1) to a four 
base insertion (DR4). The core RE is sometimes repeated in a sense and 
antisense orientation to produce an IR and IR also has spacing variation. Finally, 
the core REs can be found as a palindrome (P), an inverted palindrome (IP) or 
hemisite. As described above, specific sequence, spacing, and orientation of the 
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core REs determine the specificity of receptor–DNA interactions (Fig. 10). For 
example, class III steroid hormone receptors bind palindrome sequence 
separated by three nucleotides. In contrast, class I receptors typically bind DRs 
with different spacing variations after heterodimerization with RXR (Forman and 
Evans, 1995). 
 
Inverted palindrome 
Hemisite
A/T   
Direct repeat
Palindrome
=TGACCA/T
=A/TGGTCA
Fig. 10.  Schematic representation of the core response elements  
               (Foreman and Evans, 1995). 
 
It is now recognized that activity of nuclear receptors can be regulated by 
at least 3 other different mechanisms of actions. Nuclear receptor activity can be 
regulated by covalent modifications including phosphorylation, acetylation, and 
ubiquitination. Secondly, crosstalk between nuclear receptors themselves or with 
other transcription factors via direct protein-protein interactions can modulate 
nuclear receptor functions. Finally, some nuclear receptors are also involved in 
nongenomic action that occurs within a few minutes after addition of ligand. The 
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ER can function through all of these pathways and will be described in the 
following section.        
1.5  Mechanisms of estrogen receptor action 
1.5.1 Overview 
Estrogens exert most of their activity through the estrogen receptor (ER), 
a member of the nuclear receptor (NR) superfamily and a ligand-dependent 
transcription factor. There are two isoforms of ER, denoted as ERα and ERβ 
(Green et al., 1986a, 1986b; Kuiper at al., 1996). The discovery of ERβ from a 
rat prostate cDNA library has paved the way for studying the comparative roles 
of ERα and ERβ in normal cancerous tissues. Like other NRs, both ER consist 
of six defined structural domains. There is considerable variability in AF1, hinge, 
and F domains of ERα and ERβ. However, ligand binding and DNA binding 
properties associated with E and C domains of two ERs are similar (Mosselman 
et al., 1996; Tremblay et al., 1997). However, the two receptors have distinctly 
different tissue distribution and levels in normal tissues and in human breast 
tumors (Couse et al., 1997; Leygue et al., 1998). The following sections will 
primarily focus on ERα functions (Fig. 11).  
In the classical model, 17β-estradiol (E2) passively diffuses across the 
cell membrane and binds ER associated with heat shock proteins (HSPs) in the 
cytoplasm. Ligand-bound ER is released from HSPs due to conformational 
changes and forms homo- or hetero-dimers. Transcriptionally active ER dimers 
interact with specific palindromic DNA sequences, called estrogen responsive 
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elements (EREs; GGTCANNNTGACC), on target gene promoters. This 
consensus sequence was first identified from the vitellogenin genes of xenopus 
and chicken (Burch et al., 1988; Klein-Hitpass et al., 1988).  
 
A                                                                  B 
 
Fig. 11. The homology between ERα and ERβ. The numbers in the ER β 
diagram show the % sequence identity (A). The distribution of ERα and ERβ is 
also shown (B) (Gustafsson, 1999). 
 
However, EREs from other E2 responsive genes exhibit considerable 
variability in the sequence and location compared to that of the consensus 
elements identified in the vitellogenin A2 gene promoter (Stancel et al., 1995). 
DNA-ER complexes subsequently recruit other coactivators and/or chromatin 
remodeling factors, and the general transcriptional machinery to the target gene 
promoter, resulting in gene transcription (Nilsson et al., 2001).  
The ER contains two distinct transcriptional activation domains; activation 
function 1 (AF1) at the N-terminal and activation function 2 (AF2) at the carboxy 
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terminal. AF2 is located within the ligand binding domain (LBD)(E) and ligand 
binding regulates its activity. In contrast, AF1 activity is typically regulated by 
phophorylation in the absence of ligand. Either Independent or synergistic 
transcriptional activation by AF1 and/or AF2 has been observed and these 
activities are influenced by the ligand, the promoter context, and cell type. For 
example, tamoxifen inhibits AF2 activity but not AF1, and exhibits agonist and 
antagonist activities in a tissue-specific manner. This partial agonist activity has 
been observed in cells where AF1 activity is dominant  (Tora et al., 1988; Berry 
et al., 1990; Tzukerman et al., 1994) 
1.5.2 ER DNA binding domain structure and function 
The DNA binding domain (DBD) of ER was first defined by deletion 
mutagenesis (Kumar et al., 1987). The DBD is composed of two zinc finger 
subdomains in which the zinc ion is tetrahedrally coordinated by four cysteine 
residues. Each zinc finger domain forms distinct and complementary surfaces. 
The first zinc finger domain adopts the S-configuration in its chirality with respect 
to the zinc coordination, whereas the second zinc finger domain adopts the R-
configuration, suggesting these structures are not derived from a duplication 
event in evolution (Lee et al., 1993). The two-amphiphatic α-helices that follow 
the zinc finger domains are packed perpendicularly to each other. The inner side  
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Fig. 12. Schematic representation of the DNA binding domain of estrogen 
receptor formed by a zinc finger Motif (Modified from Schwabe et al., 1990 and 
1993). 
 
of the first α-helix, which contains hydrophobic residues, forms the central 
hydrophobic core whereas the outer side, containing charged residues, provides  
an ideal contact surface for recognizing the major groove of the DNA-half site. 
Thus, this first α-helix is referred to as the DNA recognition helix that determines 
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DNA-half site specificity. This region in the DBD is called the P-Box (Fig. 12). In 
fact, mutations of three critical residues in the P-box of ER to the corresponding 
amino acids in the Glucocorticoid Receptor (GR) (denoted as GSV mutant) 
changed the specificity of DNA–half site recognition and resulted in 
transactivation from a glucocorticoid response element (GRE)-linked reporter 
gene, but not from a ERE-linked reporter gene (Mader et al., 1989).  
The second α-helix in the second zinc finger domain appears to provide a 
number of phosphate contacts to the DNA backbone and is important for the 
receptor dimerization. This region in the DBD, which is required for stabilization 
of DNA/ER dimmer complex, is denoted as the D-Box (Schwabe et al., 1990 and 
1993). 
1.5.3 ER ligand binding domain structure and function 
The ER ligand binding domain (LBD) is a wedge–shaped structure that 
consists of 12 α helices (H1-H12). These α helices are arranged into three 
antiparallel layers with H4, H5, H6, H8 and H9 flanked by H1 and H3 on one 
side and by H7, H10, and H11 on the other side (Brzozowski et al., 1997; 
Tanenbaum et al., 1998). The LBD forms a dimerization interface for homo-and 
heterodimerzation and a binding surface for coactivators and corepressors. The 
ER ligand-binding pocket is closed on one side by an antiparallel β-sheet 
structure and by H12 on the other side is also critical for regulating AF2 activity. 
The ER LBDs form dimers within the crystal when bound to agonists or 
antagonists (Fig. 13).   
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BA C
Fig. 13. Agonist- or antagonist-bound ER LBD structures. The unliganded (apo) 
estrogen receptor LBD. (B) The agonist-bound (holo) estrogen receptor LBD. (C) 
The antagonist-bound ER LBD. The α-helices (H1–H12) are depicted as rods 
whereas broad arrows represent the β-turn. The various regions of the LBD are 
coloured depending on their function: the dimerization surface is shown in green, 
the co-activator and co-repressor binding site, which also encompasses the 
nuclear receptor LBD signature motif 6, is shown in orange and the activation 
helix H12 that harbours the residues of the core activation function 2 (AF-2) 
activation domain (AD) is shown in red; other structural elements are shown in 
mauve. Abbreviation: LBP,ligand-binding pocket (Bourguet et al., 2000). 
  
The residues from H8 up to H11 are mainly involved in receptor 
dimerization. H10 and H11 from each respective monomer contribute important 
contact surfaces for receptor dimerization by using a stretch of leucine-zipper 
like hydrophobic residues (Brzozowski et al., 1997). 
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The dimer interface in both ER isoforms is mainly composed of H10 and 
H11, which make contact with the cognate ligands and provide the link between 
ligand binding and dimerization (Ogawa et al., 1998). ER binds a variety of 
structurally diverse chemical compounds (Anstead et al., 1997). Either agonist- 
or antagonist-bound ER LBD structure has been determined. All of these ligands 
interact with the binding cavity in the LBD that is composed of residues from H3, 
H6, the loop region between H7, H8, H11, and H12.  Ligand recognition is 
achieved via a combination of specific hydrogen bonds, and the complementary 
hydrophobic interactions between hydrophobic residues in the cavity and the 
non-polar moieties of ER ligands. Two polar regions located at opposite sides of 
the ligand-binding pocket are involved in anchoring the 3 and 17 hydroxyl 
moieties of E2. Glu353 from H3, Arg394 from H5, and a water molecule form a 
polar pocket between H3 and H6 and are hydrogen-bonded to the phenolic 
hydroxyl group of the A-ring (3-OH) of E2. On the other side, the hydroxyl group 
of the D-ring forms a single hydrogen bond to His 524 from H11 (Brzozowski et 
al., 1997).   Antagonists such as raloxifene and tamoxifen bind across the cavity 
in a similar manner to agonists. However, their bulky sidechains cannot be fully 
accommodated within the binding cavity. Instead, the side chains protrude from 
the binding cavity, resulting in the displacement of H12. This repositioning of 
H12 in the LBD by ER antagonists  disrupts interactions between the 
hydrophobic groove in the LBD with nuclear coactivators (Brzozowski et al., 
1997; Shiau et al., 1998).  
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Coactivators that serve as links between liganded NRs and GTFs are 
recruited to the AF2 domain of ERα and contain a distinctive common signature 
motif termed NR-box, comprising the core consensus sequence LxxLL where L 
is leucine and X is any amino acid (Heery et al., 1997). A conformational 
rearrangement induced by agonist binding in the LBD results in formation of 
specific binding sites for an LxxLL motif or NR-box composed of coactivators. 
This binding site on ERα is a shallow, hydrophobic groove that is formed by 
residues from H3, H4, H5 and H12. The LxxLL motif functions as a hydrophobic 
docking module in a helical conformation and all the three leucines of the motif 
make contacts with the groove, in which is stabilized by a charge clamp. 
Introduction of mutations in either partner abrogates this interaction (Shiau et al., 
1998). The antagonist-bound ER LBD exhibits major structural differences 
compared to agonist-bound LBD. The large bulky sidechain of raloxifene or 
tamoxifen provokes steric clashes that hinder the H12 to adopt its characteristic 
conformation for coactivator recruitment. Instead, H12 (which contains an NR-
box like sequence of LxxML) lies tightly in the hydrophobic groove and perfectly 
mimics the interaction made by NR-box from coactivators (Pike et al., 1999).  
The crystal structures of ERβ isoform bound to genistein, a partial agonist 
for ERβ, and raloxifene, a pure antagonist for ERβ, have been determined (Pike 
et al., 1999). Genistein, an isoflavonoid phytoestrogen, displays 7-30 fold higher 
affinity for ER β over ERα. The orientation of H12 in genestein–bound ER β LBD 
is in a partially occupied antagonistic position compared to an agonist, and this 
 
 
 64
explains the partial agonistic activity of genistein. However, in raloxifene-bound 
to the LBD of ERβ, the piperidine ring of the ligand protrudes from the cavity and 
prevents H12 from adopting its agonist position. This feature is responsible for 
pure antagonistic properties of raloxifene on ERβ.    
1.5.4 Classification of LXXLL motifs (NR-boxes) 
Many nuclear receptor coactivators appear to bind the AF2-cleft induced 
by agonists and contain at least one or more copies of the LxxLL motifs (Heery 
et al., 1997; McInerney et al., 1998). However, not all the LxxLL motifs are the 
same and variations in flanking sequences determine their functional specificity 
(Chang et al., 1999a). In addition, over 60 different peptide sequences, which 
interact with agonist-bound ERα, have been identified by  
phage display (Paige et al., 1999). These peptide sequences are divided into 
three classes; SRLxxLL motifs regarded as class I, PLLxxLL motifs as class II, 
and SψLxxLL (ψ=L/I) motifs as class III (Table 5) (Chang et al., 1999a). With a 
series of ER mutants that form altered or nonfunctional AF2-clefts, the functional 
differences between these peptides were investigated in a mammalian two-
hybrid assay. Unexpectedly, the F6 peptide of class III still interacts with an AF2-
nonfunctional ER mutant containing three point mutations in the core AF2-cleft 
whereas all other peptide classes fail to bind this mutant ER.   
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Table 5 
Classification of LXXLL motif (Chang et al., 1999a) 
        -2 -1 1 2 3 4 5        
Class I ER4 
D2 
D11 
D30 
S S 
G
V
H 
N 
S
E
P 
H 
E
S 
T 
Q 
P 
G 
H 
S 
K 
S
S 
S 
S 
S 
S 
R 
R 
R 
R 
L 
L 
L 
L 
I 
L 
M 
W
E 
E 
Q 
E 
L 
L 
L 
L 
L 
L 
L 
L 
S 
S 
M
 M
R 
A 
A 
E 
    
P 
N 
A 
  
V 
D 
T 
 
T 
L 
P 
 
D 
L 
T 
  
V 
T 
M
Class II D14 
D47 
C33 
 Q 
H 
H 
E 
V 
V 
A 
Y 
E 
H 
Q 
M
G 
H 
H 
P 
P 
P 
L 
L 
L 
L 
L 
L 
W 
L 
M 
N 
S 
G 
L 
L 
L 
L 
L 
L 
S
S 
M
R 
S 
E 
S 
E 
S 
D 
H 
Q 
T 
E 
W
D 
S 
G 
W
G 
A 
Class III F6 
D22 
D48 
D43 
D17 
D41 
D26 
D40 
D15 
F4 
 G
L 
S
A
G
H 
L 
S
P
P 
H
P
G
H
V
H
G
G
S
V 
E
Y
W
G
F
N
E
W
G
G 
P
E
E
E
C
G
R
N
G
E 
L
G
N
S
D
H
A
E
S
P 
T 
S
S
S
S
S
S
S
S
G 
L 
L 
I 
L 
I 
I 
L 
I 
V 
L 
L 
L 
L 
L 
L 
L 
L 
L 
L 
L 
E 
L 
Y 
A 
C 
Y 
D 
Y 
E 
W
R 
K 
S 
W
Q 
G 
M 
R 
Y 
R 
L 
L 
L 
L 
L 
L 
L 
L 
L 
L 
L 
L 
L 
L 
L 
L 
L 
L 
L 
L 
M
R 
S 
S 
A 
A 
R 
Q 
T 
S 
D 
A 
D 
G 
H 
G 
Q 
A 
H 
A 
D 
P 
R 
E 
D 
S 
E 
D 
D 
P 
K 
V 
V 
Y 
N 
D 
N 
A 
T 
V 
Q 
E 
S 
S 
A 
A 
P 
F 
S 
E 
A 
E 
L 
S 
R 
P 
A 
D 
I 
R 
V 
V 
D 
A 
L 
S 
W
V 
L 
E 
ERβ sp. #293 S S I K D F P N L I S L L S R      
GRIP-1 NR1 
NR2 
NR3 
 D 
L 
K 
S
K
K 
S
K
K 
G
K
E 
Q
H
N 
T 
K
A 
L 
L 
L 
L 
L 
L 
L 
H 
R 
Q 
Q 
Y 
L 
L 
L 
L 
L 
L 
T 
Q 
D 
T 
D 
K 
K 
S 
D 
S 
S 
D 
D 
S 
T 
Q 
P 
K 
M
V 
D 
SRC-1 NR1 
NR2 
NR3 
 Y 
L 
E 
S 
T 
S 
S 
T 
S 
T
R
D 
S
H
H 
H
K
Q 
L 
L 
L 
L 
L 
L 
V 
H 
R 
K 
R 
Y 
L 
L 
L 
L 
L 
L 
T 
Q 
D 
T 
E 
K 
T 
G 
D 
A 
S 
E 
E 
P 
K 
Q 
S 
D 
Q 
D 
L 
 
∗ Sequences from the center three copies of LXXLL motifs in the SRC-1 and 
GRIP-1 coactivators are also included for comparison and the first conserved 
leucine was defined as position 1. 
 
These data support idea that distinct conformational rearrangements in 
the AF2 induced by different ligands recruit different types of coactivators and 
this explains the distinct pharmacology of many ER ligands in vivo.  
However, other distinct receptor interacting motifs has been identified. 
Androgen receptor (AR) and certain AR coregulators are distinguished by an 
FXXLF motif that specifically interacts with the AR AF2 site (He at al., 2002; He 
and Wilson, 2003). Moreover, some of nuclear corepressor proteins interact with 
 
 
 66
other NRs through I/LXXII motifs (Webb et al., 2000; Perissi et al.,1999). Even 
some of coactivators of NR-mediated transactivation do not require LxxLL motifs 
for their function. For example, the LxxLL motif is not required for RIP140 
binding to AhR and for enhancing AhR-mediated transcription (Kumar and 
Perdew, 1999).  
1.5.5 Estrogen receptor-dependent coactivators 
Ligand-bound ER activates gene expression by stimulating recruitment of 
functionally different coactivator complexes and the general transcriptional 
machinery through activation domains. 
Direct interaction of ER with components of general transcriptional 
machinery has been described. ER interacts with TFIIB through its AF2 domain 
(Ing et al., 1992). Human TAFII30, a TBP-associated factor within the TFIID 
complex also binds the AF2 domain of ER, but not AF1, and this binding 
enhances transcription (Jacq et al., 1994). A human TBP enhances both AF1 
and AF2 activity of ER and TBP is associated with both domains of ER in vitro. 
However, over the past few years, many different types of coregulator proteins 
have been identified. They either act as adaptor molecules to facilitate 
recruitment of GTFs to the target promoters through direct interaction or they 
mediate chromatin remodeling to increase access of TFs and GTFs to their 
respective promoters. 
Steroid receptor coactivators (SRC) or P160 family of proteins are ligand-
dependent coactivators that enhance transcriptional activation of several nuclear 
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receptors such as ER, PR (McKenna and O’Malley, 2002). These proteins are 
divided into three classes based on their sequence homology. The N-terminal 
domains of SRC/p160 family of proteins exhibit the most extensive sequence 
similarity and contain conserved helix-loop-helix and PAS (per/ARNT/sim) motifs 
that mediate homo-and heterodimerization. Representatively, SRC-1/NcoA-1 
belong to class I, TIF2/GRIP1/NCoA-2 belong to class II, and 
pCIP/ACTR/AIB1/SRC-3 are class III coactivators. One of the most distinct 
structural features of this family of coactivators is the presence of multiple LxxLL 
signature motifs. Upon ligand binding, the hydrophobic cleft is formed by 
repositioning of helix 12 in the ER-LBD which acts as “a charged clamp” to 
interact with LxxLL motifs in the coactivators. A majority of identified coactivators 
contain this motif. Some coactivators such as SRC-1 and ACTR exhibit weak 
intrinsic histone acetylase activity. More interestingly, the C-terminal domain of 
class II coactivators GRIP1 can recruit CARM1, a novel arginine 
methyltransferase, whereas the N-terminal LxxLL motif in GRIP1 interacts with 
several NRs. This arginine methyltransferase can methylate histone H3 in vitro. 
Another protein arginine methyltrasnferase, PRMT2, directly interacts with 
multiple regions of ERα and enhances both AF1 and AF2 activity (Qi et al., 
2002), suggesting the involvement of these coactivators in chromatin 
remodeling.         
CREB Binding Protein (CBP) and its homologue p300 are another class 
of coactivators that exhibit histone acetylase activity. CBP was initially identified 
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as transcription factor CREB associated protein and p300 was purified as a 
binding protein of adenovirus protein E1A. Both CBP and P300 have been 
associated with regulation of a large numbers of transcription factors (Goldman 
et al., 1997) Competition for limiting levels of these proteins within a cell can 
result in cross-talk between different signaling pathways, suggesting that 
CBP/p300 proteins are key mediators of signal integration (Janknecht and 
Hunter, 1996). For NRs, the interaction also occurs between the LxxLL motifs in 
the CBP/p300 and their LBD in ligand–dependent manner. In addition, purified 
p300 significantly enhances ligand-dependent ER action only on a chromatin 
template, suggesting a role for the histone acetyltransferase activity of p300 in 
chromatin remodeling (Kraus and Kadonaga, 1998). PCAF, p300/CBP 
associated factor, also exhibits histone acetyltransferase activity and enhances 
transcriptional activation of several NRs including ER, independent of p300/CBP 
binding but in ligand-dependent manner (Blanco et al., 1998). 
Brahma-related gene 1(BRG1), a catalytic subunit in the mammalian 
SWI/SNF complexes that are ATP-dependent chromatin remodeling enzymes, is 
required for transcriptional activation of ER (Ichinose et al., 1997). BRG-1-
mediated coactivation of ER involves in histone acetylation and Inhibition of 
histone deacetylation by trichostatin A, a reversible histone deacetylase inhibitor, 
significantly increases BRG-1-mediated coactivation of ER signaling. This 
enhancement is reversed by overexpression of histone deacetylase 1(Direnzo et 
al., 2000). However, the mechanisms by which the complex is recruited to 
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estrogen-responsive gene promoters are unknown. Recent data reveals that 
estrogen stimulates the interaction between ER and BAF57, a subunit present 
only in mammalian SWI/SNF complexes, and an additional interaction between 
BAF57 and p160 family of coactivators has also been reported (Belandia et al., 
2002).  
The multisubunit complex that interacts with vitamin D receptor (VR) and 
thyroid hormone receptor (TR) was identified and was called the DRIP/TRAP 
complex (Rachez et al., 1999; Fondell et al., 1996). At least seven subunits out 
of 13-15 proteins in the complex are homologous to the proteins identified in Srb 
mediator complex that is associated with carboxyterminal repeat domains 
(CTDs) of a large subunit in the RNA polymerase II complex (Hampsey and 
Reinberg, 1999). DRIP205/TRAP220, the largest subunit in the complex, 
interacts with the ER-LBD through its LXXLL motifs in ligand–dependent manner 
(Burakov et al., 2000). In addition, a cyclic association and dissociation of 
different types of coactivators with the estrogen responsive pS2 gene promoter 
in MCF-7 cells has been observed and recruitment of p160s and DRIPs occurs 
in opposite phases, suggesting coactivator exchange between these coactivator 
complexes at the target promoter (Burakov et al., 2002).  
E6-associated protein (E6-AP/UBE3A) directly interacts with and 
potentiates the transcriptional activity of ER in a ligand-dependent manner. E6-
AP protein can function as an ubiquitin-protein ligase (E3) in the presence of the 
E6 protein from human papillomavirus types 16 and 18. However, the ubiquitin-
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protein ligase function of E6-AP is dispensable for its ability to coactivate ER 
(Nawaz et al., 1999). ER α transcriptional activity is also enhanced by T:G 
mismatch-specific thymine DNA glycosylase (TDG) that is required for base 
excision repair of deaminated methylcytosine, providing an important link 
between DNA repair proteins and estrogen receptor function (Chen et al., 2003). 
As indicated above, full activity of ER requires a synergy between AF1 
and AF2. It was reported that some SRC/p160 coactivators enhance 
transcriptional activation of ERα via both AF1 and AF2 (Webb et al., 1998). The 
p68 helicase protein was identified as an AF1 specific coactivator of ERα but not 
ERβ. This protein displays enhanced affinity toward phosphorylated ER-AF1 
domain, providing a link between phosphorylation and transactivation (Endoh et 
al., 1999). In addition, an in vitro association of p68 helicase protein with 
p300/CBP was observed, suggesting a possible role of p68 as a bridging factor 
in recruitment of AF2-dependent coactivators. Another AF1-dependent 
coactivator, steroid RNA activator (SRA), acts as an RNA transcript rather than a 
translated protein and mediates transcriptional activation of ER. SRA exists as a 
large riboprotein complex that contains SRC-1 and may serve as a scaffold that 
facilitates SRC-1 recruitment to ER (Lanz et al, 2003).   
1.5.6 Modulation of ER activity by posttranslational modifications 
Several growth factors can also stimulate ER activity in the absence of 
ligand (Smith, 1998). Epidermal growth factor (EGF) can mimic estrogenic 
effects in ovariectomized mice, resulting in increased uterine-and vaginal cell 
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proliferation (Ignar-Trowbridge et al., 1992). The inhibitory effects of ICI 164,384 
on EGF-stimulated cell proliferation was observed in wild type mice but not in 
ER-knock out mice, suggesting association of growth factor signaling with 
ligand-independent activation of the ER (Curtis et al., 1996). In fact, growth 
factor-activated ER transcriptional activity is dependent on the phosphorylation 
states of ER. Phosphorylation of serine 118 within AF1 of ERα is mediated by 
the mitogen activated protein kinases (MAPKs; ERK1/2), which are activated by 
treatment with EGF or IGF, leading to ligand-independent transactivation of ER 
(Kato et al., 1995).  A 90k Da ribosomal S6 kinase (RSK) is an ERK substrate 
and a mediator of ERK signaling pathway (Frodin and Gammeltoft, 1999). EGF- 
or phorbol myristate-activated RSK specifically phophorylates serine 167 within 
AF1 and ectopic expression of RSK also increased serine 167 phosphorylation 
(Joel et al., 1998). ER phosphorylation is also ligand–dependent and serine 118 
is phosphorylated by CDK7, a cyclin-dependent kinase associated with the 
general transcription factor TFIIH. Interestingly, CDK7 overexpression 
significantly enhances agonistic activity of tamoxifen  (Chen et al., 2000).  
AKT is a serine/threonine protein kinase that promotes cell proliferation 
and anti-apoptotic responses and is a downstream target of phosphatidylinositol 
-3-OH kinase (PI3K)(Datta et al., 1999). PI3K and AKT activate hER in the 
absence of estrogen. AKT increased only AF1-dependent activity through 
phosphorylation of serine 167 (Martin et al., 2000; Campbell et al., 2001). 
Frequent alterations of the PI3K-AKT pathway can occur by increased activity 
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and expression of all three AKT family members or by inactivation of PTEN, a 
negative regulator of AKT, suggesting possible role for this pathway in breast 
cancer. In addition, ERα directly binds p85, the regulatory subunit of PI3K, in a 
ligand-dependent manner, leading to AKT activation and induction of endothelial 
nitric oxide synthase (eNOS) ( Simoncini et al., 2000). Other In vitro transcription 
studies showed that casein kinase II also phosphorylated human ER (hER) at 
serine-167. This data suggested that a conformational change of hER induced 
by E2 binding may expose serine-167 to casein kinase II, resulting in ER-
mediated transactivation (Castano et al., 1997).  
Cyclins are subunits of cyclin-dependent kinase (CDK) complexes and 
that regulate cell cycle progression. The CyclinA/CDK2 complex phosphorylates 
serine 104 and 106 of ERα and these modifications potentiate transcriptional 
activity of ER in ligand–independent manner (Rogatsky et al., 1999). Direct 
interaction between Cyclin D1 and ER also enhance ER activity without involving 
phosphorylation and CDK activity (Zwijsen et al., 1997; Neuman et al., 1997).                       
Protein kinase A (PKA) regulates ligand-independent ER activity by 
phosphorylating serine 236 within the DNA binding domain of ER α. This 
phosphorylation induced by PKA overexpression or activation inhibits 
dimerization and DNA binding of ER α (Chen et al., 1999b). It has been reported 
that PKA overexpression is associated with high proliferation in normal breast, 
malignant transformation in the breast, poor prognosis in established breast 
cancer, and resistance to antiestrogens (Miller, 2002).  
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Phosphorylation of ERα has not only been observed in AF1 but also in 
AF2 of ERα. The phosphrylation of tyrosine 537 on human ER by Src kinase 
regulates receptor dimerization, DNA binding and estrogen binding (Arnold and 
Notides, 1995). Interestingly, not only phosphorylation but also direct acetylation 
of ERα regulates its activity. Two conserved lysine residues (302 and 303) 
within hinge/LBD region of ERα are acetylated by p300, resulting in altered 
ligand sensitivity (Wang et al., 2001). 
1.5.7 Nonclassical ER actions 
ER homodimers binds to EREs in target gene promoter and recruit 
various coactivators to stimulate gene transcription. This classical nuclear ER-
dependent ER transcriptional activation pathway has been well characterized. 
However, some of E2-responsive genes do not contain consensus or 
nonconsensus EREs in their promoters. In fact, ligand-bound ER can activate 
many target genes through protein-protein interactions without direct DNA 
binding of ER. The following section will focus on two major nonclassical actions 
of ER; namely, ER/AP-1 and ER/Sp1 pathways.  
1.5.7.1 ER/AP-1 pathway 
An E2-responsive AP-1 element was initially identified in the proximal 
promoter of the ovalbumin gene (Tora et al., 1988) and other E2-responsive AP-
1 elements have been identified in the collagenase, insulin-like growth factor 1, 
quinone reductase, and cyclin D1 gene promoters (Gaub et al., 1990; 
Tzukerman et al., 1991; Philips et al., 1993; Umayahara et al., 1994; Montano 
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and Katzenellenbogen, 1997; Geum et al., 1997; Altucci et al., 1996). Fos and 
Jun family proteins bind AP-1 elements as homo-or heterodimers. These 
proteins contain leucine zipper domain that mediates DNA binding and are 
typically associated with genes that rapidly response to various extracellular 
stimuli (Shaulian and Karin, 2002).  
The antiestrogen tamoxifen activates AP-1 target genes in uterine cells 
but not in breast cancer cells (Webb et al., 1995). This cell-type specific ER/AP-
1 action is intriguingly parallel to the effect of tamoxifen on growth of these cell 
types where tamoxifen acts as an ER agonist in uterine cells and stimulates cell 
growth. In contrast, tamoxifen inhibits the growth of breast cancer cells where 
tamoxifen acts as antagonist.  
Mechanistic studies of ER/AP-1 actions have shown that the requirement 
for ER structural domains is dependent on ligand structure. For example, the ER 
DBD is not necessary for estrogen-mediated AP-1 actions but is required for 
tamoxifen-activated ER/AP-1-depedent activity. Furthermore, ICI, 182,780, 
another SERM that inhibits ER dimerization and ER DNA (ERE) binding, 
activates an AP-1 reporter construct. Interestingly, the ER LBD alone can 
strongly activate an AP-1 reporter construct and requires an intact AF2 function. 
The p160 coactivator GRIP1 synergistically enhances ER/AP-1-mediated 
transcription in an LXXLL-dependent manner. However, full length ERα 
containing mutations in AF1 also compromised estrogen-mediated AP-1 activity, 
indicating that ER/AP-1 action requires both AF1 and AF2 (Webb et al., 1999).  
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ERβ also activates transcription from an AP-1 element. However, the 
effects of estrogen and antiestrogen on ERβ/AP-1 exhibits contrast to those 
observation for ERα/AP-1. E2, ICI,182,780, tamoxifen, and raloxifene all activate 
AP-1 reporter construct in cells cotransfected with ERα whereas, in the 
presence of ERβ, E2 not only acts as antagonist but also inhibits the activity of 
tamoxifen and raloxifene dependent induction of ERβ/AP-1. However, either 
tamoxifen or raloxifene alone behave as full agonists (Peach et al., 1997). 
Direct protein-protein interaction between ER and c-Jun is required for 
ER/AP-1 action. Recent data have shown that the hinge region of ERα is 
associated with the C-terminal region of c-Jun in a ligand–independent manner 
whereas ER does not interact with c-Fos.  Moreover, the coactivator GRIP1 
forms a triple complex with c-Jun and ERα in both in vitro and in intact cells, 
suggesting that GRIP1 stabilizes the ERα/c-Jun complex (Teyssier et al., 2001).   
1.5.7.2 ER/Sp1 pathway 
E2-responsive GC-rich elements were initially identified in the c-myc gene 
promoter (Dubik and Shiu, 1992). This site contains a nonconsensus ERE-half 
site (ERE½) and an Sp1 binding site that was required for estrogen-mediated 
induction. Similar ERE½/Sp1 elements have been subsequently characterized in 
the cathepsin D (Krishnan et al., 1994), heat shock protein 27 (Hsp27) (Porter et 
al., 1996), TGF α (Vyhidal et al., 2000), prothymosin α (Martini and 
Katzenellenbogen, 2001), and human PR A (Petz and Nardulli, 2000), and rabbit 
uteroglobulin gene promoters (Scholz et al., 1998). With exception of Hsp27, 
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these promoters require ERα binding to ERE ½ sites for E2-mediated induction 
since mutations of the ERE ½ site abolish estrogen-responsiveness of these 
promoters. In the Hsp27 promoter, ERα/Sp1 also mediated transactivation when 
the ERE ½ sites was mutated (Krishnan et al., 1994; Porter et al., 1997) and 
ERα/Sp1 action is observed in cell transfected with wild type ER or mutant ER 
with a deletion of the DBD.  
ERα/Sp1 protein-protein interaction was investigated in vitro using 
GSTpull down assays, which showed interaction between the C-terminal end of 
Sp1 and multiple regions of ERα. Interestingly, the antiestrogens such as 
tamoxifen and ICI 182,780 activated ERα/Sp1 in cells transfected with construct 
containing a GC-rich promoter (pSp1 or pSp13). DNA-independent ERα/Sp1 
action has been observed for several genes including retinoic acid receptor α 
(Sun et al., 1998), c-Fos (Duan et al., 1998), insulin-like growth factor-binding 
protein-4 (Qin et al., 1999), bcl-2 (Dong et al., 1999), adenosine deaminase (Xie 
et al, 1999), thymidylate synthase (Xie et al., 2000), cyclin D1 (Castro-Rivera et 
al., 2001), cad (Khan et al., 2003), E2F-1 (Ngwenya and Safe, 2003). 
Although both ERα and ERβ forms complexe with Sp1 protein, only ERα 
induces consensus Sp1 element-linked reporter gene activity whereas ERβ, 
exhibits minimal or decreased the basal reporter gene activity and these 
responses are ligand- and cell type-specific. Additionally, it has been shown 
using a series of ER α deletion mutants and ERα/ERβ chimeric mutants that the 
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AF1 domain of ERα is critical for ERα/Sp1-mediated transactivation. These data 
indicated that ERα/Sp1 action is dependent on cell type, ligand, and ER subtype 
(Saville et al., 2000). Interestingly, it was recently reported that both ERα and 
ERβ regulate EGF receptor gene expression through GC-rich elements and, 
depending on ligand, ER β exerts full agonist activity on this promoter, indicating 
that promoter context is also an important factor in ERβ/Sp1 action (Salvatori et 
al., 2003).          
ERα not only interacts with Sp1 but also with Sp3 protein, another 
member of Sp protein family that can also act as transcriptional repressor. It was 
found that vascular endothelial growth factor (VEGF) gene expression is 
regulated by ERα/Sp1 or ERα/Sp3 either positively or negatively and Sp1/Sp3 
ratios and critical for VEGF gene regulation.  By using Sp protein deficient SL2 
cells, upregulation of the VEGF promoter activity with E2 treatment was 
observed in cells cotransfected with ERα and Sp1 expression plasmid whereas 
downregulation of the same promoter activity was observed when cells 
cotransfected with ERα and Sp3 expression plasmid (Stoner et al., 2000 and 
2004). 
1.6 Sp family of transcription actors 
Sp1 was originally identified as a mammalian transcription factor that 
binds and activates transcription from multiple GC-rich sequences in the simian 
virus 40 (SV40) early promoter and the thymidine kinase promoter (Dynan and 
Tijan, 1983; Gidoni et al., 1984; Jones et al., 1985). The human cDNA that 
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partially encodes the C-terminal 696 amino acids of Sp1 was initially cloned from 
Hela cells and the entire Sp1 cDNA from rat and mouse have also been cloned 
later (Kadonaga et al., 1987; Imataka et al., 1992). Other Sp1-related 
transcription factors including Sp2, Sp3, and Sp4 were cloned and form a 
multigene family of transcription factors (Hagen et al., 1992: Kingsly and Winoto, 
1992; Supp et al., 1996). All four human Sp proteins share similar domain 
structures (Fig.15) and contain DNA binding domains at the C-termini and 
glutamine rich domains adjacent to serine/threonine stretches at the N-termini. 
The DBD consists of 81 amino acids that contain three C2H2 type zinc finger 
motifs and this region is a highly conserved region among Sp proteins. Sp1, 
Sp3, and Sp4 recognize the classical GC-rich Sp1 element with similar affinities 
(Pavletich and Pabo, 1991; Hagen et al., 1992 and 1994). In contrast, Sp2 does 
not bind GC-rich elements but to a GT-rich motif since the conserved histidine 
residue in first zinc finger domain is replaced by leucine residue (Kingsly and 
Winoto, 1992). The following sections primarily focus on Sp1 and Sp3 proteins 
(Fig. 14). 
1.6.1 Sp1 
Sp1 protein is ubiquitously expressed and is important for regulation of 
TATA-less genes that encode housekeeping proteins (Pugh and Tjian, 1991).  It 
has been shown that its activity and cellular content is regulated during 
development, cell proliferation and apoptosis (Armstrong et al., 1997; Jane et al., 
1993; Piedrafita and Pfahl, 1997). Sp1-dependent gene regulation occurs 
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through direct protein-protein interactions, post-translational modifications, and 
alterations in Sp1 protein levels. 
 
C D BA
Zinc fingers 
Glutamine rich
Serine/Threonine rich
Sp1 778aa 
Sp2 606aa 
Sp3 697aa 
Sp4 784aa 
  
Fig. 14. Schematic representation of the functional domains of Sp family proteins 
(Modified from Suske et al., 1999). 
 
The glutamamine-rich A and B regions of Sp1 act as strong 
transcactivation domains (Courey and Tjian, 1988) and the interspersed bulky 
hydrophobic amino acids within the activation domain play critical role (Gill et al., 
1994). Sp1 activates transcription synergistically by forming homomultimeric 
complexes, which requires the activation domains A and B and carboxy-terminal 
domain D (Pascal and Tjian, 1991; Tanese et al., 1991). Sp1 directly interacts 
with subunits of general transcription machinery including TBP, TBP-asoociated 
factors TAFII110, and TAFII55 to stabilize the transcriptional initiation complex 
(Emili et al., 1994; Chiang and Roeder, 1995). Recent studies show that 
cofactors required for Sp1 activation (CRSP) complex is required for Sp1-
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mediated transactivation and is composed of six to eight proteins that range in 
size from 30-200kDa (Naar et al., 1998). Sp1 also interacts with many 
transcription factors to modulate transcription including GATA1, YY1, E2F, c-
Jun, p53, pRb (Gregory et al., 1996; Seto et al., 1993; Karlseder et al., 1996; 
Wang and Chang, 2003; Schavinsky-Khrapunsky et al., 2003; Datta et al., 1995).  
Phosphorylation and glycosylation are posttranslational modifications that 
modulate Sp1-dependent activity. DNA-dependent protein kinase 
phosphorylates Sp1 by viral infection and is associated with DNA damage 
responses (Jackson et al., 1990; Anderson, 1993). Casein Kinase II (CKII) 
phosphorylates a threonine residue in the second zinc finger of Sp1 and this 
inhibits DNA binding whereas N-terminal phosphorylation by PKA increases 
transcriptional activity of Sp1 in part through increasing its DNA binding affinity 
(Armstrong et al., 1997; Rohlff et al., 1997; Zheng et al., 2000). Cyclin A/cdk2 
complex directly binds to and phosphorylates Sp1 and increases its DNA binding 
activity (Haidweger et al., 2001). In contrast, direct cyclin D1 binding to Sp1 
inhibits its transcriptional activity (Opitz and Rustgi, 2000). Glycosylation of Sp1 
through O-linkage of monosaccharide, N-acetylglucosamine (O-GlcNAc) is 
another important posttranslational modification. Sp1 acetylation is linked to 
multiple functional changes including altered self association, altered interaction 
with GTFs and proteasome-dependent degradation (Roos et al., 1997; Han and 
Kudlow, 1997).  
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1.6.2 Sp3 
There are 3 isoforms of Sp3, which were derived from three different 
initiation sites from the same gene (Kingsly and Winoto, 1992). Sp3 is 
ubiquitously expressed and acts as either a transcriptional activator or repressor 
dependent on promoter and cell context. Initial studies implicated Sp3 as strictly a 
repressor because Sp3 did not activate GC-rich elements containing promoters 
from HIV-1 and HTLV-1 genes (Hagen et al., 1994; Dennig et al., 1995). 
However, later studies show that Sp3 also has activator function in both 
mammalian and SL2 cells (Dennig et al., 1996; Majello et al., 1997). In fact, Sp3 
stimulates expression of the HERV-H long terminal repeat in teratocarcinoma 
cells but acts as a repressor in both Hela and insect cells (Sjottem et al., 1996). 
Therefore, It has been suggested that the relative abundance of Sp1 and Sp3 in 
specific cells determines the activity of Sp3 as an activator or a repressor. 
Sp1/Sp3 cellular ratios are highly variable; endothelial cells contains high levels of 
both Sp1 and Sp3 whereas Sp3 level is lower in non-endothelial cells, which 
regulates KDR/flk-1 promoter activity (Hata et al., 1998). The repression domain 
of Sp3 is mapped to a small amino acid stretch (KEE) located at the 5’ of the zinc 
finger domain (Dennig et al., 1996). Sp3 interacting protein (SIF-1) that is 
associated with the repressor domain has been cloned (Suske, 1999). Post-
translational modifications also modulate Sp3 repressor activity in conjunction 
with cellular location. For example, removal of a small ubiquitin-related modifier-1 
(SUMO-1) from Sp3 by mutation of the SUMO acceptor lysines or expression of 
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the SUMO-1 protease Senp1 converted Sp3 to a strong activator with a diffuse 
nuclear localization (Ross et al., 2002).  
Sp1-/- embryos are retarded in development, exhibit a broad range of 
abnormalities and die around day 11 of gestation. Cell cycle-regulated genes are 
not affected in Sp1-/- embryos and CpG islands remain methylation free (Marin 
et al., 1997). Sp3-deficient embryos are also growth retarded and invariably die 
at birth due to respiratory failure. In addition, histological studies of individual 
organs indicate a pronounced defect in late tooth formation in Sp3(-/-) mice 
(Bouwman et al., 2000). Recent data shows that the absence of Sp3 also results 
in impaired hematopoiesis by affecting in some of the erythroid and myeloid cell 
lineages (Van Loo et al., 2003). These comparisons of the Sp1 and Sp3 
knockout phenotype show that Sp1 and Sp3 have distinct functions in vivo. 
1.7  Research objectives 
1.7.1 Objective 1 
The DBD of ER consists of two zinc finger motifs. Each motif establishes 
a distinct and complementary surface with different chirality; the first zinc finger 
motif exhibits an S-configuration and the second zinc finger motif exhibits an R-
configuration, suggesting that these substructures were not derived from a 
duplication event in evolution. The first zinc finger motif (ZF1) contains a DNA 
recognition helix that contacts the major groove at the DNA halfsite. In contrast, 
zinc finger 2 (ZF2) contacts the phosphate backbone and provides the dimer 
interface (Schwabe et al., 1990 and 1993). The introduction of point mutations to 
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either ZF1 or ZF2 resulted in different patterns of agonistic or antagonistic 
activities on ER/AP-1 action. ERα mutated in zinc finger 1 (E207A/G208A) did 
not affect ICI 182,760-induced transcriptional activity on an AP-1 promoter 
whereas a zinc finger 2-point mutation (A227T) resulted in loss of inducibility by 
ICI 182,760 (Jakacka et al., 2001).  Therefore, the first objective of this project is 
to characterize and compare the functional properties of ER mutants containing 
deletions of either the first zinc finger or the second zinc finger motif in cells 
transfected with constructs containing 3 tandem EREs (pERE3) or GC-rich 
(pSp13) elements linked to a luciferase reporter gene and treated with estrogen, 
antiestrogens or their combination. Additionally, immunocytochemistry will be 
employed to determine if the zinc finger domain deletion mutants translocate into 
the nucleus after treatment with E2 or antiestrogens. 
1.7.2 Objective 2 
Previous studies in this laboratory showed the critical role of the AF1 
domain in hERα/Sp1 action. Deletion of aa 51-117 resulted in loss of E2-
dependent transcriptional activation in cells transfected with a GC-rich construct 
(pSp1). In contrast, ERβ or a chimeric ERβα consisting of the AF1 domain of 
ERβ and the DEF domain from ERα induced minimal reporter gene activity in 
cells transfected with pSp1 (Saville et al., 2000). However, the role of the AF2 
domain including the hinge region (D) and E/F domains of hERα on hERα/Sp1 
action has not previously been investigated. Deletion of either D or F domain of 
hERα does not results in loss of hormonal dependent transactivation in cells 
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transfected with pERE (Kumar et al., 1987). However, in cells transfected with 
hERα mutants lacking the F domain or containing point mutation in the F domain 
showed altered responses to antiestrogens, suggesting that a predicted helix 13 
or beta strand substructure in the F domain may form distinct conformations 
through interaction with other domains of ERα (Nichols et al., 1998; Schwartz et 
al., 2002). The second objective of this research is to investigate the effects of 
deletions or mutations of the hinge region, the AF2 core, or the F domain of 
hERα on E2/antiE2-induced transactivation in breast cancer cells transfected 
with pSp13 or pERE3. hERαTAF1 contains three amino acid mutations in helix 
12 (D538Q, E542Q and D545N) and has a nonfunctional AF2 that does not 
interact with SRC family coactivators through LxxLL motifs (NR box). By 
generating hERαTAF1 expression plasmid containing either zinc finger 1 
(hERαTAF1∆ZF1) or zinc finger 2 (hERαTAF1∆ZF1), the effects of estrogen and 
antiestrogen-induced transcriptional activity can be determined in cells 
transfected with pSp13. 
1.7.3 Objective 3 
GAL4 fusion peptides containing LxxLL motifs derived from NR boxes of 
different coactivators inhibit estrogen-induced transactivation in cells transfected 
with pERE3. Depending on flanking amino acid sequence and variation of the 
LxxLL motif, these peptides exhibit different affinities in the hydrophobic groove 
formed in the LBD (ligand binding domain) after binding to estrogen or 
antiestrogens. This suggests that the conformation of the LBD induced by 
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various ligands may recruit different coactivator complexes for gene transcription. 
Peptides derived from helix 10/11 or 12 specifically inhibited ERα binding to an 
ERE (Norris et al., 1999; Chang et al., 1999a). The effects of these different 
peptides on ERα/Sp1 action in breast cancer cells will be determined in this 
study. The identification of selective inhibitory peptides for activation of 
hERα/Sp1 will provide fundamental information on the contribution of this 
pathway to gene expression of breast cancer cells. Disruption of transcriptional 
activation by different classes of peptides containing LxxLL motifs derived from 
coactivators will be investigated in transient transfection assay in breast cancer 
cells transfected with pERE3 or pSp13. 
1.7.4 Objective 4 
Direct interactions between ERs and Sp proteins have been detected 
using coimmunoprecipitation and GST pull down assay in vitro; Both ERs bind to 
the zinc finger domain of either Sp1 or Sp3 protein (Porter et al., 1997; Saville et 
al., 2000; Stoner et al., 2000). However, direct physical interactions between 
ERα and Sp1 protein have not been investigated in vivo. 
Fluorescence resonance energy transfer (FRET) can be used to quantify 
the distance between two different fluorophores by measuring the transfer of 
energy from a fluorescent donor in its excited state to another excitable 
fluorescent moiety, the acceptor (Clegg, 2002). With the development of spectral 
variants of the green fluorescent protein (Heim, 1999), FRET has been 
extensively used as a method to image molecular events in living cells such as 
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protein-protein interactions (Mahajan et al., 1998) or protease and kinase 
activities (Heim and Tsien, 1996; Sato et al., 2002). Bascically, FRET requires 
the overlap between the donor molecule’s fluorescence emission spectrum and 
the acceptor molecule’s excitation spectrum, a limited distance between the 
donor and the acceptor molecules (1-10nm), and the appropriate orientation 
between the two fluorophores reside in both the donor and the acceptor 
molecules (Gordon et al., 1998; Elangovan et al., 2003). Recently, ligand-
dependent ERα-LxxLL peptide interactions, NRs-Steroid Receptor Coactivators 
(SRCs) interactions have been detected in living cells using FRET (Liopis et al., 
2000; Weatherman et al., 2002; Bai and Giguere, 2003). Here, ligand-dependent 
hERα-Sp1 protein interactions will be investigated in living cells by using FRET 
microscopy and image analysis. 
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CHAPTER II 
 
                               MATERIALS AND METHODS 
 
2.1  Chemical and biochemicals 
DMEM nutrient mixture F-12 (DME/F12) without phenol red, PBS, E2, 4-
OHT, BSA (Fraction V), and 100x antibiotic/antimycotic solution were purchased 
from Sigma (St Louis, MO). Fetal bovine serum (FBS) was obtained from JRH 
Biosciences (Lenexa, KS). ICI 182,780 was kindly provided by Dr. Alan 
Wakeling (Astra USA, Inc.-Zeneca Pharmaceuticals, Macclesfield, UK). [ -
32P]ATP (3000 Ci/mmol) was purchased from NEN Life Science Products 
(Boston, MA). Polydeoxy-(inosinic-cytidylic)acid, and T4-polynucleotide kinase 
were purchased from Roche Molecular Biochemicals (Indianapolis, IN). All the 
restriction enzymes and modifying enzymes (T4 DNA ligase, calf intestinal 
alkaline phosphatase) used in this study were purchased from Promega Corp. 
(Madison, WI) or Roche Molecular Biochemicals. Plasmid preparation kits were 
purchased from QIAGEN (Valencia, CA), and 40% polyacrylamide was obtained 
from National Diagnostics (Atlanta, GA). All other chemicals were obtained from 
commercial sources at the highest quality available.  
2.2  Cell maintenance and transient transfection assay 
MCF-7, Chinese Hamster ovary (CHO), and MDA-MB-231 cells were  
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obtained from the American Type Culture Collection (ATCC, Manassas, VA).  
MCF-7, MDA-MB-231 and CHO cells were grown in DME/F12 (Sigma) 
supplemented with 2.2 g/L sodium bicarbonate, 5% fetal bovine serum (FBS), 
bovine serum albumin (Sigma), and 10ml/L antibiotic/antimycotic solution 
(Sigma).  Cells were cultured and maintained in 150 cm2 tissue culture dishes in 
a 37°C in 5% CO2:95% air.  For transient transfection assays, cells were seeded 
onto 6-well tissue culture plates in DME/F12 without phenol red supplemented 
with 2.2 g/L sodium bicarbonate, 5% dextran-coated charcoal-stripped FBS, 
bovine serum albumin, and 10 ml/L antibiotic/antimycotic solution (Sigma). After 
24 h, cells were transfected with the calcium phosphate method with 2 µg of 
luciferase reporter construct (pSp13, pERE3, pADA, and pRARα1), 250 ng 
pcDNA3/His/lacZ (Invitrogen, Carlsbad, CA) as a standard reference for 
transfection efficiency, and 1 µg or 100 ng (for cotransfection with pERE3) of the 
appropriate ER expression plasmid.  In studies where variable amounts of 
coactivators were also used, the amount of DNA transfected was kept at a 
constant value by adding sufficient amount of empty vector.  After 5 to 6 h, the 
media was removed and the cells were shocked with 20% glycerol in phosphate 
buffered saline (PBS) (pH 7.4) for 1 min. Cells were rinsed twice with 1 ml of 
PBS and treated with 5% charcoal-stripped DME/F12 either containing Me2SO, 
E2 (10 nM), HOTAM (1 µM), or ICI 182, 780 (1 µM) for 36 to 40 h. After 
harvesting cells by scraping in 1X reporter lysis buffer (Promega, Madison, WI), 
luciferase activity of aliquots of this extract was determined using the luciferase 
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assay system (Promega).  β-Galactosidase activity was performed using Tropix 
Galacto-Light Plus assay system (Tropix, Bedford, MA).  Light emission was 
detected on a lumicount micro-well plate reader (Packard, Meriden, CT) and 
luciferase reporter gene activity was corrected by normalizing against β-
galactosidase activity, obtained from the same sample.  Results are expressed 
as means ± SD with at least three determinations for each treatment group. 
2.3  Oligonucleotides and plasmids 
hERα expression plasmid was kindly provided by Dr. Ming-jer Tsai 
(Baylor College of Medicine, Houston, TX); ER-null and hERαTAF1 were 
obtained from Dr. D. McDonnell (Duke University, Durham, NC).  The human ER 
deletion construct hER11C was originally obtained from Dr. Pierre Chambon 
(Institut de Genetique et de Biologie Moleculaire et Cellulaire, Illkirch, France). 
Mouse estrogen receptor (MOR) was generously provided by Dr. Malcom G. 
Parker (Imperial Cancer Research Fund, London, United Kingdom) and hERβ 
was supplied by Dr. J. A. Gustafsson (Karolinska Institute, Huddinge, Sweden).  
ERα DBD point mutants (K210A, A227T, 207AA, and 207GS) were obtained 
from Dr. Larry Jameson (Lurie Comprehensive Cancer Center, Northwestern 
University, Chicago, USA). Our experiments were carried out using a shorter 
variant form of ERβ; however, in preliminary experiments using a longer form of 
ERβ (provided by Dr. S. Mosselman, N.V. Organon, Oss, Netherlands), minimal 
induction of ERβ/Sp1 was also observed. SRC-1, SRC-2 (GRIP1), SRC-3 
(A1B1) and p68 RNA helicase were graciously provided by Drs. B. O'Malley 
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(Baylor College of Medicine, Houston, TX), M. R. Stallcup (University of 
Southern California, Los Angeles, CA), P. Meltzer (National Cancer Institute, 
Bethesda, MD) and S. Kato (University of Tokyo, Tokyo, Japan), respectively.  
The hER cDNAs and the MOR cDNA were inserted into vectors pcDNA3 or 
pcDNA3.1/His C (Invitrogen, Carlsbad, CA) in this laboratory for in vitro 
translation and for expression in mammalian cells in transient transfection 
assays. For gel mobility shift assays, a consensus estrogen response element 
(ERE); 5' GTCCAAAGTCAGGTCACAG TGACCTGATCAAAGTT 3' (SENSE) 
was used and obtained from the Gene Technologies Laboratories, Texas A&M 
University (College Station, TX). The DNA oligonucleotides used for construction 
of plasmids were synthesized by the Gene Technologies Laboratories (College 
Station, TX).  pXP1 luciferase reporter construct was obtained from ATCC and 
the minimal TATA sequence were inserted into pXP1 in this laboratory.  The 
following promoter sequences were cloned into HindIII and BamHI sites of pXP1 
TATA-luciferase reporter construct; three consensus GC-rich Sp1 binding sites 
for pSp13; 5' GCTTATTCGATCGGGGCGGGGCGAGCATTCGATCGGGG 
CGGGGCGAGCATTGATCGGGGCGGGGGCGAGCG 3' (sense); three 
consensus EREs for pERE3; 5' AGCTTTCCGGATCTAGGTCACTGTGA 
CCCGGGATCCTAGGTCACTGTGACCCGGGATCCTAGGTCACTG 
TGACCTGATCAAAGTG 3' (sense); consensus AP1 binding site for pAP1; 
5’GATTCGAGGTGTCTGACTCATGACT 3’ (sense). The GC-rich genomic 
promoter sequence from RARα1 gene (pRARα1; -79 to -49); 5' AGCTTGA 
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TTGGTCGGTGGGCGGGCAGGGGCGG GCCT 3' (sense) and the GC-rich 
genomic promoter sequence from the adenosine deaminase gene (pADA; -86 to 
-65); 5' AGCTTGGCGAGAGGGCGG GCCCCGGGA 3' (sense) were also 
cloned into HindIII and BamHI sites of pXP1 luciferase reporter construct. The 
GC-rich and ERE motif are underlined.  
2.4  Generation of ER deletion mutant constructs 
ER DBD deletion constructs were prepared by site-directed mutagenesis 
by overlap extension using the polymerase chain reaction as previously 
described (Ho et al., 1989).  For example, hERα∆ZF1 in pcDNA3 was 
constructed by carrying out the following procedures. One set of primers (A1/B1) 
from the Hind III site (A1) in the multiple cloning site in pcDNA3 to the site before 
the first amino acid in the region to be deleted was amplified by PCR; the latter 
primer (B1) has an overlapping region of about 15 to 20 bp that starts at the next 
amino acid in the deletion construct. In addition, another set of primers 
beginning just after the last amino acid to be deleted to the Hind III site in hERα 
cDNA sequence were also used and amplified by PCR. This second set of 
primers (A2/B2) contained a 15 to 20 bp overlapping region complementary to 
the last 15 to 20 bp DNA sequence in the first PCR product. Both PCR reaction 
products have their own regions of overlap, and these were coincubated to 
anneal the overlapping regions; this was followed by PCR amplification with the 
primer (A1) that starts at the multiple cloning site and the primer (B2) that starts 
at the hERα cDNA sequence.  
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Table 6 
Summary of primers used for mutagenesis of the DNA binding domains of hERα 
and MOR 
ER Deletion 
Mutant 
PCR-Primer Sets (A1/B1, A2/B2) for Mutagenesis Deletion 
HERα∆ZF1 A1; 5’ GCAAATGGGCGGTAGGCGTGTA 3’ 
B1; 5’ CTTGAAGAAGGCCTTGTAGCGAGTCTCCTTGG 3’ 
A2; 5’ AAGGAGACTCGCTACAAGGCCTTCTTCAAGAG 3’ 
B2; 5’ GAGACCAATCATCAGGA 
21 amino 
acid deletion 
(185 aa - 205 
aa) 
HERα∆ZF2 A1; 5’ GCAAATGGGCGGTAGGCGTGTA 3’ 
B1; 5’ CATTCCCACTTCGTAGTTATGTCCTTGAATACT 3’ 
A2; 5’ GTATTCAAGGACATAACTACGAAGTGGGAATGAT 
3’ 
B2; 5’ GAGACCAATCATCAGGA 3’ 
28 amino 
acid deletion 
(218 aa - 245 
aa) 
HERβ∆ZF1 A1; 5’ GACGTCAATGGGAGT 3’ 
B1; 5’CTTTTAAAAAAGGCCTTGAAGTGAGCATCCCTCTT 
C 3’ 
A2; 5’ GGATGCTCACTTCAAGGCCTTTTTTAAAAG 3’ 
B2; 5’ GAGACCAATCATCAGGA 
21 amino 
acid deletion 
(96 aa - 111 
aa) 
HERβ∆ZF2 A1; 5’ GTGTACGGTGGGAG 3’ 
B1; 5’ CATTCCCACTTCGTAATTATGTCCTTGAATGCTTC 
3’ 
A2; 5’ CAAGGACATAATTACGAAGTGGGAATGG 3’ 
B2; 5’ AACTCTCGAAACCTTGAA 3’ 
28 amino 
acid deletion 
(124 aa - 131 
aa) 
MORβ∆ZF1 A1; 5’ GCATCGCCTACGG 3’ 
B1; 5’ CTTAAAGAAAGCCTTGTAGCGAGTCTCCTTGGC 3’ 
A2; 5’ GGAGACTCGCTACAAGGCTTTCTTTAAGAGAAGC 
3’ 
B2; 5’ GGTCAATAAGCCCATCA 3’ 
21 amino 
acid deletion 
(189 aa - 209 
aa) 
MOR∆ZF2 A1; 5’ GCATCGCCTACGG 3’ 
B1; 5’ CATGCCCACTTCGTAATTGTGTCCTTGAATGCT 3’ 
A2; 5’ TCAAGGACACAATTACGAAGTGGGCATGATG3’ 
B2; 5’ GGTCAATAAGCCCATCA 3’ 
28 amino 
acid deletion 
(222 aa - 249 
aa) 
*  Overlapping regions are noted in bold type. 
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The resulting PCR product containing the desired deletion and a unique 
restriction site at both ends (Hind III) was purified, digested with HindIII, and 
finally cloned into pcDNA3 construct to give the appropriate expression plasmid 
for electrophoretic mobility shift and transient transfection assays.   
The primers used for the mutagenesis assays are summarized in the 
previous Table 6).  hERα∆ZF2 in pcDNA3 was also generated by using a unique 
Hind III restriction site for cloning into this vector.  
Generation of hERβ∆ZF1 and hERβ∆ZF2 used the unique Nhe I and 
EcoR I sites of previously modified hERβ in pcDNA3.1 (Saville et al., 2000).  
MOR cDNA was inserted into EcoR I site of pMT2 mammalian expression vector 
that contains unique Not I and Xba I sites in MOR cDNA sequence suitable for 
cloning the PCR-amplified insert containing deletion of one of zinc finger domain, 
into pMT2. The EcoR I fragment containing the desired deletion from pMT2 
MOR vector was cloned into EcoR I site of pcDNA3.1for in vitro translation.  The 
hERαTAF1 construct (in pcDNA3) has three point mutations (D538N, E542Q, 
and D545N) in AF2 (Tzukerman et al., 1994). hERαTAF1∆ZF1 and 
hERαTAF1∆ZF2 constructs were created by cloning the Xba I fragment (≅ 0.7 
Kb) from hERαTAF1 (in pcDNA3) into pcDNA3.1 and zinc finger mutants were 
prepared as described above. All constructs were mapped by restriction 
enzymes and sequenced to confirm that proper deletion or insertions were 
introduced into the target cDNA.  
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2.5  In vitro translation and detection of the translated proteins 
Wild-type ER and ER deletion mutants were synthesized in vitro using 
TNT T7 quick coupled transcription/translation System (Promega) in the 
presence or absence of [35S] methionine for electrophoretic mobility shift assays 
and separation by 10% SDS polyacrylamide gel electrophoresis. 
2.6  Electrophoretic mobility shift assays 
The consensus [32P]ERE oligonucleotide was annealed and end-labeled 
using T4-polynucleotide kinase and [ γ-32P]ATP.  To characterize DNA binding 
of wild-type ER and corresponding zinc finger deletion mutants, 0.5 µl of in vitro 
translated protein or 0.5 µl of unprogrammed lysate, was incubated in 1X 
binding buffer (25% glycerol, 0.5 mM EDTA, 0.5 mM dithiothretiol, 50 mM 
potassium chloride, 10 mM HEPES at pH 8.0) for 5 min at 4°C.  Radiolabeled 
consensus ERE oligonucleotide (60,000 cpm) was added to the reaction and the 
reaction mixture incubated at 25°C for 15 min.  Samples were then applied to 
the gel and separated by polyacrylamide gel electrophoresis at 120 V in 0.9 mM 
Tris, 0.9 M borate, 2 mM EDTA (pH 8.0) for 2 to 3 h.  Protein-DNA complexes 
were visualized by autoradiography using X-OmatTM film (Eastman Kodak, Co., 
Rochester, NY). 
2.7  Fluorescence immunocytochemistry 
MDA-MB-231 cells were subcultured in four-well Lab-Tek chambered 
slides (Nunc Inc., Naperville, IL) in DME/F12 medium without phenol red 5% 
FBS stripped with dextran-coated charcoal. After 24 h, cells were transiently 
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transfected with 500 ng of hER  or hER  mutant expression plasmids. For 
transient transfection studies, cells were incubated with FuGENE Transfection 
Reagent (Roche) at 37 C for 5 h, followed by 24 h of recovery in DME/F12. 
Before fixation, slides were washed three times in Dulbecco’s PBS (DPBS) and 
then fixed for 10 min at -20 C at 100% methanol. Slides were subsequently 
washed three times in DPBS followed by a 1-h blocking step in 3% normal goat 
serum (G-9023; Sigma). For nuclear localization of ER, the rat monoclonal 
antibody raised against the N-terminal domain of the hER  (H184; Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) was diluted to a final concentration of 3 
µg/ml in DPBS containing 0.5% BSA, 0.1% goat serum, and 0.3% Tween 20. 
Rat IgG at the same concentration was used as a control. Tween 20 (0.3%) was 
included in all antibody, blocking steps, and washes for nuclear localization of 
ER. Following by incubation with H184 antibody for 16 h, cells were washed with 
DPBS (three times) and then incubated for 1 h in a 1:200 dilution of fluorescein 
isothiocyanate-conjugated goat-antirat IgG (62–9511; Zymed Laboratories, Inc., 
South San Francisco, CA) in DPBS containing 0.1% goat serum. Cells were 
then washed (four times) over a period of 2 h and transferred to DPBS before 
coverslip mounting with ProLong Antifade mounting reagent (Molecular Probes, 
Inc., Eugene, OR). For each treatment, representative fluorescence images 
were recorded using an Axioplan microscope (Carl Zeiss, Thornwood, NY) 
equipped with a Hamamatsu chilled three charge-coupled device color camera 
(Hamamatsu, Japan) using Adobe Photoshop 5.0 (Adobe Systems, Seattle, WA) 
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image capture software. Images from all treatment groups were captured at the 
same time using identical image capture parameters.  
2.8  Statistics 
For transient transfection studies result are expressed as means ± SD for 
at least three separate experiments for each treatment group.  Statistical 
differences (p < 0.05) between control (Me2SO) and treatment groups or 
between E2-induced responses and treatment groups (coactivator experiments) 
were determine by ANOVA and Scheffe's post hoc test.  
2.9  Coimmunoprecipitation and Western blot analysis 
Cells were seeded into 35-mm six-well tissue culture plates in phenol red-
free medium (Dulbecco's modified Eagle's medium [DMEM] Ham F-12) 
containing 2.5% charcoal-stripped fetal bovine serum (FBS) and when cells 
were 60-80% confluent, YFP-hERα and Sp1 expression plasmids were 
transfected using LipofectAMINE Plus Reagent (Invitrogen).  After 24 hr, 
transfected cells were treated with DMSO, E2 10 nM, 4OHT 1 µM, and ICI 1 µM 
for 30min, 1 ml of RIPA buffer (1x PBS, 1% Nonidet P-40 or Igepal CA-630, 
0.5% sodium deoxycholate, 0.1% SDS, 10 mg/ml PMSF in isopropanol, 
aprotinin, 100 mM sodium orthovanadate) was added and cells were disrupted 
by repeated aspiration through a 21-gauge needle.  Cellular debris was removed 
by centrifugation at 10,000xg for 10 min at 4º C and the supernatant was 
transferred to a fresh microcentrifuge tube on ice. Lysate was precleared by 
adding 1.0 µg of the appropriate control normal rabbit IgG together with 20 µl of 
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appropriate suspended (25% v/v) protein A/G-Agarose agarose conjugate and 
incubated at 4º C for 30 min. After centrifugation for 30sec, the supernatant (800 
µg total cellular proteins) was transferred to a new microcentrifuge tube, 5 µl of 
rabbit polyclonal anti-GFP antibody (1 µg) (Santa Cruz) was added and incubate 
for 2–3 hours at 4º C.  20 µl of protein A/G-agarose (Santa Cruz) was added and 
incubated at 4º C for 1 hr. The immunoprecipitate was collected by 
centrifugation and the pellet was gently washed 2 times with 1.0 ml RIPA buffer 
and then with PBS.  The agarose pellet was then resuspended in 50 µl of 1x 
Laemmli buffer (50 mM Tris-HCl, 2% sodium dodecyl sulfate [SDS], 0.1% 
bromphenol blue, 175 mM ß-mercaptoethenol), boiled, and centrifuged. The 
suspended sample was separated by SDS-10% PAGE, electrophoresed to a 
PVDF membrane. The membrane was blocked in Blotto (5% milk, Tris-buffered 
saline [10 mM Tris-HCl, pH 8.0, 150 mM NaCl], and 0.05% Tween 20) and 
probed with primary antibodies for Sp1 PEP2 (1:500) for 3 hr at room 
temperature. Following incubation with peroxidase-conjugated secondary 
antibody, immunoglobulins were visualized using the ECL detection system 
(NEN, Boston).  
2.10 siRNA transfection 
siRNA for Sp1 were prepared by IDT (Coralville, IA) and targeted the 
coding region 1811-1833 relative to the start codon of Sp1 gene (Abdelrahim, et 
al., 2002). Scrambled siRNA as negative control was purchased from Ambion 
(Austin, TX). Cells were cultured in 12-well plates in 1 ml of DME/F12 medium 
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supplemented with 5% fetal bovine serum. After 16-20 hr when cells were 60-
75% confluent, iRNA duplexes and reporter gene constructs were transfected 
using LipofectAMINE Plus Reagent (Invitrogen); 0.375 µg of iRNA duplex to give 
a final concentration of 50 nM, pSp13 (500 ng), and β-galactosidase control 
plasmid were transfected in each well. The effects of small interfering Sp1 RNA 
(iSp1) transfection on hormone-induced transactivation were investigated in ZR-
75 cells treated with 50 nM E2, 1µM 4OHT, 1µM ICI 182, 780. Cells were 
harvested 36-44 h after transfection by manual scraping in 1x lysis buffer 
(Promega) and luciferase activity was measured by the same method described 
in section 2.2. 
2.11 FRET microscopy and analysis  
To perform fluorescence resonance energy transfer (FRET), cells were 
washed with DME/F12 medium containing 5% serum and then put on the stage 
of the BioRad 2000MP system equipped with a Nikon TE300 inverted 
microscope with a 60x (NA 1.2) water immersion objective lens and a Titanium: 
Saphire laser tuned to 820 nm wavelength. Control images were acquired before 
treatment of cells with DMSO, E2, 4OHT or ICI. Additional images were acquired 
between 8 and 18 min after addition of each ligand at a speed of 25lps. FRET 
data in MCF-7 cells transfected with CFP and YFP fusion constructs alone or in 
combination, were collected using 2 photon-820 nm excitation wavelength.   
Emission of CFP (donor signal) was collected using a 500DCLP dichroic and 
450 nm /80 nm filter while emission of YFP (acceptor signal or FRET signal) was 
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collected using a 528 nm/50 nm filter. Donor bleed through signal to the FRET 
channel was calculated by measuring the FRET channel signal resulting from 
MCF-7 cells transfected only with the CFP fusion construct. Acceptor bleed 
through to the FRET channel was calculated by measuring the FRET channel 
signal resulting from MCF-7 cells transfected with YFP fusion construct alone. 
To correct for variations in fluorophore expression resulting from different 
transfection efficiencies, minimum levels of YFP expression and maximum levels 
of CFP were selected based on data collected from each experiment. Cells that 
did not match the selection criteria were eliminated from the FRET analysis.  
Negative (CFP empty and YFP empty) and positive (CFP-YFP chimera) controls 
were used to calculate the approximate FRET efficiency in cells treated with 
different ligands; it was assumed that the signal from cells transfected with the 
positive CFP-YFP chimera construct will exhibit 50% FRET efficiency when 
compared to signals from cells transfected with CFP/YFP empty constructs.  
For identification of Region Of Interest (ROI) and FRET analysis, 
MetaMorph software version 6.0 was used (Universal Imaging Corp. 
Downingtown, PA). Acceptor signal acquired with the FRET channel was 
corrected by subtracting the background signal as well as the donor bleed 
through signal. Ten to fifteen images were collected from each sample and 1-5 
cells per image captured were analyzed. Three to five experiments per each 
combination of transfected fusion constructs were conducted on different days. 
Student’s t test was used to analyze the statistical significance between control 
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and ligand-treated cells at p<0.05 and this analysis was performed using Prism 
software version 4.0 (GraphPad Software Inc. San Diego, CA). 
2.12 Plasmid construction for FRET studies 
CFP-C1 and YFP-C1 mammalian expression vectors were obtained from 
BD Biosciences CLONTECH Laboratories, Inc. (Palo Alto, CA). The CFP-YFP 
chimera was generated by PCR using the following primer set:  5' 
TCCCCGCGGTAGCCGCCATGGTGAGCAAGGGC-GAGGAGCTG 3’ (sense) 
and 5-CGGGATCCCTTGTACAGCTCGTCCATGCCGAG 3’ (antisense). The 
PCR product was digested with SacII and BamHI and cloned into the CFP-C1 
vector (Bai and Giguere, 2003). CFP-hERα and YFP-hERα were made by PCR 
using following primer set: 5’ TTCGAATTCTATGACCATGACCCTCC 
ACACCAAAGCA 3’ (sense) and 5’ TAGTCGACTCAGACTGTGGCAGGGA 
AACCCTC 3’ (antisense) and the primer set for CFP-Sp1 is 5’ 
TTCGAATTCTACAGGTGAGCTTGACCTCACAGCC 3’ (sense) and 5’ 
TAGTCGACTCAGAAGCCATTGCCACTGATATT 3’ (antisense). The PCR 
product was digested with EcoRI and Sal I and cloned into either the CFP or 
YFP construct. Dominant negative Sp1 plasmid (Sp1DN) was provided by 
Drs.Yoshihiro Sowa and Toshiyuki Sakai (Kyoto Prefectural University of 
Medicine, Kyoto, Japan). 
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CHAPTER III 
 
RESULTS* 
 
3.1  Role of zinc fingers 1 and 2 of ERα and ERβ in hormonal activation of 
GC-rich promoters 
Previous studies in this laboratory showed that hormone-induced 
activation of hERα/Sp1 in breast cancer cells required the AF1 domain of 
hERα (Saville et al., 2000), and activation by E2 was also observed in cells 
cotransfected with the DBD deletion mutant (aa 185–251) hER11 (Porter et al., 
1997; Wang et al., 1999; Xie etal., 1999; Sun et al., 1998; Qin et al., 1999; 
Duan et al., 1998; Dong et al., 1999; Samudio et al., 2001). The role of other 
domains of hERα on estrogen and antiestrogen activation of hERα/Sp1 has 
not been defined and has been investigated in this study. Although 
hERα11/Sp1 is activated by E2 in transactivation assays, deletion of the entire 
DBD resulted in loss of antiestrogen-induced transactivation (Xie et al., 2000; 
Saville et al., 2000), and therefore initial studies determined the role of zinc 
fingers 1 and 2 deletion mutants on estrogen/antiestrogen activation of 
ERα/Sp1.    
*Reprinted with permission from “Domains of estrogen receptor alpha (ERalpha) required for  
ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in  
breast cancer cells” by Kim et al., 2003, Molecular Endocrinology, 17, 804-817. Copyright © 
2003 by The Endocrine Society.                                                                  
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Wild-type and zinc finger deletion mutants for hER (α and β) and mouse 
ERα (MOR) were cloned into pcDNA3 and translated in vitro using 
[35S]methionine and the radiolabeled proteins were separated by SDS-PAGE 
(Fig. 15). The results show that in vitro translated proteins gave distinct 
bandswith comparable intensities and the expected molecular weights, 
indicating that the ∆ZF1 or ∆ZF2 deletions did not cause unexpected frame 
shifts.  
 
hER α
hER β
MOR 
(66kD)
(55kD)
(≅ 67kD)
WT     ∆ZF1    ∆ZF2 11C
 
Fig. 15. SDS-PAGE separation of in vitro translated 35S-labeled proteins.  
Wild-type hERα, MOR, and hERβ and their corresponding zinc finger deletion 
mutants were in vitro translated using [35S]methionine and separated by  
SDS-PAGE as described in Materials and Methods. 11C refers to a DBD 
deletion mutant (aa 185–281) of hERα. Intensities of the radiolabeled proteins 
were similar and electrophoretic mobilities were consistent with their expected 
molecular masses. 
 
The effects of ∆ZF1 and ∆ZF2 mutations on DNA binding were 
determined by EMSAs of the in vitro expressed proteins. The results showed 
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that only wild-type hERs and MOR formed retarded bands after incubation with 
[32P]ERE (lanes 3, 7, and 10), whereas DNA-bound complexes were not 
observed with the zinc finger deletion mutants (Fig. 16). Transcriptional 
activation assays in ER-negative MDA-MB-231 cells cotransfected with an 
ERE-dependent promoter (pERE3) and wild-type ER or ER deletion mutants 
showed that E2 induced activity only in cells transfected with wild-type hER (α 
or β) or MOR (Fig. 16).  
W T   ∆ Z F 1  ∆ Z F 2 1 1 C W T   ∆ Z F 1  ∆ Z F 2 W T   ∆ Z F 1  ∆ Z F 2
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Fig. 16. Gel mobility shift assays. Unlabeled wild-type hERα, MOR, and hERβ 
and their corresponding zinc finger deletion mutants were in vitro translated, 
incubated with [32P]ERE, and analyzed by gel mobility shift assays as 
described in Materials and Methods. UPL refers to unprogrammed lysate. Only 
wild-type hERα (lane 3), hERβ (lane 7), and MOR (lane 10) formed retarded 
bands. Competition with excess unlabeled ERE decreased intensities of these 
bands (data not shown). 
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Fig. 17. Transactivation in MDA-MB-231 cells transfected with pERE3. MDA-
MB-231 cells were treated with 10 nM E2, cotransfected with pERE3 and wild-
type hERα, MOR, and hER or their zinc finger deletion mutants, and luciferase 
activities were determined as described in Materials and Methods. Significant 
(P < 0.05) induction is indicated (*). Results are expressed as means ± SD for 
at least three separate determinations for each treatment group. 
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Fig. 19. Transactivation in MCF-7 cells transfected with pSp13 and zinc finger 
deletion mutants. Cells were treated with 10 nM E2, transfected with pSp13 and 
wild-type hERα or MOR and their zinc finger deletion mutants. Luciferase 
activities were determined as described in Materials and Methods. Significant 
(P < 0.05) induction is indicated (*). Only minimal responses were observed for 
hERß/Sp1 (data not shown) as previously reported (Saville et al., 2000), and 
similar results were obtained with the hERβ zinc finger deletion mutants. 
Results are expressed as means ± SD for three separate determinations for 
each treatment group. 
 
These results were consistent with the gel mobility shift assays showing 
that the zinc finger mutants do not bind EREs (Fig. 17). E2 induced reporter 
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gene activity in MDA-MB-231 and MCF-7 cells transfected with pSp13 and 
expression plasmids for wild-type hERα or MOR (Figs.18 and 19). 
In contrast to results obtained in cells transfected with pERE3, induction 
responses were observed for both zinc finger deletion mutants of hERα and 
MOR. hERβ and the DBD deletion mutants were only minimally active in MDA-
MB-231 cells (≅2-fold induction) and inactive in MCF-7 cells (data not shown). 
The fold-induction using wild-type and zinc finger deletion mutants of hERα and 
MOR was lower in MDA-MB-231 than MCF-7 breast cancer cells due, in part, 
to higher basal activity in the former cell line. The highest induction responses 
using pSp13 and E2 were observed in MCF-7 cells transfected with ∆ZF2 
mutants; in MCF-7 cells, all the ER-DBD deletion mutants were more potent 
activators of pSp13 than wild-type hERα or MOR. The overall pattern of 
induction responses was similar for wild-type hERα and MOR and their zinc 
finger deletion mutants, and subsequent studies used only hERα. 
Several genes that are induced by E2 in MCF-7 breast cancer cells 
through hERα/Sp1 interactions with GC-rich motifs have previously been 
identified (Porter et al., 1997; Wang et al., 1999; Xie et al., 1999; Sun et al., 
1998; Qin et al., 1999; Duan et al., 1998; Dong et al., 1999; Samudio et al., 
2001; Khan et al., 2003; Ngwenya et al., 2003), and these include retinoic acid 
receptor α1 and adenosine deaminase (Xie et al., 1999; Sun et al., 1998). 
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Fig. 20. MDA-MB-231 cells transfected with pRARα1 and pADA. Cells were 
treated with E2 or DMSO, transfected with pADA or pRARα1 constructs, wild-
type hERα, or zinc finger deletion mutants of hERα, and luciferase activities 
were determined as described in Materials and Methods. Significant (P < 0.05) 
induction by E2 is indicated (*). Results are presented as means ± SD for three 
separate determinations for each treatment group. 
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hERα (Figs. 20 and 21). The pattern of induction by E2 was dependent on 
expression of wild-type or variant hERα, promoter, and cell context. For 
example, hormone inducibility was higher in MDA-MB-231 cells transfected 
with either pADA or pRARα1 and wild-type hERα compared with responses 
observed for the zinc finger deletion mutants. In MCF-7 cells, hormone 
inducibility was highest in cells transfected with pADA or pRARα1 and the 
∆ZF2 deletion mutant of hERα. 
3.2  Role of zinc fingers 1 and 2 in antiestrogen activation of GC-rich pSp13 
The results in Fig. 22 summarize the effects of E2 and the antiestrogens 
ICI 182,780 and 4-OHT on induction of luciferase activity in MCF-7 cells 
transfected with pSp13 and wild-type or zinc finger deletion mutants of hERα. 
Both estrogens and antiestrogens induce transactivation in cells transfected 
with wild-type hERα, whereas E2, but not the antiestrogens, were active in cells 
transfected with ∆ZF1 or ∆ZF2 deletion mutants of hERα. These results 
suggest that antiestrogen-bound zinc finger mutants of hERα are 
transcriptionally inactive and their recruitment of functional coactivators requires 
cooperative interactions that are directly or indirectly dependent on the zinc 
finger domains of hERα. 
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Fig. 22. Effects of zinc finger DBD mutants of hERα on activation of pSp13 by 
estrogens and antiestrogens in MCF-7 cells. MCF-7 cells were treated with 10 
nM E2, 1 µM 4-OHT, 1 µM ICI 182,780 (ICI), or antiestrogens plus E2, 
transfected with pSp13 and hERα, hERα∆ZF1, and hERα∆ZF2, and luciferase 
activities were determined as described in Materials and Methods. Significant 
(P < 0.05) induction (*) and inhibition of E2-induced activity (**) are indicated. 
 
Although deletion of one or both zinc fingers resulted in loss of 
antiestrogen-dependent hERα/Sp1 agonist activity, 4-OHT and ICI 182,780 
inhibited E2-induced ERα/Sp1 action using these DBD deletion constructs, 
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suggesting that the antiestrogen-mediated responses are intact in cells 
expressing zinc finger mutants of hERα.  
We also investigated the possibility that the failure to observe 
antiestrogen activation of zinc finger mutants of hERαSp1 may be due to failure 
of the transfected constructs to accumulate in nuclei of breast cancer cells.  
 
hERα∆ZF1 hERα∆ZF2hERαwt hERαTAF1
DMSO
E2
4OHT
 ICI
 
Fig. 23. Immunostaining of transfected wild-type and mutant hERα constructs in 
MDA-MB-231 cells. Cells were transfected with hERα, hERα∆ZF1, or 
hERα∆ZF2, treated with 10 nM E2, 1 µM 4-OHT, or 1 µM ICI 182,780 for 24 h, 
and immunostaining of transfected ER constructs was determined as described 
in Materials and Methods. Nuclear staining was observed in all groups; however, 
cells treated with ICI 182,780 exhibited perinuclear staining.                                                  
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However, results of immunofluorescent studies in MDA-MB-231 cells 
transfected with hERα or the zinc finger mutants showed that wild-type and 
mutant constructs were primarily nuclear in cells treated with dimethylsulfoxide 
(DMSO) or E2/antiestrogens, although some perinuclear staining was observed 
with hERα∆ZF1 using ICI 182,780 (Fig. 23). 
3.3  Role of zinc fingers 1 and 2 or DBD in estrogen or antiestrogen 
activation of AP1 promoter 
ERs also regulate transcription of AP1-depedent promoters not by direct 
DNA-protein interactions but by indirect protein-protein interactions as observed 
for ERα/Sp1, and this involves ER interaction with the AP1(Fos and Jun) 
complex (Pfahl, 1993). It has been previously reported that estrogen regulates 
AP1 dependent transcription either positively or negatively, depending on cell 
type and promoter context (Gaub et al., 1990; Philips et al., 1993; Umayahara et 
al., 1994; Webb et al., 1995). ERα containing a point mutation in the first zinc 
finger or complete deletion of DBD was shown to be efficient in regulating AP1 
responses (Gaub et al., 1990; Webb et al., 1995; Philips et al., 1998). Direct 
physical interactions between the C-terminal part of c-Jun and amino acids 259-
302 present in the ERα hinge domain are responsible for the formation of c-
Jun•ERα•GRIP1 coactivator complex (Teyssier et al., 2001). 
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Fig. 24. Effects of zinc finger DBD mutants of hERα on activation of pAP1 by 
estrogens and antiestrogens in MCF-7 cells. MCF-7 cells were treated with 
10nM E2, transfected with pAP1, and wild type hERα, 11c, or their zinc finger 
deletion mutants (A). MCF-7 cells were treated with 10 nM E2, 1 µM 4-OHT, 1 
µM ICI 182,780 (ICI), transfected with pAP1 and hERα, hERα∆ZF1, and 
hERα∆ZF2 (B). Luciferase activities were determined as described in Materials 
and Methods. Significant (P < 0.05) induction (*) is indicated. 
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ERα-mediated regulation of AP1 activity was investigated in this study 
using deletion constructs of either zinc fingers or the complete DBD and these 
expression plasmids were transfected into MCF-7 cells along with an AP1- 
TATA luciferase reporter construct.   
In agreement with previous results (Philips et al., 1998), either deletion of 
entire DBD or one of zinc fingers did not show any effect on estrogen-induced 
AP-1 activity (Fig. 24 A). The highest induction responses were observed in 
MCF-7 cells transfected with hERα wt and hERα∆ZF2 mutants. The effects of 
E2, antiestrogen ICI 182, 780 or 4OHT were observed in MCF-7 cells 
transfected with hERwt or deletion mutants and pAP-1 luciferase reporter 
construct (Fig. 24 B).  Only wild type hERα exhibited hormone inducibility after 
treatment of MCF-7 cells with estrogen and antiestrogen treatments. In contrast, 
cells transfected with DBD or zinc finger domain deletion mutants showed 
minimal inducibility with antiestrogen treatment and the results with the mutant 
constructs were similar to those coresponding estrogen/antiestrogen activation 
of GC-rich promoters.   
3.4  ERα/Sp1-mediated transactivation in cells transfected with hERα zinc 
finger point mutants 
The three mutants of E207G/G208S (207GS), E207A/G208A (207AA) 
and K210A have point mutation in the “P-box” of the first zinc finger whereas the 
A227T mutant contains a point mutation in the “D-box” of the second zinc finger.  
It was previously reported that with the exception of the K210A mutant these 
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mutant ERs retained their hormonal responsiveness on an AP-1 promoter but 
did not activate an ERE-dependent promoter (Jackacka et al., 2001).  
To assess transcriptional activation of the GC-rich promoter (pSp13) by 
these mutants, MCF-7 cells were transfected with pSp13 and treated with 
estrogen and antiestrogens. Only two mutants, A227T and K210A, exhibited 
hormone responsiveness after treatment with estrogen whereas no 
transactivation was observed after treatment with antiestrogens (Fig. 25). 
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Fig. 25. Effects of hERα zinc finger point mutants on activation of of pSp13 by 
estrogens and antiestrogens in MCF-7 cells. MCF-7 cells were transfected with 
pSp13, and wild type hERα, A277T, K210A, 207AA or 207GS point mutation(s) 
mutants. MCF-7 cells were treated with 10 nM E2, 1 µM 4-OHT, 1 µM ICI 
182,780 (ICI) and luciferase activities were determined as described in Materials 
and Methods. Significant (P < 0.05) induction (*) is indicated. 
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Surprisingly, unlike the hERα deletion mutants, the 207AA and 207GS 
mutants did not show hormone responsiveness demonstrating significant 
differences between the ZFdeletion and ZF point mutant ERα in activation of 
ERα/Sp1. 
3.5  Role of histone deacetylase inhibitors in ERα/ERE- or ERα/Sp1-
mediated transactivation 
Acetylation and deacetylation of histones in nucleosomes are linked to 
formation of transcriptionally active chromatin structure (Kuo and Allis, 1998; 
Struhl, 1998; Workman and Kingston, 1998). Histone deacetylase inhibitors, 
such as trichostatin A (TSA) and sodium butyrate, increase the histone 
acetylation in many types of cells (Yoshida et al., 1995).  In addition, it has 
previously been reported that TSA significantly enhanced estrogen-induced 
transactivation in cells stably transfected with the E2-reponsive vitellogenin-CAT 
construct (Mao and Shapiro, 2000). 
In order to assess the role of histone acetylation/deacetylation processes 
in ERα/ERE- or ERα/Sp1-dependent transactivation, two reversible histone 
deacetylase inhibitors, TSA and sodium butyrate were added to MCF-7 cells 
transfected with pERE3 and pSp13, respectively. Both TSA and sodium butyrate 
significantly increased the fold E2-induced activity in cells transfected with 
pERE3. In contrast, the overall fold induction level was not affected in MCF-
7cells transfected with pSp13 and this was due to a parallel increase in basal 
and induced activation (Fig. 26).  
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Fig. 26. Effects of histone deacetylase inhibitors on activation of pERE3 and 
pSp13 in MCF-7 cells. Luciferase activities were determined as described in 
Materials and Methods. Significant (P < 0.05) induction (*) is indicated. 
 
These results show that ERα/ERE-dependent transcription is more 
sensitive to histone deacetylase inhibitor treatments than ERα/Sp1-dependent 
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transcription, suggesting that differences in nucleosomal accessibility in vivo, 
which are dependent on promoter context. 
3.6  Activation of hERα/Sp1 by E2, 4-OHT, and ICI 182,780 does not require 
AF2-helix 12-coactivator interactions 
It was previously reported that activation of hER/Sp1 by E2 was lost after 
deletion of aa51–117(Saville et al., 2000); however, this did not exclude a role 
for AF2 alone or as a modifier of AF1-dependent hERα/Sp1 action. hERαTAF1 
contains three aa mutations (D538N, E542Q, and D545N) that do not affect 
ligand binding but inactivate AF2 by selectively blocking interactions with AF2-
dependent coactivators (Chang et al., 1999a; Schaufele et al., 2000; Tzukerman 
etal., 1994; McDonnell et al., 2000). In MCF-7 cells transfected with pSp13 and 
hERαTAF1, E2 significantly induced reporter gene activity, and ICI 182,780 and 
4-OHT also slightly increased this response (Fig.27). Hormone-mediated 
transactivation was also observed in MCF-7 cells transfected with pSp13 and 
hERαTAF1 containing deletions of zinc finger 1 or zinc finger 2 in the DBD; in 
contrast, the antiestrogens ICI 182,780 and 4-OHT did not activate luciferase 
activity using the hERαTAF1 DBD mutants, and similar results were observed 
for hERα∆ZF1 and hERα∆ZF2 (Fig.22). Increased hormone-induced 
transactivation was observed in MCF-7 cells transfected with pSp13 and 
hERα∆ZF1 or hERα∆ZF2 compared with wild-type hERα (Figs. 19 and 22). In 
contrast, deletion of zinc fingers 1 or 2 in hERαTAF1 did not result in increased 
hormone responsiveness in MCF-7 cells transfected with the zinc finger deletion 
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mutants compared with hERαTAF1 (Fig. 27). This suggests that helix 12 may 
contribute to E2-induced hERα∆ZF1/Sp1 and hERα∆ZF2/Sp1 action. hERα19 
and hERαnull were also inactive, and this was consistent with previous studies 
showing the importance of AF1 for hERα/Sp1 action (Saville et al., 2000).  
The results in Figs. 28 and 29 shows that expression of the LXXLL- 
peptide 2XF6 and Grip (Chang et al., 1999a) significantly decreased hormone-
induced transactivation in MDA-MB-231 cells and MCF-7 cells transfected with 
pERE3, and inhibition was not observed in cells transfected with pSp13. 
Furthermore, various LXXLL peptides including 2XF6, Grip, and C33 inhibited 
E2-induced transactivation in ZR-75 cells transfected with pERE3 but not with 
pSp13 (Fig. 30). These data suggest that interactions of hERα with prototypical 
steroid receptor coactivators containing LXXLL motifs may not be critical for 
hERα/Sp1 action.  
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Fig. 27. Activation of hERα/Sp1 by helix 12 and zinc finger mutants of hERα. 
MCF-7 cells were treated with DMSO, 10 nM E2, 1 µM 4-OHT, or 1 µM ICI 
182,780, transfected with several hER point and/or deletion mutants, and 
luciferase activity was determined as described in Materials and Methods. The 
hER19c and hERNull mutants do not express AF1 (aa 1–178) of hER, and 
hERnull also contains D538N, E542Q, and D545N point mutations in the AF2 
domain of hERα. Results are expressed as means ± for three separate 
determinations for each treatment group and significant (P < 0.05) induction is 
indicated (*).  
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Fig. 28. Inhibition of transactivation by 2XF6 peptide. MDA-MB-231 cells were 
treated with DMSO or 10 nM E2, transfected with pERE3 or pSp13 and different 
amounts of 2XF6 expression plasmid, and luciferase activity was determined as 
described in Materials and Methods. Results are expressed as means ± SD for 
three replicate determinations for each treatment group, and significant (P < 
0.05) inhibition of induced activity is indicated (**).  
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Fig. 29. Inhibition of transactivation by pMGAL4 fusion Grip peptide. MCF-7 cells 
were treated with DMSO or 10 nM E2, transfected with pERE3 or pSp13 and 
different amounts of pMGrip expression plasmid, and luciferase activity was 
determined as described in Materials and Methods. Results are expressed as 
means ± SD for three replicate determinations for each treatment group, and 
significant (P < 0.05) inhibition of induced activity is indicated (**).  
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Fig. 30. Inhibition of transactivation by various pMGAL4-fusion peptides. MCF-7 
cells were treated with DMSO or 10 nM E2, transfected with pERE3 or pSp13 
and different amounts of pMGAL4 fusion expression plasmid, and luciferase 
activity was determined as described in Materials and Methods. Results are 
expressed as means ± SD for three replicate determinations for each treatment 
group, and significant (P < 0.05) inhibition of induced activity is indicated (**). 
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Coactivators of hERα and other nuclear receptors have been extensively 
investigated, and these include AF2-dependent steroid receptor coactivators 
(SRCs) and AF1-dependent p68 RNA helicase (Kumar et al., 1987; Endoh et 
al., 1999). However, many of these coactivators have not been investigated in 
breast cancer cells, and their coactivation of hERα/Sp1 through LXXLL-
dependent or -independent pathways have not been reported previously. The 
effects of selected coactivators on hERα/Sp1-dependent transactivation in 
breast cancer cells transfected with pSp13 and on hERα/ERE-dependent 
transactivation in Chinese hamster ovary (CHO) cells are summarized in 
Figures 32, 33, and 34. MCF-7 cells were treated with 10 nM E2, transfected 
with pSp13 and hERα, and different amounts (10, 50, and 100 ng) of 
expression plasmids for SRC-1, SRC-2 (glucocorticoid receptor interacting 
protein 1), SRC-3 (AIB1), and p68 RNA helicase, an AF1-dependent coactivator 
of ERα (on an ERE promoter; Endoh et al., 1999). E2 induced activity (~2-fold; 
Figs. 31 and 32); however, cotransfection with SRC-1, SRC-2, SRC-3, or p68 
did not enhance activity in this cell line, and similar results were observed for 
the RNA coactivator SRA or p300 and for higher amounts (500 ng) of 
transfected coactivators (data not shown). A parallel experiment was carried out 
in MDA-MB-231 cells (Figure 33), and E2 induced activity (~2-fold), but 
cotransfection with SRC-1, SRC-2, SRC-3, and p68 did not enhance hERα/Sp1 
action. Moreover, many of these coactivators significantly inhibited the induction 
response in breast cancer cells. As a positive control for coactivation, we also 
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investigated effects of p160 coactivators and p68 in CHO cells treated with 10 
nM E2 and transfected with pERE3 and hERα.  
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Fig. 31. Coactivator interactions with ERα/Sp1in MCF-7 cells. Cells were 
transfected with pSp13, hERα, and different amounts of coactivators SRC-1, 
SRC-2, SCR-3, and p68 RNA helicase (10, 50, or 100 ng), treated with E2, and 
luciferase activities were determined as described in Materials and Methods. 
Significant (P < 0.05) coactivation (*) or inhibition (**) of E2-induced activities 
are indicated; similar results were observed after transfecting higher amounts 
(500 ng) of each coactivator in both cell lines. Results are expressed as means 
± SD for three separate experiments for each treatment group.  
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Fig. 32. Coactivator interactions with ERα/Sp1 in MDA-MB-231 cells. Cells were 
transfected with pSp13, hERα, and different amounts of coactivators SRC-1, 
SRC-2, SRC-3, and p68 RNA helicase (10, 50, or 100 ng), treated with E2, and 
luciferase activities were determined as described in Materials and Methods. 
Significant (P < 0.05) coactivation (*) or inhibition (**) of E2-induced activities 
are indicated; similar results were observed after transfecting higher amounts 
(500 ng) of each coactivator in both cell lines. Results are expressed as means 
± SD for three separate experiments for each treatment group.  
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Fig. 33. Coactivation of hERα action in CHO cells transfected with pERE3. Cells 
were transfected with pERE3 and treated as described above. Significant (P < 
0.05) coactivation of E2-induced activity is indicated (*). Results are expressed 
as means ± SD for three separate experiments for each treatment group. 
 
This cell line has frequently been used by other investigators to 
demonstrate coactivation of hERα using ERE-dependent promoter-reporter 
constructs. E2 induced luciferase activity (8- to 15-fold) and SRC-1, SRC-2, and 
SRC-3 (but not p68) enhanced the induction response (Figure 33). Coactivation 
of hERα/Sp1 by SRCs was not observed in ER-positive or negative breast 
cancer cell lines; this was consistent with the importance of AF1 for hERα/Sp1-
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mediated transactivation (Saville et al., 2000). Surprisingly, we did not observe 
coactivation of hERα or hERα /Sp1 by the AF1-interacting coactivator p68 in 
ER-negative or- positive cell lines, suggesting that cell context modulates the 
effects of p68 as a coactivator.   
3.7  Role of the AF1 domain in ERα/Sp1 action 
It has been recognized that ERα is subject to phosphorylation, which 
regulates its transcriptional activity. Phosphorylation of serines 104 and 106 in 
the AF1 domain by cyclin A/CDK2 complex potentiates hERα-dependent 
transcriptional activity (Rogatsky et al., 1999) and serine 118 is phosphorylated 
by MAP kinase (Kato et al., 1995).  AKT and p90RSK1 kinases catalyze 
phosphorylation of serine 167 and regulate AF1-dependent transcriptional 
activation (Joel et al., 1998; Campbell et al., 2001).  
To assess the role of these phosphorylation events in hERα/Sp1-
mediated transactivation, hERα mutant containing point mutation(s) on the 
phosphorylation sites in the AF1 domain were transfected into ER-negative 
MDA-MB-231 cells along with the pERE3 or pSp13 constructs. Estrogen induces 
luciferase activity in MDA-MB-231 cells transfected with pERE3, and hERα wt or 
hERα mutants containing point mutation in AF1, but not with hERα15c that 
contains complete deletion of AF1. Increased level of basal  transcription were 
observed in cells transfected with S104A, S106A, S118A, and S167A mutants.   
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Fig. 34. Effects of hERα point and deletion on ERα/Sp1 action. MDA-MB-231 
cells were treated with DMSO or 10 nM E2, transfected with pERE3 (top) or 
pSp13 (bottom) and luciferase activity was determined as described in Materials 
and Methods. Results are expressed as means ± SD for three replicate 
determinations for each treatment group, and significant (P < 0.05) induction is 
indicated (*).  
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Fig. 35. Effects of hERα point mutations in the AF1 domain on ERα/Sp1 action 
in MCF-7 cells. Cells were treated with DMSO or 10 nM E2, transfected with 
pSp13 and luciferase activity was determined as described in Materials and 
Methods. Results are expressed as means ± SD for three replicate 
determinations for each treatment group, and significant (P < 0.05) induction is 
indicated (*).  
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Fig. 36. Effect of hERα AF1 or hERβ AF1 peptide in hERα/Sp1-mediated 
transactivation. Cells were treated with DMSO or 10 nM E2, transfected with 
pSp13 and hERα AF1(1-182aa) or hERβ AF1 (1-98aa) and luciferase activity 
was determined as described in Materials and Methods. Results are expressed 
as means ± SD for three replicate determinations for each treatment group, and 
significant (P < 0.05) induction is indicated (*) or inhibition (**).  
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In addition, hERα 15c mutant constitutively activated pERE3 reporter 
gene activity in ligand-independent manner (Fig. 34). In contrast, estrogen only 
activated luciferase activity in cells transfected with pSp13 and wild type hERα 
or S118A. Higher basal activities have also been observed in cells transfected 
with S104A, S106A, S118A, and S167A mutant (Fig. 34).  
We have also tested the transcriptional activity of these mutants in MCF-
7 cells under the same experimental condition. Consistently, estrogen did not 
induce luciferase activity in MCF-7 cells transfected with pSp13 and S104 A or 
S106A whereas significant induction was observed in cells transfected with 
S118A, S167A, and S118A/S167A mutant containing double point mutations 
(Fig. 35).  
To further assess the role of the AF1 domain of hERα in hERα/Sp1-
mediated transactivation, hERαAF1 (1-182aa) peptide was generated and 
increasingly overexpressed in cells transfected with pSp13 and wild type hERα. 
Overexpression of the AF1 peptide inhibited luciferase activity in cells 
transfected with pSp13 and wild type hERα whereas hERβ AF1 peptide (1-
98aa) did not exhibit any inhibitory effect in hERα/Sp1-mediated transactivation 
(Fig. 36).  These results summarized in Figs. 34-36 confirm the important role of 
the AF1 domain of hERα in ERα/Sp1 action. 
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3.8  Role of AF2/Hinge (DEF) region for activation of hERα/Sp1 by 
estrogen and antiestrogens 
The requirements for other regions within the DEF domains of hERα for 
activation of hERα/Sp1 by estrogens and antiestrogens have also been 
investigated in MCF-7 cells. E2, 4-OHT, and ICI 182,780 did not induce 
luciferase activity in MCF-7 cells transfected with pSp13, whereas a 2.5- to 4.5-
fold induction was observed by all three compounds in cells cotransfected with 
hERα (Fig. 37). E2 did not induce activity in MCF-7 cells transfected with hERα 
(∆271–300) or hERα (∆265–330), which contain deletions of the hinge (D) or 
hinge (D) plus helix 1 of the E domain. ICI 182,780 and 4-OHT were also 
inactive in cells transfected with hERα (∆265–330), whereas induction by the 
antiestrogens was observed in cells transfected with hERα (∆271–300). 
Estrogen/antiestrogen-dependent activation of hERα/Sp1 was also investigated 
in MCF-7 cells transfected with a series of C-terminal deletion mutants, namely 
hERα (∆538–595), hERα (∆554–595), and hERα (∆579–595). These mutants 
contain deletions of helix 12 (E) and the C-terminal F domain (538–595), the F 
domain (554–595) alone, and the β-strand region of the F domain (579–595). In 
MCF-7 cells, both 4-OHT and ICI 182,780 induced luciferase activity in cells 
transfected with these hERα deletion mutants, whereas E2 was inactive. The 
failure of E2 to induce transactivation in cells transfected with pSp13 and hERα 
(∆579–595) suggests that the C-terminal aa 579–595, which contains a 
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QKYYIT β-strand motif (Schwartz et al., 2002), may be critical for transcriptional 
activation by E2 but not 4-OHT or ICI 182,780. 
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Fig. 37. Effects of DEF domain mutants of hERα on hormone and antiestrogen-
Induced transactivation. MCF-7 cells were transfected with pSp13 and wild-type 
or variant hERα, and induction of luciferase activity by 10 nM E2, 1 µM 4-OHT, 
or 1 µM ICI 182,780 was determined as described in Materials and Methods. 
Significant (P < 0.05) induction is indicated by an asterisk. 
transactivation in cells cotransfected with pERE3 and hERα (∆271–300) or  
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We further confirmed the F domain requirement for hormonal activation 
of hERα/Sp1 by examining a similar series of hERα deletion mutants in MDA-
MB-231 cells cotransfected with pSp13 or pERE3 (Fig. 38). E2 induced hERα 
(∆554–595), confirming results of previous studies in other cell lines showing 
that the hinge region and F domain are not necessary for hormonal activation of  
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Fig. 38. Hormonal activation of pERE3 or pSp13 in MDA-MB-231 cells. Cells 
were treated with DMSO or 10 nM E2, transfected with wild-type or variant 
hERα and pERE3 or pSp13, and luciferase activity was determined as described 
in Materials and Methods. Significant (P < 0.05) induction is indicated by an 
asterisk. 
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ERα/pERE (Kumar et al., 1987; Schwart etal., 2002; Nichols et al., 1998). E2 
did not induce transactivation in MCF-7 or MDA-MB-231 cells cotransfected 
with pSp13 and hERα (∆554–595). Thus, hormonal activation of hERα/Sp1 by 
E2 was dependent on the hinge (D) and F domains of hERα, whereas these 
same regions of hERα were not required for activation of pERE3. Peptides 
targeted to different regions of hERα block hormone-induced transactivation of 
ERE-dependent promoters/genes (Chang et al., 1999a; Schaufele, et al., 2000). 
This has been extensively investigated with peptides containing LXXLL motifs 
that block coactivator interactions with ERα (Chang et al., 1999a;Schaufele, et 
al., 2000) and inhibit hormone-induced activation in cells  
transfected with pERE3 (Fig. 39). Hormone-induced transactivation in MDA-MB-
231 cells transfected with pERE3 was not significantly decreased after 
cotransfection with the Fβ strand peptide containing aa575–595 from the F 
domain of hERα fused to the DBD of the yeast GAL4protein. In contrast, the F 
domain peptide blocked hormone-induced transactivation in MDA-MB-231 cells 
transfected with pSp13, whereas the 2XF6 peptide was inactive, and similar 
results were obtained with other peptides containing LXXLL sequences (data 
not shown). These results are consistent with the activity of wild-type and 
variant hERα constructs and confirm that the F domain of hERα is also 
essential for E2-dependent activation of hERα/Sp1.  
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Fig. 39. Inhibition of transactivation by Fβ peptide. MDA-MB-231 cells were 
transfected with pERE3 or pSp13, treated with DMSO or 10 nM E2, and 
cotransfected with Fβ (F domain) peptide, and luciferase activity was 
determined as d scribed in Materials and Methods. Significant (P < 0.05) 
decreases in ho
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It has been reported that the cyclin A/cdk2 complex phosphorylated 
serines 104 and 106 in the AF1 domain of hERα and these modifications 
enhanced transcriptional activity of hERα independent of AF2 function 
(Trowbridge et al., 1997 and Rogatsky et al., 1999). In addition, cyclin A/cdk2 
and cyclin E/cdk2 complexes also phosphorylated glucocorticoid receptor to 
enhance its transcriptional activity (Krstic et al., 1997). The results shown in Fig. 
40 indicated that overexpression cyclinA or cyclin E did not enhance 
transcriptional activity in MDA-MB-231 cells transfected with pSp13 and hERα; 
basal transcriptional activity was increased by cyclin A and E expression and 
this decreased the overall fold induction level.  
Ets-1 transcriptional factor, generally known as a target of MAP kinase 
signaling, exhibited AF2-independent coactivation of several nuclear receptor 
(Tolon et al., 2000). Both MCF-7 and ZR-75 cells were transfected with pSp13 
and increasing amounts of transfected Ets-1 expression plasmid. Increased 
amount of Ets-1 expression enhanced both the basal and E2-induced reporter 
gene activity in cells transfected with pSp13 and hERα without any significant 
changes in overall fold-induction (Fig. 41).  
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Fig. 40. Coactivation of hERα/Sp1-mediated transactivation by cyclin A or cyclin 
E. MDA-MB-231 cells were transfected with pSp13, hERαexpression plasmid 
and increasing amount of cyclin A or cyclin E expression plasmid and luciferase 
activity was determined as described in Materials and Methods. Significant (P < 
0.05) induction is indicated by an asterisk.  
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Fig. 41. Coactivation of hERα/Sp1-mediated transactivation by mETS-1. MCF-7 
and ZR-75 cells were transfected with pSp13, hERαexpression plasmid, and 
increasing amount of mouse ETS-1 expression plasmid and luciferase activity 
was determined as described in Materials and Methods. Significant (P < 0.05) 
induction is indicated by an asterisk.  
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Fig. 42. Coactivation of hERα/Sp1-mediated transactivation by Drip proteins. 
MCF-7 cells were transfected with pSp13, hERαexpression plasmid, and 
increasing amount of Drp92 or Drip72 expression plasmid and luciferase activity 
was determined as described in Materials and Methods. Significant (P < 0.05) 
induction is indicated by an asterisk.  
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DRIPs were first identified as Vitamin D receptor interacting proteins 
which coactivate several nuclear receptors in cell culture and in cell free system 
(Rachez et al., 1999). To assess the role of DRIPs in ERα/Sp1-mediated 
transactivation, two DRIP proteins, Drip 92 and Drip 77, have been investigated. 
Drip 92 slightly increased E2-induced reporter gene activity with the highest 
amount of transfected plasmid (500ng). However, Drip72 did not enhance the 
luciferase activity under the same conditions. The results shown in Fig. 42 
suggest that Drip92 possibly acts as weak coactivator of ERα/Sp1-mediated 
transactivation whereas Drip72 did not exhibit coactivator activity.     
3.10 Detection of direct physical interactions between ERα and Sp1 
proteins in vivo by FRET 
To investigate ERα/Sp1 protein-protein interactions in vivo, we first 
generated various CFP and YFP fusion constructs expressing CFP-YFP 
chimera, CFP-hERα, YFP-hERα, and CFP-Sp1 (Fig. 43). First, transcriptional 
activities of CFP-hERα and YFP-hERα were assayed in a transient transfection 
system. ER-negative MDA-MB-231 cells were transfected with pERE3 or pSp13 
along with CFP-hERα, YFP-hERα or unfused hERα. Both CFP-hERα and 
YFP-hERα were active and the levels of E2-induced transactivation between 
unfused hERα and fused hERα were similar in cells transfected with pERE3 or 
pSp13 (Fig. 44).   
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Overexpression of CFP-Sp1 alone increased the basal level of 
transactivation in cells transfected with pSp13 and this increase was reduced by 
cotransfection of dominant negative Sp1 (Sp1DN) expression plasmid (Fig. 45 
(top)). When cells were cotransfected with CFP-Sp1 and YFP-hERα, both 
basal and E2-induced level was significantly increased without changing the 
fold-induction (Fig. 45 (bottom)). Thus, CFP-hERα, YFP-hERα, and CFP-Sp1 
fusion proteins are transcriptionally active and give results comparable to those 
obtained with hERα or Sp1 proteins.  
To establish FRET in our system, the CFP-YFP chimera was generated and 
used as a positive control. Cotransfection of CFP empty and YFP empty was used 
as negative control.  Strong FRET signal from cells transfected with CFP-YFP 
chimera construct whereas a minimal FRET signal was detected from cells 
transfected with   CFP empty and YFP empty constructs (Fig. 46).  
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Fig. 43. CFP and YFP fusion proteins used for FRET studies.  
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Fig. 44. Effects of CFP-hERα and YFP-hERα on activation of pSp13 and pERE3. 
MDA-MB-231 cell were cotransfected with pSp13 or pERE3 and CFP or YFP 
fusion construct and treated with DMSO or 10 nM E2. Luciferase activities were 
determined as described in Materials and Methods. Significant (P < 0.05) 
induction (*) is indicated.                                                                         
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Fig. 45. Effects of CFP-Sp1 and YFP-hERα on activation of pSp13. ZR-75 cells 
were transfected with unfused Sp1 construct and Sp1 dominant negative 
(Sp1DN) or CFP-Sp1 and Sp1DN (top). Cells were treated with DMSO or 10 
nM E2 after transfection with pSp13 and CFP-Sp1, YFP-hERα or both fusion 
constructs (bottom). Luciferase activities were determined as described in 
Materials and Methods. Significant (P < 0.05) induction (*) of activity by E2 or 
inhibition of this activity (**) is indicated. 
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After subtraction of background signal, the ratio of positive control FRET 
signal to negative FRET signal is ≅ 2.01 where it is assume that FRET 
Efficiency is equal to 50% maximum and used as a standard for further 
calculation of FRET efficiency.  
In order to detect ligand-dependent protein-protein interactions, cells 
were transfected with CFP-hERα and YFP-hERα constructs and then images 
were acquired under the same conditions for a negative and a positive control. 
After treatment with E2 for 8 min, translocation of CFP-hERα and YFP-hERα 
into the nucleus was observed and acquired images showed stronger FRET 
signal in E2-treated cells when compared to DMSO-treated cells (Fig. 47).  
Based on the FRET conditions established above, ligand-dependent 
CFP-hERα/YFP-hERα and CFP-Sp1/YFP-hERα interactions were analyzed 
and FRET efficiency was calculated for each treatment. The results (Fig. 48) 
indicated that E2, 4OHT, and ICI treatment increased FRET efficiency in cells 
transfected with CFP-hERα and YFP-hERα. The highest FRET efficency was 
observed after treatment with 4OHT and the order of FRET efficiency was 
4OHT > E2 > ICI.  
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Fig. 46. Visualization of FRET in MCF-7 cells. Cells were transfected with CFP 
and YFP empty constructs (top) as a negative control or CFP-YFP chimera 
fusion construct as a positive control (bottom). The higher FRET signal was 
observed from cells transfected with CFP-YFP chimera construct. The 
conditions for acquiring images were described in Materials and Methods. 
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Fig. 47. Representative FRET images from cells transfected with CFP-hERα 
and YFP-hERα. Images were acquired 8 mins after treatment with DMSO or E2 
(10 nM). The colocalization of CFP-hERα and YFP-hERα and translocation of 
fusion proteins to the nucleus after treatment with E2 were observed. The 
higher FRET signal was detected from cells treated with E2. The conditions for 
acquiring images were described in Materials and Methods. 
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Fig. 48. FRET efficiency of CFP-hERα/YFP-hERα and CFP-Sp1/YFP-hERα. 
MCF-7 cells were transfected with each CFP/YFP fusion construct set. Images 
were acquired between 8-18mins after each ligand treatment. 10-15 images 
were acquired per treatment and each image contains 1-5 cells to be analyzed. 
The subtraction of background signal from the images was described in 
Materials and Methods. 
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However, in cells transfected with CFP-Sp1 and YFP-hERα, E2 and 
 except ICI significantly increased FRET efficiency and the order of 
 efficiency is 4OHT> E2 > ICI. Furthermore, after ligand treatment, YFP 
l intensity changed over time and was measured to confirm ligand-
dent protein interactions between hERα and Sp1. As shown in Fig. 49, 
 treatment did not change YFP intensity over time. However, E2, 4OHT, 
I treatments increased YFP intensity.  
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Fig. 50. Coimmunoprecipitation of ligand-dependent hERα/Sp1 protein complex. 
Whole cell extracts from cells transfected with YFP-hERα and Sp1 were 
isolated and immunoprecipitated with anti-YFP antibody and the cell extracts 
were analyzed for immunoreactive Sp1 protein by Western blot analysis with 
Sp1 antibody described in Materials and Methods.  
 
Consistent with the previous observation, 4OHT induced the most 
significant changes in YFP intensity and the order of YFP intensity change was 
followed by E2 and ICI, respectively. Thus, these experiments suggest that ERα 
interactions with Sp1 interactions are enhanced in ligand-dependent manner in 
living cells.  ERα/Sp1 interactions were not only investigated by FRET analysis 
but also by coimmunoprecipitation. MCF-7 cells were transfected with YFP-
hERα and Sp1 expression plasmids and their ligand-dependent interactions 
were investigated Immunoprecipitation of whole cell lysate with anti-YFP 
antibody, followed by Western blot analysis with Sp1 antibodies. As shown in 
Fig. 50, all ligands, including E2, 4OHT, and ICI, enhanced hERα/Sp1 
interactions in ligand-dependent manner and these results are consistent with 
the FRET data, showing interactions of these proteins In addition, coexpression 
of YFP-hERα and CFP-Sp1 expression plasmid significantly increased both the 
basal and estrogen- or antiestrogen-induced luciferase activities in cells 
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transfected with pSp13 compared to the luciferase activity in cells transfected 
with only CFP-Sp1, YFP-hERα, or hERα ( Fig. 51). These results also suggest 
that Sp1 is involved in both in estrogen- and in antiestrogen-induced ERα/Sp1 
action.  
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Fig. 51. Effects of CFP-Sp1 and YFP-hERα on antiestrogen-induced activation 
of pSp13 in MCF-7 cells. Cells were transfected with hERα, CFP-Sp1, YFP-
hERα or both fusion constructs along with pSp13  and then treated with 10 nM 
E2, 1 µM 4-OHT, 1 µM ICI 182,780 (ICI).  Luciferase activities were determined 
as described in Materials and Methods. Significant (P < 0.05) induction (*) was 
indicated. 
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Fig. 52. Effects of siRNA  for Sp1 ( iSp1) and control scrambled siRNA (CT 
siRNA) on luciferase activity in MCF-7 cells. Cells were transfected with pSp13 
and treated with 50 nM E2, 1 µM 4-OHT, 1 µM ICI 182,780 (ICI). Luciferase 
activity was determined as described under Materials and Methods. Significant 
(p < 0.05) induction by E2 is indicated by an asterisk and inhibition of the 
induced responses is also indicated(**). 
 
Finally, the role of Sp1 in ERα/Sp1 action was further investigated by 
using small interfering RNA (siRNA) for Sp1 protein. To achieve the highest 
level of induction in the absence of exogenous hERα expression, ZR-75 cells 
were transfected with pSp13 along with scrambled siRNA (CT siRNA), Sp1 
siRNA (iSp1) or without siRNA (CT) by using LipofectAMINE Plus Reagent. The 
results (Fig. 52) show that E2 or 4OHT significantly induced luciferase activity 
whereas luciferase activity induced by ICI was not observed in cells transfected 
with CT siRNA or CT.  However, iSp1 transfected cells significantly decreased 
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E2- or 4OHT-induced luciferase activity, suggesting the critical role of 
endogeneous Sp1 protein in ERα/Sp1 action.      
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CHAPTER IV 
 
DISCUSSION AND CONCLUSIONS* 
 
4.1  The role of zinc finger domain in ERα/Sp1 and ERα/AP1-mediated 
transactivation 
Development of selective ER modulators (SERMs) for treatment of 
breast cancer and other hormone-related problems is dependent on their 
tissue-specific activation or inhibition of ER-mediated genes/responses 
(Mcdonnell and Norris, 2002; Smith and O’Malley, 1999; Jordan, 2001; Fuqua 
et al., 2001; Krishnan et al., 2000). There are an increasing number of factors 
that regulate cell context-dependent ER action, and these include relative 
expression of ER subtypes and a complex network of nuclear proteins that 
uniquely interact with specific surfaces or domains of ERα, ERβ, and other 
coregulatory proteins (Horwitz et al., 1996; Glass et al., 1997; Edwards, 2000; 
McKenna et al., 1999; Robyr et al., 2000., Lemon and Freedman,  1999; Klinge, 
2000). The classical mechanism of ER activation involves ligand-dependent 
formation of ER dimers that bind consensus or nonconsensus EREs and recruit 
SRCs and other nuclear proteins that facilitate interactions with basal 
transcription factors (Tsai and O’Malley, 1994; Beato et al., 1995; Mangelsdorf 
et al., 1995; Enmark and Gustafsson, 1996; Perlmann and Evans, 1997; 
*Reprinted with permission from “Domains of estrogen receptor alpha (ERalpha) required for 
ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in 
breast cancer cells” by Kim et al., 2003, Molecular Endocrinology, 17, 804-817. Copyright © 
2003 by The Endocrine Society.                                                                  
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Horwitz et al., 1996; Glass et al., 1997; Edwards, 1999; McKenna et al., 1999; 
Robyr et al., 2000., Lemon and Freedman,  1999; Klinge, 2000). In contrast, 
nonclassical pathways that involve ligand activation of ER/Sp1 and ER/AP1 do 
not require interactions of ER with promoter DNA but with other DNA-bound 
transcription factors, namely Sp1 and c-Jun, respectively. Research in this 
laboratory has identified a number of E2-responsive genes regulated by 
ERα/Sp1 in breast cancer cells (Porter et al., 1997; Sun et al., 1998; Duan et 
al., 1998; Qin et al., 1999; Dong et al., 1999; Xie et al, 1999; Xie et al., 2000; 
Castro-Rivera et al., 2001; Khan et al., 2003; Ngwenya and Safe, 2003; Stoner 
et al., 2000 and 2004). This suggests that the nonclassical pathways for 
activation of ERα are important in breast cancer cells and may play a significant 
role in cell context-dependent regulation of genes by E2 and SERMs.  
For the last 10 years, not only ER but also many other nuclear receptors 
that interact with Sp family proteins have been identified. For examples, the 
progesterone receptor (PR) coimmunoprecitates with Sp1 and p300, and this 
PR/Sp1 complex is involved in the activation of p21 promoter (Owen et al., 
1998). Androgen receptor also forms a complex with Sp1 to activate p21 
promoter in LNCaP-FGC cells (Lu et al., 2000). Retinoic acid receptor 
heterodimer/Sp1 complex induces transglutaminase gene activation in bovine 
aorta endothelial cells (BACE) via GC-rich element in the gene promoter  
(Shimada et al., 2001). IkappaB alpha gene is activated via GC-rich sites by 
peroxisome proliferator-activated receptors α (PPARα) in a DNA binding-
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independent manner (Delerive et al., 2002). The thromboxane receptor gene is 
transcriptionally suppressed by PPAR γ/Sp1 complex in vascular smooth 
muscle cells (Sugawara et al., 2002). Thus, biochemical interactions between 
NRs and Sp family proteins may play important roles in the expression of a 
variety of genes containing GC-rich sites on their promoters. 
Previous studies showed that both estrogens and antiestrogens 
activated a construct containing a GC-rich promoter (pSp1) in breast cancer 
cells and this response was AF1 dependent (Saville et al., 2000). Moreover, the 
DBD of hERα was not required for activation by E2, whereas deletion of this 
region resulted in loss of transactivation by 4-OHT/ICI 182,780 (Saville et al., 
2000; Porter et al., 1996). In this research project I have further investigated the 
effects of slective mutations (deletions and point mutations) of zinc fingers 1 
and 2 on estrogen and antiestrogen activation of hERα/Sp1 and hERα/AP1 in 
breast cells. As expected, the zinc finger deletion mutants of hERα, hERβ, and 
MOR did not bind [32P]ERE in gel mobility shift assays or activate an ERE 
promoter (Figs. 17 and 18). However, E2 activated pSp13, pADA, and pRAR in 
MCF-7 and MDA-MB-231 cells transfected with wild type hERα (and MOR) and 
both zinc finger mutants (Figs. 19, 20, 21 and 22), and similar results were 
obtained in MCF-7 cells transfected with wild-type and zinc finger mutants of 
hERαTAF1 (Fig. 28). In contrast, minimal responses were observed for 
hERβ/Sp1 (data not shown) as previously reported (Saville et al., 2000). Zinc 
fingers 1 and 2 are important for DNA binding, and the D box region of zinc 
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finger 2 plays a role in ERα homodimerization (Kumar et al., 1987; Schwabe et 
al., 1990). The DBD of ERα is also an important determinant not only for 
antiestrogen activation of ERα/Sp1 but also ERα/AP1. Deletion of either of 
these zinc fingers or the entire DBD did not affect E2-induced AP1-luciferase 
activity (Fig. 25 A) but decreased or eliminated antiestrogen-induced AP1-
luciferase activity (Fig 25 B).  
It was previously reported that point mutations in zinc finger 1 of ERα 
either decreased (E207G/G208S), eliminated (K201A), or did not affect 
(E207A/G208A) ICI 182,780 activation of ERα/AP1 in TSA cells, whereas an 
A227T mutation in zinc finger 2 resulted in loss of ICI 182,780 inducibility 
through an AP1 element (Jakacka et al., 2001). E2 decreased activation of 
ERα/AP1 in MCF-7 and TSA cells, and this was also observed in all but one 
(K210A) of the DBD point mutants (Jakacka et al., 2001). I also investigated 
activation of hERα/Sp1 by these zinc finger point mutants in breast cancer cells. 
Unlike the results with hERα point mutants on hERα/AP1, minimal 
transactivation was observed in cells transfected with 207AA or 207GS after 
treatment with E2, 4-OHT, or ICI 182,780   (Fig. 26) whereas E2, but not 
antiestrogens, induced significant activation of ERα/Sp1 in cells transfected with 
A227T or K210A. Previous studies indicated that deletion of the DBD of hERα 
did not affect activation of hERα/Sp1 by E2 in breast cancer cells (Fig. 19, 20, 
21, and 22).  These results suggest that, under the different promoter context, 
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point mutation(s) in the DBD may cause the distinct conformational changes 
that ultimately affect the overall transactivation function of hERα whereas 
deletion of zinc finger or entire DBD did not induce this effect. My results also 
indicate that both zinc fingers of hERα and hERαTAF1 are required for the 
activity of antiestrogens in hormone-dependent activation of hERα/Sp1 (Fig. 
28). Thus, depending on the type or the location of mutation(s) in the DBD, 
hERα mutants exhibit distinct transcriptional activation patterns with different 
promoter. The results clearly show that there are significant differences 
between hERα/Sp1 and ERα/AP1 and their requirements for regions within the 
DBD for activation by E2 and SERMs. This implies that cell context-specific 
interactions of other nuclear proteins with the DBD region of hERα may be 
important for ligand-dependent activation of hERα/Sp1 and hERα/AP1. DBD-
interacting proteins that coactivate hERα and other hormone receptors have 
been reported (Moilanen et al., 1998; Saville et al., 2002) and current studies 
are focusing on investigating potential coactivators of hERα/Sp1.  
Finally, we investigated how a histone deacetylase inhibitor affects  
hERα/Sp1 action and compared this responses to the effects on hERα/ERE 
action. Interestingly, the results (Fig. 27) show different levels of sensitivity to 
treatment with HDAC inhibitors; both basal and E2-induced luciferase activities 
were greatly increased in MCF-7 cells transfected with pSp13 whereas only E2-
induced luciferase activity was increased in cells transfected with pERE3, 
suggesting that different levels of promoter-specific nucleosomal accessibility 
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exist in vivo by histone acetylation/deacetylation processes (Kuo and Allis, 
1998; Struhl, 1998; Workman and Kingston, 1998). These results are consistent 
with previous data showing that classical ERE-mediated transactivation was 
significaltly increased with HDAC inbitbitor treatment using cells stably 
transfected cells with the vitellogenin-CAT reporter construct (Mao and Shapiro, 
2000).  
4.2  The role of AF2-helix 12 interactions in ERα/Sp1-mediated 
transactivation 
Previous studies with AF1 deletion mutants of hERα showed that AF1 
domain of aa51-117 were critical for ERα/Sp1-mediated responses (Saville et 
al., 2000); however, contributions of the DEF domains have not been 
determined. The AF2 domain of hERα and other nuclear receptors is required 
for ligand-dependent activation of hERα through classical DNA-dependent 
pathways, and this activation process involves recruitment of AF2-interacting 
coactivators (Horwitz et al., 1996; Glass et al., 1997; Edwards, 1999; McKenna 
et al., 1999; Robyr et al., 2000., Lemon and Freedman, 1999; Klinge, 2000). NR 
box (LXXLL) motifs in SRCs and other coactivators specifically interact with 
helix 12 of hERα. D538N, E542Q, and D545N mutations in helix 12 give 
hERαTAF1 and these mutations abrogate interactions with most AF2-
interacting coactivators and decrease transactivation from ERE promoters 
(Chang et al., 1999a;Schaufele et al., 2000; Tzukerman et al., 1994; Mcdonnell 
et al., 1995). Maximal ERα/AP1 activation by E2 requires intact activation 
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surfaces of both AF1 and AF2, and AF2-dependent responses require helix 12 
and the corresponding NR box interacting sites. Moreover, the AF1 domain of 
ERα inhibits antiestrogen-induced ERα/AP1 action (Webb et al., 1999). In 
contrast, both estrogens and antiestrogens activated hERα/Sp1 and 
hERαTAF1/Sp1, and overexpression of the NR box peptides, Grip and 2XF6 
(Chang et al., 1999a) derived from SRC-2, did not affect activation of hERα/Sp1 
but inhibited ERα on an ERE promoter (Figs. 29 and 30). In addition, these 
peptides, including C33, also inhibited ERα/ERE-mediated transactivation but 
not ERα/Sp1-mediated transactivation in ZR-75 cells (Fig. 31). These results 
imply that regions of AF2 that interact with coactivators through their NR boxes 
are not necessary for hERα/Sp1 action, and this is supported by studies 
showing that prototypical AF2-interacting SRCs did not enhance hERα/Sp1-
mediated transactivation in breast cancer cells transfected with pSp13 (Figs. 32 
and 33). Interestingly, p68, an AF1-interacting protein, also did not enhance 
hERα/Sp1 activation of a GC-rich promoter in breast cancer cells, indicating 
that AF1-dependent p68 coactivation of hERα previously observed in COS-1 
and HeLa cells transfected with an ERE promoter is also dependent on cell 
context (Endoh et al., 1999). Results obtained with hERαTAF1, the SRCs, and 
peptide competition experiments clearly define that some mechanistic 
differences between hormone-dependent activation of hERα/Sp1 and hERα are 
due, in part, to helix 12 of hERα.  
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4.3  The role of AF1 domain and its phosphorylation in ERα/Sp1-mediated 
transactivation 
It is well known that phosphorylation of the AF1 domain of hERα 
regulates hERα transcriptional activity in both ligand-dependent and-
independent ways. For examples, serine 118 in the AF1 is phosphorylated 
either by EGF- and IGF-activated MAP kinase or by E2-activated TFIIH/cyclin 
dependent kinase complex (Kato et al., 1995; Chen et al., 2000). Both AKT and 
p90RSK kinases phosphorylate serine 167 to modulate ligand–dependent 
transcriptional activity of hERα (Campbell et al., 2001; Joel et al., 1998). It was 
previously reported that serines 104 and 106 phosphorylation occurs by 
cyclinA/ cdk2 complex to enhance hERα transcriptional activity in both ligand-
dependent and-independent manner (Rogatsky et al., 1999).  
By using a variety of hERα mutants and AF1 peptide(s), we further 
analyzed the functional role of AF1 in ERα/Sp1-mediated transativation. As 
shown in Fig. 35, mutations of these phophorylation sites results in a slight 
decrease in the fold induction of activation in cells treated with E2 on ERE 
promoter. In contrast, S104A and S106A mutants did not exhibit ligand-
dependent inducibility of ERα/Sp1 and the basal transcriptional activity was 
significantly increased in both MDA-MB-231 and MCF-7 cells (Figs. 35 and 36). 
However, other mutants, including S118A, S167A, or S118/167A double mutant, 
still exhibited their E2-dependent transcriptional inducibility. Interestingly, 
increased basal transcriptional levels were also observed in cells 
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overexpressing cyclin A, which stimulate cyclinA/cdk2 kinase activity, and leads 
to phosphorylation of serine 104 or 106 (Fig 41). These results suggested that 
both serines 104 and 106 may play critical a role in hERα/Sp1activation via 
phosphorylation/dephosphorylation processes whereas other phosphorylation 
sites seem to be indispensable. Furthermore, the results (Fig. 37) show that 
inhibition of ERα/Sp1-mediated transactivation by hERα AF1 peptide but not by 
ERβ AF1 peptide are consistent with important role of phosphorylation sites in 
AF1 for E2-dependent activation of in hERα/Sp1.  
Since AF1 is important for ERα/Sp1 activation, we selected a known 
ERα LBD-independent coactivator, Ets-1, and investigated its possible 
coactivation of hERα/Sp1. Coactivation of hERα/Sp1 by Ets-1 was both 
hormone-dependent and-independent (Fig 42). We also tested Drip 92 and 77 
proteins, identified as subunits for Sp1 coactivation complex, and Drip92 
exhibited weak coactivation only with a high amount of transfected construct 
(Fig. 43). Identification of ligand-dependent coactivator for hERα/Sp1 are 
currently being investigated in our laboratories.     
4.4  The role of DEF domains in ERα/Sp1-mediated transactivation 
We further investigated other regions within the DEF domains required 
for ligand-dependent activation of hERα/Sp1 (Fig. 37). The antiestrogens 4-
OHT and ICI 182,780 activated hERα/Sp1 in MCF-7 cells transfected with 
hERα (∆271–300), a hinge region deletion mutant (Fig. 37), whereas E2 was 
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inactive. In contrast, E2 activated an ERE promoter in MDA-MB-231 cells 
transfected with hERα (∆271–300) (Fig.38), and this was consistent with 
previous reports showing that the hinge region was not required for activation of 
ERE-dependent constructs (Kumar et al., 1987). Deletion of the hinge region 
and helix 1 [i.e. hERα (∆265–330)] resulted in loss of E2 and antiestrogen 
activation of hERα and hERα/Sp1 (Figs.37 and 38), and the importance of helix 
1 within the E domain for activation of ERE-dependent promoters has 
previously been reported (Kumar et al., 1987). It has been recently showed that 
E2, 4-OHT, and ICI 182,780 induced interactions of a helix 1-GAL4 chimeric 
protein with the ligand binding domain (LBD) or ER  in a mammalian two-hybrid 
assay (Pissios et al., 2000). Thus, helix 1 may stabilize ligand interactions with 
the LBD, and this process may be functional for both DNA-dependent and -
independent mechanisms of ERα action. However, the importance of helices 1 
and 2 as interacting domains for other nuclear factors has not been determined.  
Activation of hERα/Sp1 by estrogens was also dependent on the C-
terminal region of hERα (aa 538–595), which encompassed part of helix 12 
within the E domain (aa 538–553) and the F domain (aa 554–595), which 
potentially contains helix 13 and β-strand motifs based on secondary structure 
calculations (Schwartz et al., 2002; Montano and Katzenellenbogen, 1995). 
Helix 12 is required for E2-dependent activation of ERα in cells transfected with 
an ERE promoter (Tzukerman et al., 1994) (Fig. 38), and similar results were 
observed for activation of hERα/Sp1 by E2 (Fig. 37). In contrast, both 4-OHT 
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and ICI 182,780 activated hERα (∆538–595)/Sp1, and this result coupled with 
antiestrogen activation of hERαTAF1/Sp1 confirms that helix 12 is not required 
for this induction response by antiestrogens. The failure of E2 to activate hERα 
(∆538–595)/Sp1 was not due to the requirement for helix 12 because activation 
was also not observed in cells transfected with hERα (∆554–595) (i.e. F domain 
deletion) or hERα (∆579–595) in which only the C-terminal β-strand region of 
the F domain has been deleted. F domain deletions can modulate activation of 
ERE promoters by antiestrogens but have minimal effects on E2-mediated 
transactivation (Montano and Katzenellenbogen, 1995). However, the results in 
Fig. 37 clearly demonstrate that F domain aa 579–595 are required for 
activation of hERα/Sp1 by E2. This was also confirmed in selective NR box 
(2XF6) and F domain (aa575–595) peptide competition studies, which 
demonstrate preferential inhibition of hERα/Sp1 action in cells transfected with 
the Fβ expression plasmid (Fig.42). These results demonstrate that E2- and 
SERM-mediated activation of hERα/Sp1 in breast cancer cells is complex and 
dependent on multiple overlapping and distinct regions of hERα (Fig. 53). 
These domains of hERα may impart unique structural features required for 
hERα/Sp1 action and may also serve as binding sites for essential interacting 
nuclear coregulatory proteins. Decreased hERα/Sp1-mediated transactivation 
in cells transfected with the F domain peptide (Fig.42) suggests that this region 
of hERα may interact with other nuclear coregulatory proteins, and current 
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studies are focused on identifying F domain-interacting factors and their 
function in breast cancer cells.  
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Fig. 53. Summary of domains of hERα required for activation of hERα/Sp1 by 
E2 and antiestrogens 4-OHT and ICI 182, 780. 
 
4.5  Detection of hERα/Sp1 protein interactions in living cells by 
Fluorescence Resonance Energy Transfer (FRET) 
With advances in fluorescence microscopy and development of multiple 
color variants of green fluorescence proteins (GFP), derived from the jellyfish 
Aequoria victoria, protein-protein interactions can be visualized in living cells by 
FRET and image analysis. FRET is a quantum mechanical process in which 
energy from an excited donor fluorophore is transferred to a low energy 
acceptor fluorophore via a long range dipole-dipole interaction; in a nonradiative 
manner (Day et al., 2001; Gordon et al., 1998; Elangovan et al., 2003; Wallrabe 
et al., 2003; Miyawaki et al., 1997).  The efficiency of energy transfer varies 
inversely with the sixth power of the distance between the donor and the 
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acceptor fluorophores (1/r6; r = distance between the donor and the acceptor), 
which limits FRET to occur in a range of 1-10nm. When FRET occurs, the 
donor emission is decreased and the acceptor emission is increased; sensitized 
emission.  
The efficiency of energy transfer (FRET efficiency) also depends on the 
extent of spectral overlap between the donor and acceptor, the quantum yield of 
the donor, and the relative orientation of the donor and acceptor (Gordon et al., 
1998). Although the efficiency of energy transfer can be improved by increasing 
the spectral overlap between the donor and the acceptor, this increases 
background FRET signals derived from the donor emission into the acceptor 
channel (donor bleed through) and from direct excitation of the acceptor by the 
donor excitation wave length (acceptor bleed through), defined as spectral 
cross talk (Day et al., 2001). Therefore, it is critical to selectively extract the 
background signals from sensitized emission of the FRET pair and this requires 
extensive corrections in order to determine FRET properly.  
In order to establish a workable FRET pair, the following conditions also 
need to be fulfilled; a sufficient separation in excitation spectra between the 
donor and the acceptor, the spectral overlap between the donor and the 
acceptor, an appropriate separation in emission spectra to provide independent 
measurement of the donor or the acceptor fluorescence. A cyan fluorescent 
protein (CFP) and a yellow fluorescent protein (YFP) have been used together 
as a sutable FRET pair for detection of intermolecular protein-protein 
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interactions. Heteromerization of G proteins, dimerization of receptor tyrosine 
phosphatase, interaction between nuclear transporter factors have all been 
visualized in living cells through generation of CFP and YFP fusion proteins 
(Janetopoulos et al., 2001; Damelin et al., 2000; Tertoolen et al., 2001).  
However, when intermolecular FRET is measured in living cells via 
expression of two separate fusion proteins such as a CFP/YFP pair, it is 
important to consider that either false positive or false negative results can be 
observed due to the following artifacts. Firstly, formation of mixed complexes 
between the fluorescence lableled proteins and endogeneous protein partners 
can interrupt FRET signals; For example, complex formation of YFP-hERα and 
endogenous ERα in MCF-7 cells competes for potential productive interactions, 
which can cause a weaker FRET signal. Secondly, overexpression of the fusion 
proteins can produce false positive because high concentration of the donors 
and the acceptors as a FRET pair or their ratio difference within a cell can result 
in increased non-specific interactions. Therefore, control experiments should be 
performed in parallel studies with other fusion protein mutants that have same 
biochemical properties such as protein stability and subcellular localization. 
However, these mutant proteins should not physically interact to assess the 
contribution of non-specific interactions. Thirdly, false negative also can occur, 
even when their fusion partners are still interacting, because inappropriate 
orientation or unfavorable stoichiometry between the fusion proteins may result  
in an increased distance between the proteins that will  interrupt energy transfer 
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to measure FRET (Day et al., 2001; Zhang et al., 2003). The FRET asay for 
determing intermolecular protein-protein interactions can be assessed with 
more sophiscated methods such as the mathemathical processing of the three 
images (Gordon et al., 1998; Elangovan et al., 2003; Zimmermann et al., 2002) 
and photobleaching of the acceptor (Miyawaki et al., 2000; Siegel et al., 2000). 
The results illustrated in Figs 45 and 46 shows that individual 
transcriptional activities of CFP and YFP fusion proteins are comparable to 
those of the unfused proteins such as hERα or Sp1 in cells transfected with 
constructs contain ERE and Sp1 promoters. Coexpression of CFP-Sp1 and 
hERα increased both the basal and inducible level of luciferase activity. Thus, 
the transcriptional activities of the fusion proteins are relatively intact. Acquired 
images using 2-photon excitation fluorescence microscopy with a three filter set 
indicated that FRET signal from cells transfected with the CFP-YFP chimera 
was much higher than that observed in the negative control cells (Fig. 47). In 
cells cotransfected with CFP-hERα and YFP-hERα, E2 induced translocation of 
the fusion proteins from the cytoplasm into the nucleus and the stronger FRET 
signal, indicated ligand-induced ER homodimerization which is  consistent with 
previously described ligand-induced effect on hERα (Kumar and Chambon, 
1988; Bai and Giguere, 2003).  
In order to accurately determine ligand-dependent interactions of 
hERα/Sp1 using FRET, we first set the range from minimum to maximum levels 
of either CFP or YFP expression as the selection criterion. Values from cells 
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that did not fit this criterion for correcting variations in fluorophore expression 
level were eliminated. Secondly, we assumed that the ratio of positive control 
FRET signal to negative control FRET signal, which is ≅ 2.01, would represent 
50% FRET efficiency and, based on this assumption, further caculations for 
measuring FRET efficiency were performed. Moreover, enhanced dimerization 
between E2-bound CFP-hERα and YFP-hERα has been previously reported 
(Bai and Giguere, 2003) and this dimerization property was used as another 
positive control for confirming the method described above for quantifing FRET 
efficiency. The results shown in Fig 49 indicate that the order of FRET efficiency 
in CFP-hERα/YFP-hERα or CFP-Sp1/YFP-hERα interactions was 4OHT> 
E2>ICI; all the ligands induced an increase in protein-protein interactions in vivo. 
However, the overall FRET efficiencies in CFP-Sp1/YFP-hERα were relatively 
lower than those in CFP-hERα /YFP-hERα, implicating that the increase size of 
CFP-Sp1 or unfavorable orientation between the fusion proteins affected the 
overall FRET efficiency.  
To alternatively assess ligand dependent hERα/Sp1 interactions, 
variations in YFP intensity over time were measured after addtion of each 
ligand. As shown in Fig. 50, the addition of DMSO did not alter YFP intensity 
over time whereas all other ligands including E2, 4OHT, and ICI increased YFP 
intensity with a slightly fluctuating pattern. The final order of YFP intensity 7.5 
min after ligand addition was the same as the order of FRET efficiency and this 
was consistent with ligand-dependent hERα/Sp1 interactions in vivo. 
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Furthermore, coimmunoprecipitation for YFP-hERα/Sp1 has also been carried 
out to confirm the ligand-dependent interactions of these proteins in vivo (Fig. 
51 (top)). Cells transfected with YFP-hERα and CFP-Sp1 also exhibited 
significant estrogen-and antiestrogen-induced activation of hERα/Sp1 (Fig. 50 
(bottom)).  
Finally, transfection of small interfering RNA for Sp1 significantly 
inhibited endogenous hERα/Sp1 action in ZR-75 cells, suggesting that hERα-
mediated transactivation of consensus GC-rich promoter, at least in part, 
depends on hERα/Sp1 protein-protein interactions. RNA interference is also 
being used in current studies on the role of Sp3, another GC-rich region binding 
proteins that can act as a transcriptional repressor or enhancer.  
In this study, it has been shown that multiple but distinct domains of 
hERα are required for hERα/Sp1-mediated transactivation and NR-box motifs 
(LxxLL) in coactivation do not play a significant role in hERα/Sp1 action 
compared to their function as coactivators of hERα/AP1 or hERα/ERE. 
Although it has been shown that many other nuclear receptors interacts with Sp 
family proteins, this study is the first to observe ligand-dependent hERα/Sp1 
protein-protein interactions in living cells.  
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